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9Scope and outline of this thesis
Injury to the peripheral nerve is a serious condition that causes sensory and motor 
impairments of the affected limb. At present, the only treatment strategy for severe 
nerve lesions is microsurgical repair. Surgical techniques have evolved significantly 
over the past decades, but nonetheless, a considerable degree of functional impairment 
remains in the majority of patients after nerve reconstruction. It is generally accepted 
that surgery has reached an optimal technical refinement. New concepts are therefore 
needed to improve the functional recovery of patients with severe peripheral nerve 
injury. As described in introductory Chapter 1, it is likely that in the future such con-
cepts will arise from insights obtained by molecular neurobiological research. Viral 
vector-mediated gene transfer in the nervous system has matured significantly over 
the last decades and is now a clinically viable tool for the long-term, local delivery of 
proteins that may enhance peripheral nerve regeneration at a molecular level. 
The overall objective of this thesis can be divided in two distinct, but related aims: 
1) to investigate the molecular properties of the human peripheral nerve lesion and 
2) to explore the possibilities to manipulate regeneration of the peripheral nerve at a 
molecular level with the aid of lentiviral (LV) vectors.
Scar formation in the injured peripheral nerve (e.g. after a stretch injury) is considered 
to be detrimental for the regeneration of axons and subsequent functional recovery, 
although the molecular basis for this phenomenon is not fully understood. In Chapter 
2, we show that the chemorepulsive axon guidance protein semaphorin 3A is present 
in the human peripheral nerve scar and may contribute to its outgrowth-inhibitory 
properties. Building on this result, we performed a genome-wide analysis of gene 
expression in the human peripheral nerve scar, the results of which are described 
in Chapter 3. We discovered that the expression of many proteins was differentially 
regulated in the nerve scar, and a significant proportion of these are involved in either 
scar formation or guidance of regenerating axons.
The newly discovered proteins that influence regeneration described in Chapters 2 and 
3 may in the future become targets for therapies to enhance the functional outcome of 
peripheral nerve surgery, but this approach depends on the ability to locally increase 
(or decrease) their expression. In the following chapters, we explored the use of viral 
vectors as a means to enhance the expression of so-called neurotrophic factors in the 
peripheral nervous system.
In Chapter 4, we develop a method to insert a gene into cells of the cultured human 
nerve by means of LV vectors. Furthermore, we show that the application of an LV 
vector carrying a gene encoding nerve growth factor (NGF) leads to long-term pro-
duction of biologically active NGF. With the method described in this chapter, the LV 
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vector could theoretically be applied without changing the routine practice of nerve 
grafting, so this approach could be a powerful novel adjuvant therapy for peripheral 
nerve surgery. However, a key question is whether the application of viral vectors can 
actually improve the outcome of nerve repair surgery. 
Therefore, in Chapter 5, we studied the effect of LV vector-mediated overexpression 
of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic 
factor (GDNF) on regeneration of motoneurons after nerve root avulsion and reim-
plantation in the rat. LV vector-mediated overexpression of GDNF does indeed reduce 
atrophy of avulsed motoneurons and increase the sprouting of regenerating axons into 
reimplanted roots, but unfortunately, these axons fail to exit the area of high GDNF 
expression, resulting in impaired long distance regeneration. 
In Chapter 6, we studied the effect of LV vector-mediated overexpression of NGF and 
GDNF on regeneration of the rat peripheral nerve. Similar to the results described in 
the previous chapter, high levels of GDNF trap regenerating motor axons, whereas the 
regeneration of sensory neurons is unaffected. The effects of NGF on the regeneration 
of either motor or sensory neurons appeared to be very limited. Lentiviral vector-me-
diated overexpression of both NGF and GDNF causes profound but different changes 
in regenerating sensory neurons, specifically those sensory neurons that play a role in 
the perception of pain. These findings have important implications for future research 
into difference between the regenerative response of motor and sensory neurons and 
for a better understanding of the pathogenesis of pain. 
The final chapter, Chapter 7, is a summary of the preceding chapters, followed by a 
discussion on how the obtained results will influence future research. Specifically, I 
will speculate in this Chapter on how the clinical practice of peripheral nerve surgery 
will be influenced by a better understanding of the molecular basis of regeneration 
and on ways to fully realise the potential of emerging therapeutics from the field of 
molecular neurobiology.
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Chapter 1
Introduction: the application of viral vectors to enhance regeneration after 
peripheral nerve repair
Martijn R Tannemaat, Joost Verhaagen, Martijn J Malessy
Neurological Research (in press)
Abstract
Despite great advances in surgical repair techniques, a considerable degree of func-
tional impairment remains in the majority of patients after peripheral nerve recon-
struction. New concepts to promote regeneration of the peripheral nerve are needed 
since it is generally held that surgery has reached an optimal technical refinement. 
These future concepts will likely be aimed at influencing peripheral nerve regenera-
tion at a molecular level using viral vectors. Several neurotrophic factors stimulate 
regeneration of the peripheral nerve, but the effects of the exogenous application of 
these factors have so far been limited, possibly as the result of their fast degradation 
and unwanted side-effects after systemic application. These problems can be resolved 
with the recent development of non-toxic, non-immunogenic viral vectors that drive 
local, long-term transgene expression. Retroviral vectors have been used successfully 
for the ex vivo transduction of Schwann cells, prior to seeding in artificial nerve guides. 
Lentiviral (LV) vectors direct long term transgene expression in Schwann cells in rat 
peripheral nerves. LV vectors are also capable of transducing cultured segments of 
human sural nerve thereby providing “proof of concept” for the feasibility of genetic 
modification of sural nerve transplants in a clinical setting. In the near future, viral 
vectors will increasingly be used to study a wide range of neurotrophic factors and 
other potentially therapeutic proteins for their effect on peripheral nerve regenera-
tion in animal models. If this approach leads to beneficial effects on regeneration and 
functional recovery, the safety and clinical applicability of these viral vectors will allow 
the rapid translation of basic research to clinical trials. This makes the use of viral vec-
tors a highly attractive concept that holds great promise as a novel adjuvant therapy 
to peripheral nerve reconstruction.
Introduction: peripheral nerve repair
The first series of successful surgical reconstructions of the peripheral nerve were 
described shortly after the Second World War 1. Since then, a better understanding of 
peripheral nerve anatomy, the evolution of surgical techniques, including epineurial 
suturing and the introduction of the operation microscope, have led to a significant 
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improvement in the clinical outcome of surgery. Surgery is currently the preferred 
treatment for the transected nerve and consists of direct, tension-free, suture coapta-
tion of nerve stumps. A detrimental factor to nerve regeneration is the occurrence 
of fibrosis in the gap, which may lead to neuroma formation thereby greatly reduc-
ing the chance of successful axonal regeneration. In such instances, the neuroma is 
resected and autologous nerve grafts are used as scaffolds to bridge the gap between 
the proximal and distal nerve stumps . 
 Functional recovery after peripheral nerve reconstruction is almost never complete, 
and a considerable degree of functional impairment usually remains. The clinical 
outcome of repair is especially limited in adults, in proximal nerve lesions such as 
brachial plexus lesions and when long nerve transplants have to be used 1. It is gener-
ally held that microsurgery has now reached an optimal technical refinement and new 
concepts have to be developed to further promote recovery of function after peripheral 
nerve repair 2. A new conceptual framework is currently emerging from a better un-
derstanding of the molecular basis of nerve regeneration and the application of novel 
intervention strategies, including viral vector mediated gene transfer. In this review, 
we first describe the pathophysiology of nerve injury. Then we discuss the molecular 
mechanisms involved in regeneration of the peripheral nerve, with a special emphasis 
on the role of neurotrophic factors and how they have been applied exogenously to 
enhance the results of nerve repair. Subsequently, we discuss the currently available 
non-viral and viral vectors for gene transfer and summarize their use in models for 
peripheral nerve repair so far. Finally we analyse both the strong points of the concept 
of gene therapy and the current limitations that have to be resolved before it can be 
applied in the clinic for peripheral nerve repair. 
The pathophysiology of nerve injury
Sunderland’s classification of nerve injuries in five degrees (based on the relative in-
tegrity of axons, endoneural tubes and epineurium and the formation of scar tissue) 
is the most commonly used today 1. MacKinnon added the term “sixth-degree injury, 
neuroma-in-continuity” 3, which is essentially a mixture of different degrees of injury 
within the same nerve. The neuroma-in-continuity is a surgically challenging problem, 
as it is difficult to clinically estimate the degree of injury and the corresponding poten-
tial for functional recovery 4. Mild lesions are characterized by spontaneous recovery, 
but this may take several months to become evident, especially in proximal nerve 
injuries such as the brachial plexus injury. Severe lesions require surgical reconstruc-
tion, but the outcome of surgery for these lesions is negatively affected by a prolonged 
waiting period 1. The current consensus is that surgical exploration is indicated when 
clinical examination does not show functional recovery of the associated muscles after 
an empirically defined waiting period 5. 
introduction
13
 It is generally accepted that fibrosis, the formation of a collagenous scar at the site 
of injury, is detrimental to functional recovery, although the molecular basis of this 
phenomenon is not fully understood 1,3,4. Myofibroblasts appear to proliferate at the 
site of nerve injury, producing collagen and thus contributing to scar formation 5. 
Fibroblasts also express the inhibitory proteoglycan NG2, which may play a part in 
blocking axon regeneration through scar tissue 6. 
Molecular mechanisms involved in peripheral nerve regeneration
Nerve regeneration starts within hours of axonal injury. Proximally, each axon sends 
out several sprouts. A growth cone at the tip of each sprout contains receptors for 
basal lamina components and neurotrophic factors 4. The regenerating axons are both 
physically guided to the appropriate targets by the basal lamina tubes and attracted by 
neurotrophic factors. If basal lamina tubes have ruptured, the chance for outgrowing 
axons to successfully re-establish contact with the appropriate end organs is greatly 
reduced 7. Successful regeneration requires more than just the outgrowth of axons 
into the distal stump. In any case, a number of elongating axons are inevitably lost due 
to malcoaptation, to suture line scarring and to discrepancies in the cross-sectional 
dimensions of the proximal and distal stump, respectively. In addition, misrouting of 
axons into functionally inappropriate endoneurial tubes results in either regenerated, 
but useless axons or dysfunctional phenomena such as synkinesia or dysesthesia 8. 
 Distal from the injured axon, Schwann cells distal from the site of transection change 
from their myelinating state into an activated nerve outgrowth-promoting state. These 
Schwann cells express a wide range of neurotrophic proteins including nerve growth 
factor (NGF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5) and brain-derived 
neurotrophic factor (BDNF), glial cell-line derived neurotrophic factor (GDNF, a 
member of the transforming growth factor superfamily) and ciliary neurotrophic 
factor (CNTF, a neuroactive cytokine) 9. Spinal motoneurons and different subtypes 
of sensory neurons in the dorsal root ganglion differ in their sensitivity for these neu-
rotrophic factors. Motoneurons express the neurotrophin receptor p75, the receptor 
for BDNF, tropomyosin receptor kinase (trk)B, and the multi-component receptor for 
GDNF composed of a common signal transduction subunit, ret and the GDNF family 
receptor (GFR)α 9. The dorsal root ganglion contains at least three subpopulations of 
sensory neurons, nociceptive, peptidergic neurons that express the receptor for NGF, 
trkA, proprioceptive neurons that express the receptor for NT3, trkC, and a population 
of neurons that are defined by their ability to bind to the Griffiona Simplicifolia isolectin 
B4, which express the receptors for GDNF, GFRα and ret 10. The function of the latter 
population of neurons is not entirely clear, but they appear to play a role in nociception 10.
 The initially elevated expression of neurotrophic factors by Schwann cells, and their 
corresponding capability to support regeneration decreases after a period of several 
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weeks to months 9. This contributes significantly to the lack of long distance regenera-
tion and poor functional recovery after proximal peripheral nerve lesions 11. Inter-
estingly, the expression of several of these factors is different in Schwann cells from 
sensory nerves and motor nerves and this differential expression improves regenera-
tion of motoneurons through motor nerve grafts compared to sensory grafts and vice 
versa 12. This demonstrates the profound and differential influence of neurotrophic 
factors on the regeneration of subpopulations of neurons (figure 1).
 Given their physiological role in regeneration and the apparent decrease of these 
factors over time, it is not surprising that neurotrophic factors have been applied 
experimentally in attempts to enhance functional recovery of the peripheral nerve. 
Unfortunately, their application has been hampered for a number of reasons. First, 
systemic or intraventricular administration of a neurotrophic factor can cause side 
Figure 1  Schematic representation of the spinal cord and the peripheral nerve, with moto-
neurons in the spinal cord and sensory neurons in the dorsal root ganglion projecting into the 
peripheral nerve. On the left, potential cellular targets for the application of gene therapy and 
their known sensitivity to various neurotrophic factors are shown. On the right, an overview 
is shown of the sites where nonviral and viral vectors have been applied and which cell types 
have been transduced. 
introduction
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effects 14 . A clinical trial with repeated local cutaneous injections of NGF to treat 
diabetic neuropathy was unsuccessful because pain at the site of injection made it 
impossible to reach the level of NGF required for neuroprotection 13. Second, neuro-
trophic factors penetrate poorly into nervous tissue. In brain parenchyma, for instance, 
they diffuse only 1 to 2 mm 14. Finally, neurotrophic factors have a short half-life and 
a tendency to degrade fast 15,16, necessitating repeated applications if the goal is to 
achieve a sustained effect on a time consuming process like regeneration 17.
 Perhaps due to these problems, the results of the experimental application of neu-
rotrophic factors to enhance regeneration in nerve repair models have not been over-
whelmingly positive. The addition of recombinant NGF or GDNF to fibrin sealant 
applied at the site of nerve repair leads to minor improvements in functional recovery 
tests, and only NGF increases the number of regenerated motoneurons 18. The ap-
plication of NT4 in a similar model led to modest, but significant improvements in 
functional recovery, axon numbers and myelination of axons 19. The application of 
NGF or NT3 through osmotic mini-pumps did not lead to long-lasting improvements 
of anatomical or functional recovery at 12 weeks post-lesion in a rat model for sciatic 
nerve transection 20. A combination of GDNF and BDNF applied at the site of repair 
through osmotic mini-pumps increased the number of regenerated motoneurons in 
a model of chronic axotomy 21, while the effect of BDNF alone appears to be either 
inhibitory or stimulatory, depending on the dose applied 22.
 In conclusion, the small and inconsistent effects previously found with exogenous 
neurotrophic factors may in part be related to the difficulties in the delivery of these 
factors. Here we will argue that a gene-therapy-based delivery strategy may resolve 
these problems.
 
Viral vectors: tools for local, sustained expression of therapeutic proteins
Gene therapy can be defined as the introduction of genetic material into living cells 
with the aim of treating a disease, and the inserted gene is referred to as a transgene. 
Cells can be genetically modified outside the body and then reimplanted (usually 
referred to as ex vivo gene therapy) or the genetic material can be applied directly to 
cells in the living organism (usually referred to as direct in vivo gene therapy).
 Compared to the local or systemic application of a protein, gene therapy has three 
main advantages: 1) Genes encoding any desired protein with therapeutic potential 
can in principle be introduced in the target cell; 2) Transduced cells will continuously 
express the therapeutic protein, effectively turning them into “biological mini-pumps”. 
This is especially useful for proteins that degrade quickly, such as neurotrophic fac-
tors; 3) Local expression of a transgene by transduced cells mimics the physiological 
situation as it results in locally elevated protein levels thereby in principle preventing 
unwanted effects on more distant cell populations. 
16
chapter 1
 There are several methods to insert genetic material into living cells, which can 
broadly be divided in non-viral and viral approaches. Transfection, which creates 
transient pores in the cell membrane to allow the uptake of DNA, is a common non-
viral method to insert genetic material to cultured cells ex vivo. For non-viral in vivo 
gene transfer to cells, DNA molecules can be linked to targeting antibodies 23.
Viral vectors are modified viruses that have retained the ability to insert foreign genetic 
material into cells, but are unable to replicate within the cell. Viral vector-mediated 
delivery of genetic material into cells is referred to as “transduction”. They contain 
an expression cassette containing a promoter, a gene of choice and other elements 
regulating expression. In the peripheral nerve, viral vectors can be used to either 
transduce Schwann cells distally from the transected nerve fibers (to induce expression 
of neurotrophic factors or extracellular matrix proteins) or to transduce neurons (to 
mediate expression of outgrowth-stimulatory proteins, survival factors or receptors 
for neurotrophic factors). Although viral vectors can be injected into the spinal cord 
to transduce neurons 24, for purposes of clinical applicability, vectors that are capable 
of retrograde transduction, i.e. after injection in the nerve, are more desirable. In 
the next section we will provide an overview of the experimental application of viral 
vectors in various models for peripheral nerve injury. Figure 1 provides a schematic 
representation of the peripheral nerve, highlighting the possible application sites and 
targets of viral vectors.
Different types of vector and their application in the peripheral nerve
Over the last 25 years, a range of viral vectors have been developed based on retrovirus, 
herpes simplex virus (HSV), adenovirus (AdV), adeno-associated virus (AAV) and 
lentivirus (LV). The characteristics of both non-viral vectors and most viral vectors 
have been studied in models for peripheral nerve regeneration. 
Non-viral gene transfer 
Experiments with Schwann cells that were genetically modified by ex vivo transfec-
tion showed that the overexpression of different isoforms of fibroblast growth factor-2 
(FGF-2) has differential effects on regeneration through synthetic nerve guides. 18-
kDa-FGF-2 appears to inhibit the myelination of regenerating axons, whereas 21-/23-
kDa-FGF-2 mediates the recovery of sensory function and long-distance myelination 
of regenerating axons 25,26. The effect of the overexpression of the different isoforms of 
FGF-2 was not compared to the autologous nerve graft.
Although these studies show significant effects of overexpression of FGF-2 on regener-
ation, the transfection protocol used requires the removal, culture and reimplantation 
of autologous Schwann cells in nerve guides and only leads to short term expression 
of the transgene.
introduction
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 Non-viral vectors have also been applied in vivo to the transected peripheral nerve. 
The injection of DNA encoding GDNF linked to an antibody that binds to the p75 re-
ceptor led to the retrograde transduction of motoneurons, expression of the transgene 
for at least 10 weeks and increased survival of axotomized motoneurons 23. An excit-
ing possibility of this approach is that in principle, specific neurons can be targeted 
with antibodies directed against specific neurotrophin receptors, but the number of 
transduced cells and the level of transgene expression with this method are relatively 
low compared to what is normally seen with the use of viral vectors.
Early retroviral vectors 
A retroviral vector based on the moloney murine leukaemia virus (MMLV) was the 
first viral vector for gene transfer 27. Retroviral vectors insert the gene of interest into 
the host genome and direct long term transgene expression. As it only infects dividing 
cells, this vector is less suitable for direct in vivo gene transfer to the nervous system, 
which mostly contains post-mitotic cells, but it is a reliable method to transduce cells 
ex vivo prior to implantation. This approach has been used to induce overexpression 
of NGF in fibroblasts prior to implantation in the brain of human Alzheimer’s disease 
patients 28. In the peripheral nerve, retroviral vectors have been applied in 2 studies 
to transduce Schwann cells ex vivo prior to being seeded in artificial nerve guides. 
Regeneration was significantly enhanced through nerve guides containing GDNF-
expressing Schwann cells compared to empty nerve guides, but similar to guides filled 
with naïve Schwann cells 28. Hence, the overexpression of GDNF had an added, al-
beit small, benefit in this specific model. In an approach aimed at stimulating nerve 
regeneration indirectly by influencing the migration of Schwann cells, a retroviral 
vector was used to transduce Schwann cells to express sialyl-transferase-X, a protein 
that enhances Schwann cell motility, prior to being seeded in silicone tubes. This led 
to significantly increased fiber diameter, myelin thickness and functional recovery 
compared to non-transduced SCs 29. 
 Both experiments described above show that ex vivo transduced Schwann cells en-
hance regeneration when compared to naïve Schwann cells in artificial nerve guides. 
Unfortunately, in both experiments regeneration through tubes with transduced 
Schwann cells was not compared to the surgical strategies currently in clinical use, 
e.g. direct coaptation of nerve ends or autologous nerve grafting. It will be essential to 
show a significantly improved regeneration compared to autologous nerve grafting in 
the future if artificial nerve guides containing modified Schwann cells are to become 
a clinically viable strategy.
Herpes Simplex viral vectors 
Among the first to be applied directly in vivo to the nervous system were viral vectors 
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based on the Herpes Simplex Virus (HSV), which was chosen for its innate neurotro-
pism, maintenance of life-long latency in neurons and its large cloning capacity 30,31. An 
interesting property of HSV-based vectors in the light of peripheral nerve regeneration 
is that they are capable of retrogradely transducing spinal motor and sensory neurons 
after injection in the rat or mouse sciatic nerve, leading to the expression of a reporter 
gene for up to 1 month 32. However, HSV vectors also have a number of limitations, 
including virus-associated toxicity 32. Furthermore, it has been notoriously difficult to 
produce HSV stocks that are of sufficient titer for in vivo use and are completely free 
of replication-competent helper virus 33. 
Adenoviral vectors 
AdV vectors are derived from adenovirus. They are relatively easy to produce and can 
transduce both dividing and non-dividing cells. Their most important limitation is 
that an immune response to transduced cell causes inflammation and tissue damage 
and limits the duration of transgene expression 32. The in vivo application of AdV 
vector to the peripheral nerve after a crush injury leads to high levels of transgene 
expression in a large number of Schwann cells 34, but disappears after approximately 2 
weeks. Such a short period of expression, however, may be enough in proof-of concept 
studies. An additional benefit of AdV is that it can be applied to transduce neurons 
either directly or retrogradely. The injection of AdV into the intact rat sciatic nerve 
led to the expression of the reporter gene in small-diameter neurons of the dorsal root 
ganglion 35. The local application of AdV leads to transduction of motoneurons in the 
nucleus ambiguous 36,37. AdV-mediated expression of GDNF in the laryngeal nerve 
after a crush injury led to improved functional recovery, an increase in the diameter 
of regenerated axons and promoted myelination 37. AdV-mediated overexpression of 
BDNF and GDNF had a neuroprotective effect in a model of vagal nerve avulsion 36. 
Treatment with adenovirus encoding GDNF, BDNF, or transforming growth factor 
beta2 significantly prevents the loss of facial motoneurons after avulsion, enhances 
choline acetyltransferase immunoreactivity and prevents the induction of nitric oxide 
synthase activity in these neurons 38.
Adeno-associated viral vectors 
Adeno-associated virus is a small virus that occurs naturally in humans and some pri-
mates. Vectors based on AAV have rapidly gained popularity, as they are non-toxic, do 
not elicit an immune response against transduced cells and direct long term transgene 
expression 39. In the AAV vector systems currently in use, all viral protein-encoding 
genes have been deleted and substituted with a transgene expression cassette. The 
AAV prototype, AAV2, preferentially infects neurons and is capable of transducing 
sensory neurons in the dorsal root ganglion 40 and motoneurons in the spinal cord 
introduction
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after direct injection 24. The AAV-mediated overexpression of BDNF and GDNF led to 
enhanced survival of motoneurons in a rat model for nerve root avulsion 24. Although 
there has been one report of the retrograde transduction of spinal motoneurons in 
mice with AAV2 42, it has been difficult to obtain similar results in larger mammals. 
Unfortunately, AAV2 does not transduce Schwann cells, but new AAV serotypes that 
are currently emerging have tropism for different cell types 39. AAV is the subject of 
several clinical trials for nervous system diseases including Alzheimer’s disease (www.
ceregene.com) and Parkinson’s disease 41. To our knowledge, no adverse effects of the 
in vivo application of AAV have been reported so far in these trials.
Lentiviral vectors 
The first lentiviral vector reported to stably transduce non-dividing cells in vivo was 
based on the human immunodeficiency virus 42. Recently, additional lentiviral vec-
tors have been developed, including a vector based on equine infectious anemia virus 
(EIAV). In general, lentiviral vectors have a favourable toxicity profile, infect divid-
ing and non-dividing cells and direct long term transgene expression in the nervous 
system 43. Lentiviral vectors insert the transgene into the host genome. Tropism for 
specific cell types depends on which vector capsid is used. Currently, the vesicular 
stomatitis virus G glycoprotein (VSV-G) is the envelope that is most commonly used to 
pseudotype LV as it infects a wide range of cells. Pseudotyping a lentiviral vector with 
Rabies G protein (RabG) makes it capable of transducing motoneurons retrogradely 
44. Overexpression of GDNF in motoneurons by a RabG coated EIAV vector enhances 
cell survival in a mouse model for amyotrophic lateral sclerosis 45. 
 In our laboratory, the direct in vivo injection of a VSV-G coated lentiviral vector in 
a peripheral nerve led to transgene expression by Schwann cells up to 16 weeks in a 
model for ventral root avulsion and reimplantation (Hendriks et al, in press). This is 
therefore an attractive vector for the long term delivery of neurotrophic factors in a 
model for peripheral nerve regeneration. Furthermore, the injection of a lentiviral vec-
tor into cultured segments of human sural nerve led to the transduction of large num-
bers of cells and the continuous production of biologically active NGF (Tannemaat 
et al, in press). In contrast to the transduction of Schwann cells in the rat peripheral 
nerve, we found that in the human nerve, predominantly fibroblasts outside nerve fas-
cicles were transduced (figure 2). This was likely the result of physical properties of the 
fascicles in the human nerve, which contains dense, highly myelinated fascicles. The 
flow of viral vector particles naturally follows a path of least resistance after injection, 
resulting in a buildup of vector particles in the loose tissue surrounding the fascicles. 
These differences between the transducibility of rat and human nerve tissue show the 
importance of performing experiments on human material as well as animal models. 
An appealing aspect of the LV-mediated transduction of nerve grafts is that it can be 
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performed without changing the routine practice of nerve grafting. Table 1 provides 
an overview of all methods of gene transfer described above, with the emphasis on 
those properties that are relevant for application in the peripheral nerve.
Future perspectives and conditions to be met for clinical application
Although viral vector mediated overexpression of neurotrophic factors has great ben-
efits as a novel method to investigate and perhaps improve the results of peripheral 
nerve repair, there are a number of technical and biological issues that have to been 
addressed before any clinical application can be considered. The sensitivity of the 
different neuronal subpopulations of the peripheral nerve to different neurotrophic 
factors 9 and recent research on the differential expression of several neurotrophic 
factors by Schwann cells of sensory and motor nerves 12 clearly show that there is 
an exciting possibility to specifically modify the regenerative response of different 
populations of neurons in the lesioned peripheral nerve with viral vectors. However, 
it must be shown unequivocally that the overexpression of neurotrophic factors has 
a beneficial effect on functional recovery in clinically relevant models for peripheral 
nerve lesions before clinical application can be considered. Other issues that need to be 
resolved can broadly be divided in three categories: potential problems with the viral 
vectors themselves, potential problems inherent to the overexpression of neurotrophic 
factors and issues related to the long term local production of these substances. These 
concerns will be discussed in more detail below.
Figure 2   Image of a cultured human sural nerve after injection of a lentiviral vector encod-
ing green fluorescent protein, showing numerous bright green cells expressing the transgene. 
Transduced cells are located within the epineurium, surrounding nerve fascicles (red), but 
no green cells are found within densely myelinated fascicles themselves. More details on this 
study can be found in Chapter 4.
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Potential issues related to viral vectors 
The two most promising vectors currently available are AAV and LV, which have highly 
favourable toxicity profiles. However, the applicability of AAV in peripheral nerve 
regeneration studies will be greatly improved with the development of serotypes that 
are capable of either retrogradely transducing neurons consistently in a rat model 46 
or effectively transducing Schwann cells. Although LV has the capacity to transduce 
Schwann cells, it has been argued that stable producer cell lines must be developed 
before lentiviral vectors can be used in a clinical setting 43.
Potential issues related to neurotrophic factors 
The second potential drawback of neurotrophic factors as therapeutic agents is that 
some of them, specifically NGF and BDNF, are important modulators of pain 10. NGF 
is upregulated in inflammatory conditions, and NGF-neutralizing molecules are effec-
tive analgesic agents in many models of persistent pain. It should be noted, however, 
that the autonomously elevated levels of NGF distal to the lesion site after a peripheral 
nerve lesion 9 do not lead to pain in patients suffering from peripheral nerve injuries 1. 
Table 1  Various properties of methods currently in use to genetically modify cells in the pe-
ripheral nervous system. *AAV2 has been reported to retrogradely transduce motoneurons 
in mice, but these results have so far not been replicated in larger mammals. ** Retrograde 
transduction of motoneurons has been reported with Rabies G protein coated lentiviral vector, 
but not with vesicular stomatitis virus glycoprotein coated lentiviral vector.
Non-viral methods Viral vectors
Trans-
fection
of a 
plasmid
Anti-
body-
linked 
DNA
Retro-
viral
Herpes 
Simplex 
Viral
Adeno-
viral
Adeno-
associ-
ated viral 
(sero-
type 2)
Lenti-
viral
Gene 
transfer
ex vivo + - + + + + +
in vivo - + - + + + +
Cell type neurons (direct) - + - + + + +
neurons (retrograde) - + - + - -/+* -/+**
Schwann cells (ex vivo) ? (ex vivo) - + - +
Transgene 
expression
short-term + + + + + + +
long-term - + + - - + +
Safety Immune response to 
transduced cells  
- - - + + - -
non-toxic vector + + + - - + +
clinical grade vector 
batches available
+ ? + - - + -
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An advantage of viral vector-mediated overexpression of NGF in this respect may 
be that the location, production and release of NGF closely mimic the physiological 
situation. After the clinical trial to treat diabetic neuropathy with recombinant NGF 
failed because of the local pain caused by injection of NGF in the skin, the principal 
investigator of that trial stated that these adverse side-effects could possibly have been 
prevented through the use of viral vector-mediated delivery of NGF 47. 
Potential issues related to long term local production 
A third possible problem with transduction of cells in the peripheral nerve, is the fact 
that neurite outgrowth appears to be the result of a gradient of neurotrophic factors, 
both in vitro 48 and in vivo 17,49. Regenerating neurites grow towards an increasing con-
centration of neurotrophic factor. Viral vector-mediated expression, however, results 
in elevated levels of neurotrophic factor confined to the area of transgene expression. 
Regenerating fibers will therefore grow towards, but not past an area of viral vector-
mediated overexpression, as this requires them to continue to regenerate against a 
negative gradient of neurotrophic factor. This phenomenon has been observed after 
viral-vector mediated overexpression of BDNF and GDNF in a model for root avul-
sion and has been described as the “candy store effect” 24. However, it may be possible 
to avoid this pitfall with the use of viral vectors in which transgene expression can be 
switched off after regenerating axons have entered the nerve repair site. Viral vectors 
in which transgene expression is regulated by a tetracycline have been developed 50. 
In cells transduced by these vectors, the production of the therapeutic protein can be 
switched on (or off) in vivo through the oral intake of doxycycline. In an animal model 
for Alzheimer’s disease this vector has been shown to effectively regulate local trans-
gene expression and neuronal rescue in the brain 51, and it has been shown recently 
that in a spinal cord lesion model, trapping of regenerating fibers could be avoided by 
transient local expression of neurotrophic factors with regulatable gene expression 52. 
However, issues regarding the potential immunogenicity of the tetracycline-controlled 
transactivator, which is of bacterial origin 50, will have to be resolved before clinical 
application can be considered.
Concluding Remarks
In recent years, the understanding of the important role that neurotrophic factors 
play in regeneration of the peripheral nerve has expanded significantly. Furthermore, 
proteomics 53 and micro-array based gene expression profiling techniques 54,55 now 
make it possible to investigate the molecular basis of both peripheral nerve injury and 
regeneration in even more detail. The discovery of novel factors, in particular axon 
guidance molecules, will be instrumental to investigate the role of these proteins in 
directing regenerating nerve fibers to the correct target cells. This is central to the 
introduction
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success of novel treatment strategies since misrouting of nerve fibers is a frequent 
problem in peripheral nerve repair 8. Combining the newly gained insights in the role 
of neurotrophic factors (and perhaps the discovery of novel axon guidance molecules) 
with viral vector-mediated gene delivery will allow future research to effectively study 
their role on peripheral nerve regeneration in vivo.
The safety and favourable toxicity profile of current viral vectors, specifically LV and 
AAV, makes them suitable for application in humans. For peripheral nerve research, 
this will make it easier to translate positive results obtained in the laboratory to clinical 
trials with human subjects. For these reasons, the use of viral vectors is a highly at-
tractive concept that holds great promise as a novel adjuvant therapy to microsurgical 
peripheral nerve reconstruction.
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Human neuroma contains increased levels of semaphorin 3A, which sur-
rounds nerve fibres and reduces neurite extension in vitro
Martijn R Tannemaat, Joanna A Korecka, Erich ME Ehlert, Matthew RJ Mason, Sjoerd G van Duinen, 
Gerard J Boer, Martijn J Malessy, Joost Verhaagen
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Abstract
Neuroma formation after peripheral nerve injury is detrimental to functional recovery 
and is therefore a significant clinical problem. The molecular basis for this phenom-
enon is not fully understood. Here we show that the expression of the chemorepulsive 
protein semaphorin 3A (sema3A), but not semaphorin 3F, is increased in human 
neuroma tissue that has formed in severe obstetric brachial plexus lesions. sema3A 
is produced by fibroblasts in the epineurial space and appears to be secreted into the 
extracellular matrix. It surrounds fascicles, mini-fascicles or single axons, suggesting 
a role in fasciculation and inhibition of neurite outgrowth. Lentiviral vector-mediated 
knockdown of Neuropilin 1, the receptor for sema3A, leads to increased neurite out-
growth of F11 cells cultured on neuroma tissue, but not of F11 cells cultured on normal 
nerve tissue. These findings demonstrate the putative inhibitory role of sema3A in 
human neuroma tissue. Our observations are the first demonstration of the expression 
of sema3A in human neural scar tissue and support a role for this protein in the inhibi-
tion of axonal regeneration in injured human peripheral nerves. These findings con-
tribute to the understanding of the outgrowth inhibitory properties of neuroma tissue.
Introduction 
Severe peripheral nerve lesions can cause life-long functional impairments. A typical 
example is the obstetric brachial plexus injury that occurs in 2-3 per 1000 births 56. 
Severe traction to the brachial plexus during birth induces the formation of intraneural 
scar tissue. This is known as neuroma-in-continuity 3, and constitutes an environment 
that inhibits nerve regeneration 1. Resection of the neuroma and bridging of the gap 
with autologous nerve grafts in order to connect proximal and distal nerve stumps 
usually results in some axonal regeneration, but functional recovery is never complete. 
Therefore, neuroma formation is a significant clinical problem.
 The molecular basis for the outgrowth-inhibitory properties of neuromas is not 
fully understood 1, but may be partly due to the excessive proliferation of fibroblasts 
which in turn produce inhibitory molecules 5,6. A number of molecules have now 
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been identified which are growth-inhibitory in the nervous system, e.g. Nogo, chon-
droitin sulphate proteoglycans and chemorepulsive axon guidance proteins 57. In the 
peripheral nerve neuroma, the secreted chemorepulsive axon guidance proteins sema-
phorins 3A (sema3A) and 3F (sema3F) may be of particular importance, for several 
reasons. First, their expression is upregulated in the rat sciatic nerve distal to a lesion 
58,59. Second, the receptor for sema3A, neuropilin 1 (npn1), is constitutively expressed 
in motoneurons and sensory neurons of the peripheral nerve 60,61 and adult sensory 
neurons remain sensitive to sema3A 62,63. Finally, in the developing brachial plexus, 
sema3A and sema3F coordinate the timing and fasciculation of motor axon growth 
and determine the dorso-ventral organisation of motor axon projections 64.
 We studied the expression of sema3A and sema3F in neuroma tissue from 9 obstet-
ric brachial plexus injury patients that was removed during reconstructive surgery. 
Tissue from the same nerve trunk proximal to the neuroma served as a control. A 
small segment of this proximal nerve stump is routinely harvested for intra-operative 
neuropathological assessment, as its quality influences surgical decision-making 65. 
The availability of this material provided us with the unique opportunity to compare, 
within a single nerve, two types of tissue with contrasting properties: the outgrowth-
inhibitory environment of the neuroma and the outgrowth-supporting environment 
in the stump proximal to the neuroma.
 Here we show that the expression of sema3A, but not sema3F, is induced in fibro-
blasts present in neuroma tissue of obstetric injuries to the upper brachial plexus. 
Sema3A is localized around fascicles or around individual axons and inhibits the 
outgrowth of neurites from a neuronal cell line cultured on slices of human neuroma 
tissue. This is the first demonstration of the expression of this chemorepulsive protein 
in human neural scar tissue and the results point to a role for sema3A in the inhibition 
of axonal regeneration in injured human peripheral nerves. 
Materials and Methods
Material
The average age of patients was 5 months (range 4 to 6 months). Nerve and neuroma 
material was harvested during reconstructive brachial plexus surgery, snap-frozen 
within 15 min after surgical removal and stored at -80ºC. All material used in this 
study was anonymised according to the proper use code of the Pathology Department 
of the Leiden University Medical Center (LUMC). Neuroma material consisted of the 
upper branches of the brachial plexus: spinal nerve C6 (n=2) or the superior trunk 
of the brachial plexus (n=7). The proximal nerve stump consisted of a segment of 
the spinal nerve C5 (n=7) or C6 (n=2). All material was diagnosed intraoperatively 
as neuroma or proximal nerve stump suitable for grafting according to previously 
described criteria 65.
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RNA isolation and qPCR
Tissue samples were homogenized in 3 ml Trizol (Life Technologies) per 100 mg 
using an ultra-turrax device. After phase separation by addition of chloroform, the 
aqueous phase was mixed with an equal volume of 70% ethanol, further purified with 
an RNeasy Mini column (Qiagen) and stored at -80˚C. The quality of the RNA was 
determined using a 2100 Bioanalyzer (Agilent). The average RNA integrity number 
was 8.2 (range 6.4-9.3). cDNA was synthesized from 150 ng RNA using Superscript II 
(Invitrogen). Real-time qPCR on sema3A and sema3F expression was performed with 
SYBR-green master mix (Applied Biosystems) on an ABI5700 (Applied Biosystems) 66. 
Expression levels were normalised using the geometric mean of the 3 reference genes 
B2M, YWHAZ and HMBS 67, which were selected from a total of 6 potential reference 
genes as being the most stably expressed genes in our samples. See supplemental table 
1 for a list of all primer sequences.
In situ hybridization 
A 590 basepair (bp) fragment ranging from bp 1726 to 2316 was cut from a plasmid 
containing the full-length human sema3A cDNA 68 with the restriction enzymes NcoI 
and HindIII and subcloned into pBluescript (Stratagene). This region was selected 
for the construction of riboprobe because of its limited homology to other secreted 
semaphorins. Digoxigenin-labeled sense and antisense cRNA probes were made as 
neuroma and nerve
Gene Forward primer Reverse primer
sema3A 5’-AGTCTGGTGAATAAATGGACAACATTC-3’ 5’-GACCTGGCACTGAGCAAATCA-3’
sema3F 5’-TTAAGTGGCTGTTCCAGCGA-3’ 5’-AAGCGGTCCTCTGCACGA-3’
B2M 5’-TGCTGTCTCCATGTTTGATGTATCT-3’ 5’-TCTCTGCTCCCCACCTCTAAGT-3’
HMBS 5’-GGCAATGCGGCTGCAA-3’ 5’-GGGTACCCACGCGAATCAC-3’
YWHAZ 5’-ACTTTTGGTACATTGTGGCTTCAA-3’ 5’-CCGCCAGGACAAACCAGTAT-3’
F11 cells
Gene Forward primer Reverse primer
npn1 5’-CTGTGCAAAACCAACAGACCTAGAT-3’ 5’-GTTCTTGTCGCCTTTCCCTTCT-3’
β-Actin 5’-GCTCCTCCTGAGCGCAAG-3’ 5’-CATCTGCTGGAAGGTGGACA-3’
GADPH 5’-TGCACCACCAACTGCTTAGC-3’ 5’-GGCATGGACTGTGGTCATGA-3’
Ef1α 5’-ACCCTCCACTTGGTCGTTTTG-3’ 5’-AGCTCCTGCAGCCTTCTTGTC-3’
Supplemental table 1  List of reference genes and their primer sequences used for quantitative 
PCR.
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described previously 68, but to increase binding specificity, alkaline hydrolysis of the 
probe was not performed, resulting in a probe length of 590 bp. In situ hybridisation 
was performed on 10 µm thick transverse cryostat sections as described previously 
69 with a probe concentration of 600 ng/ml and a hybridisation temperature of 67ºC. 
The specificity of the hybridisation signal was verified by comparison with the sections 
processed with sense probe under identical conditions.
Immunohistochemistry
Neuroma and proximal nerve stump samples were cut into transverse, 20 µm thick 
cryostat sections and fixed in 4% paraformaldehyde in 0.1 M sodium phosphate buf-
fer pH 7.4 for 20 min. Immunohistochemistry was performed 70 with the primary 
antibodies mouse anti-Neurofilament (1:1000, 2H3 ascites; Dev. Stud. Hybridoma 
Bank, Univ. of Iowa) to visualise neurites, rabbit anti-S100 to visualise Schwann cells 
(1:200, Dako) and rabbit anti-Fibronectin (1:100, Chemicon) to visualise fibroblasts. 
To visualise sema3A, N15 goat anti-sema3A (1:25, Santa Cruz), C17 goat anti-sema3A 
(1:25, Santa Cruz) and Q18 goat anti-sema3A (1:25, Santa Cruz) were used. These 
three sema3A antibodies bind to distinct epitopes in sema3A. N15 binds to an epitope 
that lies within a region corresponding to amino acids 25-75 of the human sema3A 
protein, C17 to a region corresponding to amino acids 721-771 and Q18 to an epit-
ope corresponding to a region between amino acids 675-725 (supplemental figure 1, 
information on epitopes from manufacturer).
 For neurofilament and S100/fibronectin, Donkey anti-Mouse-Cy3 and Donkey anti-
Rabbit-Cy3 were used as secondary antibodies respectively (1:400, Jackson Immu-
noReagents, Westgrove, USA). For N15, C17 and Q18, biotinylated anti-Goat antibody 
(1:800, Vector laboratories) was used followed by Streptavidin-Cy2 (1:800, Jackson 
ImmunoReagents). 
Short-hairpin-mediated knockdown of npn1 in a neuronal cell line
F11 cells are derived from a fusion of mouse embryonic neuroblastoma cells and rat 
dorsal root ganglion neurons 71. Neurite outgrowth in these cells can be induced by 
withdrawal of serum and the addition of forskolin to the culture medium. To knock 
down the expression of npn1 in F11 cells, they were transduced at a multiplicity of 
infection of 50 with a lentiviral (LV) vector expressing a short-hairpin (sh) RNA target-
ing the npn1 sequence CTTCAACCCACATTTCGAT under an H1 promoter 72 next 
to a CMV promoter driving the expression of Green Fluorescent Protein (GFP). As 
a control, F11 cells were transduced with an LV vector encoding an shRNA targeting 
the Arabidopsis sequence AGATCCTCTGTTCTCTCTC (which has no homology 
to mammalian genes). Knockdown of npn1 was determined with qPCR as described 
above using primers and reference genes listed in supplemental table 1. 
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Culture of F11 cells on neuroma sections and quantification of neurite outgrowth
2.5 x 104 F11 cells, transduced with either npn1 knockdown or control vector, were 
plated onto thawed 20 µm thick cryostat sections of freshly frozen nerve or neuroma 
from 5 patients in 500 µl Dulbecco’s modification of Eagle’s medium containing 0.5% 
fetal bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM Glutamax 
(Sigma) and 20 µg/ml forskolin. After 48 h, cells were fixed in 4% paraformaldehyde in 
Supplemental Figure 1  Antibody specificity. The anti-sema3A antibodies N15, C17 and Q18 
give a similar, punctate pattern of staining on adjacent sections. Western Blot on the lysate of 
cells transfected with a plasmid expressing myc-tagged sema3A (+), shows a single band at 
approximately 105kD with all 3 sema3A antibodies. The same band is also stained with the 
myc-antibody. No bands are visible in the lysate of untransfected cells (-). Arrowheads in de 
marker lane (m) indicate the 115 and 82 kD marker bands
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0.1 M sodium phosphate buffer and coverslipped. For each condition, three standard-
ized images of GFP positive F11 cells were randomly made using a Zeiss Axioplan 2 
microscope and an Evolution QEi digital camera (MediaCybernetics). A total number 
of 1599 cells and their neurites were manually outlined by an observer blinded to the 
treatment using Image-Pro Plus software (version 5.1, MediaCybernetics) and the 
total neurite outgrowth per cell was calculated. The values for npn1 knockdown or 
control cells were averaged for each nerve and neuroma (n=5 in four groups) before 
statistical analysis.
Statistical Analysis
All samples were tested for normality with a Shapiro-Wilk test. In cases where W 
>0.05, a paired two-tailed Student’s T-test was performed, in all other cases a Wilcoxon 
signed-rank test was performed. A p-value <0.05 was considered significant. 
Results
Neural architecture
Neurofilament staining showed a difference in the cellular architecture of the proximal 
nerve stump and the neuroma (figure 1a). In the proximal nerve stump, axons aligned 
tightly within fascicles and were oriented perpendicular to the transverse section. The 
neuroma usually had a much larger cross-sectional area (figure 1a, insets), in which 
axons could be identified in fascicles, mini-fascicles or as single axons. Fascicles were 
oriented in different directions in a chaotic pattern within the epineurium. 
qPCR
The expression levels of sema3A and sema3F as determined by qPCR and compared 
directly to the proximal nerve stump from the same patient showed a 1.8 fold higher 
level of sema3A in the neuroma tissue (p=0.008), whereas no difference was observed 
for sema3F (figure 1b). 
In situ hybridisation
In situ hybridisation was performed to determine the cell type that expresses sema3A 
in the neuroma. Hybridisation with the antisense sema3A probe resulted in strong 
staining of large epineurial and perineurial cells with a typical fibroblast-like morphol-
ogy surrounding fascicles (figures 2b and 2c) or mini-fascicles (figure 2e). Both the 
antisense and the sense probe revealed some staining of other structures, particularly 
of myelinated axons (figures 2a and 2b). This was considered to be background stain-
ing and not the result of specific binding to sema3A mRNA.
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Figure 1  Structure of the proximal nerve stump and neuroma from the human brachial plexus 
and the expression of semaphorin 3A and 3F. 
a) Neurofilament staining of cross-sections of the proximal nerve stump and the neuroma. In 
the nerve (left panel), compact fascicles contain high numbers of closely aligned nerve fibres. 
In the neuroma (right panel), nerve fibres are randomly oriented, grouped in either fascicles, 
mini-fascicles or as single fibres. Insets: Representative images of cross-sections of nerve and 
neuroma, showing that the neuroma is larger and more irregularly shaped than the nerve. 
Scale bar = 250 µm.
b) The average expression of sema3A as determined by qPCR is 1.8-fold higher in the neuroma 
than in the proximal nerve stump (p=0.008, Wilcoxon signed-rank test), whereas the expres-
sion of sema3F does not differ significantly. Bars indicate average +/- SEM for n=9.
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Immunohistochemistry
Sema3A could be visualized with the N15 antibody in some proximal nerve stumps 
(n=4), in which case it was almost always located in the epineurial space on the outer 
boundaries of the nerve (figure 3a) or in between fascicles. Very rarely, an area within 
a fascicle was weakly positive for sema3A (figure 3b). In contrast, sema3A staining 
could be seen in neuroma tissue from all 9 patients and the intensity of sema3A 
staining was much higher than in proximal nerve stumps. It was present in a typical 
punctate pattern in small, defined areas within the section, apparently secreted into 
the extracellular matrix. In some neuromas sema3A was also present more diffusely 
between nerve fascicles (figure 3c). Sema3A was observed in close proximity to mini-
fascicles (figures 3c, 3e and 3f) or single nerve fibres (figure 3d). Sema3A staining was 
not observed around all fascicles but appeared to be present around a subset of nerve 
bundles. When a mini-fascicle was cut transversely, sema3A staining often appeared 
to surround the axon bundles (figure 3f). 3-Dimensional reconstructions of z-stacked 
confocal images revealed an intimate relation between secreted sema3A and axons 
(supplemental movie 1). Highly similar and overlapping staining patterns in adjacent 
sections were obtained with all three antibodies. See the supplemental data for further 
details on sema3A antibody specificity.
 Immunohistochemistry for S100, neurofilament and sema3A (figure 2e) revealed 
S100 positive Schwann cells enveloping axons. No colocalisation of S100 and sema3A 
was observed (figure 2f). Immunohistochemistry for fibronectin and sema3A showed 
that sema3A was primarily present in fibronectin-rich areas associated with peri-
neurial fibroblasts (figure 2d), consistent with the expression of sema3A mRNA by 
fibroblast-like cells surrounding nerve fascicles (cf. figure 2). These observations dem-
onstrate that fibroblasts are the primary source of sema3A in the neuroma.
Figure 2  Extrafascicular fibroblasts are the primary source of sema3A.
a) In situ hybridisation with the sense probe shows some staining of myelin that is also seen 
with the antisense probe, but the intense staining of extrafascicular cells is not present. 
b), c) and e) Hybridisation with the antisense probe shows cells with a strong fibroblast-like 
morphology expressing sema3A. The highest expression levels are seen (b) surrounding fas-
cicles, (c) between fascicles and (e) surrounding mini-fascicles. 
d) Immune histology for fibronectin (red), sema3A (N15 antibody, green) and cell nuclei (blue): 
sema3A is present in fibronectin-rich areas between fascicles.
f) Immune histology for S100 (red), neurofilament (blue) and sema3A (green): S100-posi-
tive Schwann cells surround axons and do not colocalise with sema3A. The localisation of 
the sema3A protein closely resembles the staining of sema3A mRNA obtained with in situ 
hybridisation.
Arrows point at areas of sema3A expression, scale bar = 50 µm in all images.
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Neurite outgrowth assay
F11 cells plated on neuroma sections displayed significantly less outgrowth as compared 
to F11 cells plated on nerve sections ( 60 vs 83 µm, p<0.05; figure 4b). LV mediated ex-
pression of an shRNA targeting npn1 resulted in a knockdown of 77% of npn1 expres-
sion. Knockdown of npn1 did not affect neurite length of F11 cells grown on nerve sec-
tions (p=0.69). In contrast, on neuroma sections the total neurite outgrowth per cell was 
increased for cells with a knockdown of npn1 expression (101 vs 60 µm, p<0.01, figure 
4b). LV vector mediated knockdown of npn1 thus leads to increased neurite outgrowth 
of F11 cells when plated on neuroma tissue but not when plated on nerve tissue. This 
indicates that in the neuroma, sema3A has a chemorepulsive effect on growing neurites.
Discussion
It is widely accepted that neuroma formation at the site of a human peripheral nerve 
lesion is deleterious to functional recovery. Little is known, however, about the mo-
lecular basis for this phenomenon 1. In this study, we show for the first time that several 
months after the initial trauma the secreted chemorepulsive protein sema3A is present 
in human neuroma tissue.
 Sema3A is expressed by epineurial and perineurial fibroblasts but not by Schwann 
cells. Lesion-induced upregulation of class 3 semaphorins was first noted in meningeal 
fibroblasts that form the core of the neural scar after penetrating CNS injuries in a 
rat model 73,74. Sema3A is also induced in epineurial and perineurial fibroblasts distal 
to a rat peripheral nerve lesion 58. These observations suggest that the activation of 
fibroblasts at lesion sites in both the CNS and PNS results in enhanced expression of 
inhibitory proteins like sema3A.
 Sema3A protein appears to be secreted by fibroblasts and surrounds neurites and 
fascicles in a punctate pattern typical for extracellular matrix proteins 70,75. The close 
Figure 3  Immune histology for sema3A and neurofilament in the human proximal nerve 
stump and neuroma. sema3A (N15 antibody, green), neurofilament (2H3 antibody, red) and 
cell nuclei (Topro, blue) are visualized.
a) Proximal nerve stump: sema3A expression was usually low and limited to the epineurium 
surrounding a fascicle.
b) Proximal nerve stump: Rarely, a weak sema3A signal was observed within a fascicle.
c) Neuroma: sema3A is present in a diffuse pattern in the epineurial space in the neuroma, with 
the highest intensity of staining in the proximity of a mini-fascicle (arrowhead).
d) Neuroma: sema3A surrounding a single axon.
e) and f) Neuroma: sema3A surrounding a minifascicle. A 3-dimensional projection of a z-stack 
of Figure 2e is available online.
Arrows point at areas of sema3A expression, arrowhead points at mini-fascicle, scale bar = 20 
µm in all images.
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Figure 4  Neurite outgrowth of F11 cells is inhibited on neuroma sections in vitro. Knockdown 
of Npn1 increases neurite outgrowth on neuroma, but not on normal nerve tissue.
a) Left panel: F11 cells cultured on neuroma tissue for 48 hours. Most F11 cells extend at least 
one neurite. Right panel: cells (yellow lines) and neurites (blue lines) were manually outlined 
by an observer blinded to the treatment. Scale bar = 50 µm.
b) Quantification of outgrowth: Neurite outgrowth of wild type F11 cells is inhibited on neu-
roma tissue compared to control F11 cells on nerve tissue (*p<0.05, paired two-tailed Student’s 
t-test).  Knockdown of npn1 leads to an increase in neurite outgrowth per cell on neuroma 
tissue (**p<0.01, paired two-tailed Student’s t-test), but has no effect on the neurite outgrowth 
of F11 cells grown on normal nerve tissue.
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proximity of sema3A to axons and its neurite outgrowth-inhibitory effect on F11 
cells suggest that sema3A contributes to the fasciculation of regenerating neurites 
through a mechanism of “surround repulsion”, similar to what has been observed 
during development 64. Secreted sema3A binds to extracellular chondroitin sulphate 
proteoglycans (CSPGs) in vitro 70. CSPGs 76 and peripheral nerve-derived fibroblasts 6 
induce fasciculation in vitro. A possible interaction between secreted semaphorins and 
CSPGs may therefore stimulate fasciculation in the neuroma. 
 We propose that a severe traction injury to the brachial plexus causes a disruption 
of the normal architecture of the nerve and leads to proliferation and redistribution 
of fibroblasts from the epineurial and perineurial sheets within the nerve. During 
the process of neuroma formation sema3A is expressed by fibroblasts. In less severe 
nerve injuries, this may prevent regenerating axons from growing into epineurial tis-
sue and thus help guide them towards the distal endoneurial tubes. There, Schwann 
cells produce a wide range of neurotrophic factors 77, eventually leading to successful 
regeneration. The neuroma material used in this study, however, was obtained from 
patients without clinical signs of spontaneous functional recovery. This suggests that 
in these severe lesions, the proliferation of sema3A secreting fibroblasts contributes to 
an environment that is hostile to regenerating fibres and counteracts the outgrowth-
enhancing effects of the more distally located Schwann cells, leading to trapping of 
neurites within the fibrous scar. Recently a naturally occurring small molecule was 
discovered that antagonizes sema3A and promotes recovery of function in a rat model 
of spinal cord injury 78. Progress in creating an animal model for the peripheral nerve 
neuroma 79 will allow future studies on the effect of this compound on axonal regen-
eration through neuroma tissue. Such studies could lead to novel strategies that may 
be applied as an adjuvant therapy to peripheral nerve surgery.
Supplemental data Chapter 2
Supplemental methods: Western blot
Western blots were performed as described previously 80 of neuroma tissue extract 
and of cells transfected 48 h previously with a plasmid expressing myc-tagged sema3A 
70, with control lysate of untransfected cells. The three anti-sema3A antibodies N15, 
C17 and Q18 (1:25, Santa Cruz) and mouse anti-Myc (1:1000, Santa Cruz) served as 
primary antibodies. anti-Goat IrDye 800 (1:5000, Rockland) and Donkey anti-Mouse-
Cy5 (1:1000) were used as secondary antibodies. Blots were scanned and analysed 
using an Odyssey scanner and software (Li-COR Biosciences).
Supplemental results: Western blot
Western blotting showed that all three sema3A antibodies stained a single 105kD 
band in the lysate of cells transfected with myc-tagged sema3A, which colocalised 
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with a myc-stained band. No bands were visible in medium from untransfected cells 
(supplemental figure 1). No bands could be detected on Western blots from neuroma 
tissue homogenate (data not shown). This may have been caused by the relatively 
low abundance of sema3A in this tissue, as it is expressed in specific areas within the 
neuroma in only a subpopulation of cells.
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Gene expression profiling provides novel insights in the molecular basis of 
misrouting of axons through the neuroma in continuity in obstetrical brachial 
plexus injuries: a preliminary report
Martijn R Tannemaat, Koen Bossers, Sjoerd G van Duinen, Martijn J Malessy, Joost Verhaagen
Manuscript in preparation
Abstract
Obstetrical Brachial Plexus Injuries (OBPI) are caused by traction which only rarely 
results in a true rupture of nerve elements. The nerve lesion typically found during 
exploration is a neuroma in continuity. We performed and in-depth analysis of the 
molecular properties of the neuroma in continuity of 8 OBPI patients with no clinical 
signs of functional recovery, by combining genome-wide gene expression profiling 
with immunohistochemical staining.
 Immunohistochemical staining for neurofilament showed a reduced density and 
highly disorganised growth pattern of axons. Furthermore, axons were oriented in 
patterns that are highly suggestive for the presence of axonal guidance cues in the neu-
roma in continuity. Micro-array based gene expression analysis identified 722 genes 
that are differentially regulated in the neuroma compared to the proximal stumps. The 
Gene Ontology classes “extracellular matrix”, “cell adhesion” and “axon guidance” are 
significantly overrepresented in the list of regulated genes. A total of 18 genes with 
a previously documented role in axonal guidance were differentially regulated. Im-
munohistochemical staining for versican, one of the differentially regulated genes, 
showed that this proteoglycan is selectively expressed in the vicinity of regenerating 
axons. The results described in this paper lead to the conclusion that the human 
neuroma in continuity contains a considerable number of highly disorganised axons, 
that misrouting is a major contributing factor to the lack of functional recovery and 
that the regenerative paths of these axons appear to be influenced by a unique com-
bination of axon guidance cues that are differentially expressed by the glial cells of 
the peripheral nerve neuroma. These differentially expressed genes may govern the 
disturbed axonal regeneration process in neuroma tissue and can therefore form the 
starting point for the development of novel therapeutic intervention strategies aimed 
at promoting functional recovery following OBPI.
Introduction 
In contrast to neurons of the central nervous system, axotomised neurons of the 
peripheral nerve are capable of regeneration 81. However, the degree of functional 
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recovery depends on the severity of the lesion 1. When axons are severed, but the 
nerve fascicles remain intact (axonotmesis), the prognosis is generally good, whereas 
a disruption of the integrity of the entire nerve (neurotmesis) usually results in only 
limited functional recovery 4.
 Obstetrical Brachial Plexus Injuries (OBPI) are among the clinically most challeng-
ing nerve injuries. They occur in 2 to 3 per 1000 births and an estimated 10% of these 
do not recover spontaneously and completely 56. In these injuries, severe traction to 
the brachial plexus during birth rarely results in a true rupture of nerve elements. 
Instead, a neural scar (neuroma in continuity) is formed, which can be a mixture 
of both axonotmetic and neurotmetic injury types 3. As it is usually not possible to 
clinically determine the degree of injury of such lesions, the current approach is to 
await spontaneous recovery. At present, the consensus is that surgical exploration is 
indicated when clinical examination does not show functional recovery after a wait-
ing period of 3-9 months 82-84. However, the outcome of nerve surgery is negatively 
affected by a prolonged waiting period 1.
 Resection of the neuroma and bridging of the gap with autologous nerve grafts in 
order to connect proximal and distal nerve stumps usually results in axonal regenera-
tion. Nonetheless, even after reconstructive surgery, functional recovery of more distal 
targets such as the hand is never complete 85. Therefore, the neuroma in continuity is 
a significant clinical problem with serious consequences. 
Many outgrowth-inhibitory molecules have been discovered in the scar that forms 
after spinal cord injury (reviewed in 57). Much less is known about the biological 
mechanisms that lead to scar formation in the peripheral nerve and cause its inhibi-
tory effect on functional recovery. Fibrosis caused by activated fibroblasts has been 
described to be detrimental to functional recovery 1,5. Furthermore, the proteoglycan 
NG2 is present in human peripheral nerve scars and appears to block axon regenera-
tion through scar tissue 6. The expression of nerve growth factor (NGF) is upregulated 
in painful end-neuromas and may contribute to the pathogenesis of pain 86. Finally, we 
have recently shown that the chemorepulsive axon guidance molecule semaphorin 3A 
is expressed in the human neuroma in continuity and contributes to the outgrowth-
inhibitory microenvironment 87. 
 To investigate the molecular properties of the human neuroma in continuity, we per-
formed a genome-wide gene expression analysis of neuroma tissue that was removed 
during reconstructive surgery from 8 severe OBPI patients with no signs of spontane-
ous recovery of function. Proximal to the neuroma, the nerve has a morphology that 
closely resembles a normal unlesioned nerve. This proximal nerve stump is the source 
of nerve fibers growing into nerve transplants 65. A small segment of this proximal 
nerve stump is routinely harvested for intra-operative neuropathological assessment, 
as its quality influences surgical decision-making 65. By performing comparative gene 
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expression profiling on neuroma and proximal nerve tissue from the same patient, 
in combination with a gene ontology analysis, we identified a unique set of differen-
tially expressed genes that was enriched in genes involved in the modification of the 
extracellular matrix, cell adhesion and axonal guidance.
Materials and Methods
Patient Material
The average age of OBPI patients was 5 months (n=8; range 4 to 6 months; see table 
1 for additional patient details). Nerve and neuroma material was harvested during 
reconstructive brachial plexus surgery, snap-frozen within 15 min after surgical re-
moval and stored at -80ºC. All material used in this study was anonymised according 
to the proper use code of the Pathology Department of the Leiden University Medical 
Center (LUMC). Neuroma material was derived from the superior trunk of the bra-
chial plexus. The proximal nerve stump consisted of a segment of the spinal nerve C5 
(n=4) or C6 (n=4) (figure 1; table 1). All material was diagnosed intraoperatively as 
neuroma or high quality proximal nerve stump suitable for the application of a nerve 
graft according to previously described criteria 65.
Micro-array based gene expression analysis
RNA isolation and quality
Tissue dissection was performed by using a cryostat to cut 50 μm sections. A total of 
20-30 serial, transverse sections from neuroma and proximal nerve stump were col-
lected in pre-chilled 2 ml tubes and immediately put on dry ice. Tissue yields were 
typically around 50 mg. Total RNA was isolated using a combination of Trizol-based 
# Age (days) Nerve RIN* dye Neuroma RIN* dye
1 127 C5 8.9 Cy5 Superior trunk brachial plexus 8.0 Cy3
2 130 C5 7.9 Cy3 Superior trunk brachial plexus 7.8 Cy5
3 169 C6 7.5 Cy5 Superior trunk brachial plexus 8.6 Cy3
4 148 C5 9.3 Cy3 Superior trunk brachial plexus 9.1 Cy5
5 108 C6 8.7 Cy5 Superior trunk brachial plexus 8.6 Cy3
6 138 C6 7.4 Cy3 Superior trunk brachial plexus 8.3 Cy5
7 116 C5 7.2 Cy5 Superior trunk brachial plexus 7.8 Cy3
8 146 C6 7.2 Cy3 Superior trunk brachial plexus 7.5 Cy5
Table 1  Material used for micro-array based gene expression profiling. Table lists patient age in 
days (equals time post-injury), anatomical location of nerve and neuroma tissue, RNA quality 
and fluorescent dye used to label cRNA. *RIN: RNA Integrity Number.
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and RNeasy Mini Kit RNA isolation methods. Briefly, samples were homogenized 
in ice-cold Trizol (Life Technologies, Grand Island, New York, 3 ml Trizol per 100 
mg tissue) with an ultra-turrax (IKA-Labortechnik, Staufen, Germany). After phase 
separation by addition of chloroform, the aqueous phase was transferred to a new 
RNAse-free 1.5ml tube, and mixed with an equal volume of 70% RNAse-free ethanol. 
Samples were then applied to an RNeasy Mini column (Qiagen, Valencia, California), 
and processed according to the RNeasy Mini Protocol for RNA Cleanup (version 
june 2001, from Step 3). RNA yields and purity were determined using a NanoDrop 
ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, Delaware). RNA 
integrity was determined by the RNA Integrity Number (RIN) as measured by the 
Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, California). Overall, the 
isolated RNA was of high integrity, with an average RNA integrity number of 8.1 
(range 7.2-9.3).
Sample labeling and microarray hybridization
For microarray analysis, Agilent 44K Whole Human Genome arrays (Agilent Tech-
nologies) were used. Sample labeling and microarray hybridization and processing 
were performed according to manufacturer’s instructions. Briefly, per patient, 200 ng 
of RNA from both nerve and neuroma tissue were linearly amplified and alternatingly 
labeled with either Cy3-CTP or Cy5-CTP (Perkin Elmer) with the Agilent Low RNA 
C5
C6
C7
C8
T1
Figure 1  Schematic overview of the brachial plexus, location of the neuroma
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Input Fluorescent Linear Amplification Kit (Agilent Technologies, protocol version 
2.0, August 2003). Prior to hybridization, equal amounts (1 μg) of Cy3 and Cy5 la-
beled RNA were hydrolyzed for 30 min at 60°C in 1x fragmentation buffer (Agilent 
Technologies). The fragmented targets were hybridized to a microarray by incubat-
ing for 17 hours at 60°C in 1x target solution (Agilent Technologies) in a rotating 
hybridization chamber. After hybridization, the arrays were washed at RT for 5 min 
in 6xSSPE/0.005% N-Lauroylsarcosine (Sigma-Aldrich, St Louis, Missouri) and 1 min 
in 0.06xSSPE/0.005% N-Lauroylsarcosine. Finally, microarray slides were washed for 
30 seconds in acetonitrile (Sigma-Aldrich) and dried in a nitrogen flow. Microarrays 
were scanned using an Agilent DNA Microarray Scanner at 5 µm resolution and 
100% PMT setting. Microarray scans were quantified using Agilent feature extraction 
software (version 8.5.1). 
Gene expression analysis
Raw gene expression data generated by the feature extraction software were imported 
into the R statistical processing environment (http://www.r-project.org), and analyzed 
using the LIMMA package in Bioconductor (http://www.bioconductor.org). Intra-ar-
ray normalization was performed using the loess algorithm. For some genes or ex-
pressed sequence tags (EST), multiple probes were present on the array. In these cases, 
the relative expressions of all probes for this gene or EST were averaged to produce a 
single value resulting in a relative expression value of a total of 30,983 unique genes 
and ESTs. P-values for differential expression between nerve and neuroma were cor-
rected for multiple testing using the Bonferroni correction algorithm. Genes or ESTs 
with a corrected p-value < 0.05 were considered significantly regulated. 
Gene ontology overrepresentation analysis
Gene ontology classes (GO) 88 that were overrepresented in the final list of significantly 
regulated unique genes were identified with the TopGO analysis software package for R 
using the elim algorithm 89. This method improves the detection of biologically relevant 
classes by taking into account the underlying GO-graph topology. Approximately 56% 
of the unique genes and ESTs were GO-annotated. TopGO analysis was performed for 
the three top-level branches “biological process”, “cellular component” and “molecular 
function”, using all unique genes and ESTs as a background dataset. GO classes with 
a p-value < 0.01 were considered significant. For the three analyses described above, 
diagrams were plotted based on the 5 most significantly overrepresented GO-classes 
and their position in the gene ontology database. 
Analysis of differentially expressed genes
Following the calculation of expression levels and p-values for all genes on the array, 
and the unbiased GO analysis to identify significantly overrepresented GO-classes, 
the list of differentially expressed genes was further analysed in the following ways: 
(1) gene families of which multiple members were significantly regulated were identi-
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fied (2) a literature search was performed for individual genes of interest. In this last 
search, emphasis was placed on genes that are a member of significantly overrepre-
sented GO-classes, genes that are a member of a gene family with multiple regulated 
members and genes with a previously described or putative role in scar formation or 
modulation, peripheral nerve regeneration or axon guidance.
Immunohistochemistry
From 3 patients, all material was used for RNA isolation for microarray analysis. 
From the remaining patients, material, 20 µm thick transverse cryostat sections were 
collected from both nerve and neuroma tissue for immunohistochemistry. The fol-
lowing primary antibodies were used: mouse anti-neurofilament (1:1000, 2H3 ascites; 
Dev. Stud. Hybridoma Bank, Univ. of Iowa) and chicken anti neurofilament (1:100, 
Millipore, Billerica, USA ) to stain axons and mouse anti-versican (1:1, a gift from dr 
R. Asher) to stain versican. Wisteria floribunda agglutinin (WFA) histochemistry was 
performed by incubating sections in biotinylated WFA (20 µg/ml; Sigma, Zwijndrecht, 
The Netherlands). Immunostaining was performed as described previously 90. Briefly, 
sections were fixed in 4% paraformaldehyde in 0.1 M sodium phosphate buffer pH 
7.4 for 20 min, washed three times in 0.1 M Tris/HCl-buffered saline pH 7.4 (TBS), 
incubated in TBS containing 0.3% Triton X-100 and 5% fetal bovine serum (blocking 
buffer) for 1 h and in blocking buffer containing the primary antibody (and/or bio-
tinylated WFA) overnight at 4°C. The next day, sections were washed three times in 
TBS and incubated with blocking buffer containing Alexa594- or Alexa488-labelled 
secondary antibodies or streptavidin (Invitrogen, Carlsbad, USA) for 2 h. Finally, the 
sections were washed in TBS, mounted in Aquatex (Merck, Darmstadt, Germany) 
and coverslipped.
Results
Aberrant patterns of axonal growth in the peripheral nerve scar
A neurofilament staining of transverse sections revealed significant differences be-
tween the organisation of axons in the proximal nerve stump and in the neuroma 
(figure 1A). In the proximal nerve stump, the large majority of axons (>95%) are 
oriented perpendicular to the transverse section and axons are neatly aligned in well-
defined nerve fascicles (figure 2A). In contrast, most axons in the neuroma have lost 
their longitudinal orientation and several aberrant patterns of axon alignment can be 
distinguished. In general, the density of axons appears to be significantly lower than 
in sections of the proximal nerve stump. Most axons in the neuroma are oriented in 
different directions in a chaotic pattern (figure 2B). Single axons that appear to be 
isolated within the neuroma tissue are observed regularly, but the majority of axons 
are aligned in small “mini-fascicles” that contain several axons that appear to have 
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regenerated in the same direction. Commonly, the separation of a mini-fascicle into 
two smaller mini-fascicles, as well as the merging of two mini-fascicles into one larger 
fascicle was observed (figure 2CEF). These findings indicate that fasciculation (the 
tendency of regenerating axons to closely align in fascicles) and defasciculation occurs 
frequently in the neuroma. Occasionally, two axons enter a mini-fascicle and then 
continue their growth in opposite directions (figure 2D), while some axons appear to 
leave one mini-fascicle and join another mini-fascicle nearby (figure 2F). Finally, the 
regenerative trajectory of axons in the neuroma is not always straight and some axons 
appear to make 180 degree turns in their direction of outgrowth (figure 2G). In some 
sections of neuroma tissue, small areas were found in which axons had an orientation 
similar to the axons in nerve sections, e.g., perpendicular to the transverse section in 
an apparently normal fascicle (results not shown). These areas appeared to represent 
nerve fascicles that were relatively spared by the initial trauma.
 In conclusion, the anatomical observations described above indicate that the regen-
erative path of axons in a neuroma is disorganized as a result of an aberrant pattern 
of growth involving frequent fasciculation, defasciculation and turning events.
Gene expression analysis
To identify differences in gene expression between neuroma and the proximal nerve 
stump, we performed a genome-wide micro array analysis to compare the transcrip-
tome of these 2 types of tissue in 8 individual patients. The expression of 722 unique 
genes differed significantly in neuroma tissue compared to nerve tissue (346 genes 
up- and 376 genes downregulated). Supplemental table 1 provides a complete list of 
all significantly regulated genes. This list of significantly regulated genes was then 
analysed in 3 ways: 1) a GO overrepresentation analysis was performed, 2) the list 
was analysed for gene families of which multiple members were significantly regulated 
and 3) the list was searched for individual genes with a known or putative effect on 
scar formation/modulation, axon guidance, fasciculation and/or peripheral nerve 
regeneration.
Gene ontology analysis 
For functional data mining, the list of significantly regulated genes was subjected to 
GO analysis using the TopGO elim method. A GO-class is overrepresented if more 
genes in this class are differentially expressed in neuroma tissue than can be expected 
by chance. With a cut-off of p<0.01, a total of 36 GO-classes were significantly over-
represented in the top-level branch “biological process”, 9 in the branch “cellular com-
ponent” and 20 in the branch “biological process”. A list of all significantly overrepre-
sented GO-classes is presented in table 2. The five most significantly overrepresented 
classes in each top-level branch are listed below.
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 For the top-level branch “biological process” the most significantly overrepresented 
classes were: “cell adhesion” (GO:0007155, 51 genes), “axon guidance” (GO:0007411, 
13 genes), “phosphate transport” (GO:0006817, 12 genes), “detection of calcium ion” 
(GO:0005513, 4 genes) and “cholesterol biosynthetic process” (GO:0006695, 6 genes).
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 For the “cellular component” branch, the most significantly regulated class was 
“extracellular matrix” (GO:0005578, 30 genes), followed by “axon” (GO:0030424, 8 
genes), “guanylate cyclase complex, soluble” (GO:0008074, 3 genes), “integral to mem-
brane” (GO:0016021, 164 genes) and “extracellular space” (GO:0005615, 29 genes).
In the “molecular function” branch, the five most regulated GO classes were “neu-
rotrophin binding” (GO:0043121, 3 genes), “calcium ion binding” (GO:0005509, 46 
genes), “growth factor activity” (GO:0008083, 14 genes), “transmembrane receptor 
protein tyrosine kinase activity” (GO:0004714, 9 genes) and “serine-type endopepti-
dase activity” (GO:0004252, 13 genes). A graphic representation of the 5 classes listed 
above and their position within the hierarchical GO tree of each top level branch can 
be found in figures 3, 4 and 5 (“biological process”, “cellular component” and “mo-
lecular function”, respectively). 
Differentially expressed gene families
The list of differentially expressed genes was then searched for gene families of which 
several members were differentially expressed. Supplemental table 2 contains a list of 
all gene families of which at least two members were differentially regulated in neu-
roma tissue. Here, we will distinguish families that were predominantly upregulated, 
predominantly downregulated or families of which the members were both down- and 
upregulated. 
 Six gene families of which multiple genes were differentially expressed were predom-
inantly upregulated: collagens, spondins/thrombospondins, CSPGs, SLRPs, kallikreins 
and the WNT family. In two gene families of which several genes were differentially 
Figure 2  Axons in the peripheral nerve scar are disorganized, but appear to be subject to 
specific guidance cues in the extracellular matrix surrounding them.
a) Transverse section of proximal nerve stump that were stained with anti-Neurofilament to 
identify axons and imaged with a confocal laser scanning microscope. All axons are aligned 
perpendicular to the section within well organized fascicles.
b) Axons in a neuroma are disorganized and are oriented in different directions. They often 
appear to grow in “mini-fascicles” containing several axons.
c) Two mini-fascicles merging (or diverging, as the direction of outgrowth could not be deter-
mined on transverse sections), suggesting that they are sensitive to fasciculation/defascicula-
tion cues.
d) Higher magnification of the boxed area in (c) shows two axons entering a mini-fascicle and 
continuing to grow in opposite directions, indicating that they are sensitive to attractive cues 
present in the mini-fascicle. Two mini-fascicles diverge (e) and axons cross from one mini-
fascicle to another (f) 
g) An axon exits a mini-fascicle, makes a 180 degree turn and enters another mini-fascicle, 
pointing to the presence of repulsive guidance in the extracellular matrix.
Scale bar ABC: 50 µm, EFG: 50 µm.
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GO.ID Description An-
notated 
genes
Signi-
ficant 
genes
P-value
Biological process
GO:0007155 cell adhesion 798 51 1,60E-06
GO:0007411 axon guidance 79 13 8,20E-06
GO:0006817 phosphate transport 109 12 7,40E-05
GO:0005513 detection of calcium ion 10 4 0,00013
GO:0006695 cholesterol biosynthetic process 30 6 0,00019
GO:0006508 proteolysis 748 39 0,00028
GO:0050770 regulation of axonogenesis 33 6 0,00033
GO:0007501 mesodermal cell fate specification 2 2 0,00084
GO:0000187 activation of MAPK activity 56 7 0,00111
GO:0046928 regulation of neurotransmitter secretion 8 3 0,00121
GO:0007263 nitric oxide mediated signal transduction 9 3 0,00178
GO:0019229 regulation of vasoconstriction 9 3 0,00178
GO:0048169 regulation of long-term neuronal synaptic plasticity 9 3 0,00178
GO:0006516 glycoprotein catabolic process 19 4 0,00191
GO:0007610 behavior 338 20 0,00207
GO:0001508 regulation of action potential 47 6 0,00224
GO:0008038 neuron recognition 20 4 0,00233
GO:0007417 central nervous system development 248 16 0,00241
GO:0001747 eye development (sensu Mammalia) 50 6 0,00309
GO:0042063 gliogenesis 35 5 0,00316
GO:0019228 generation of action potential 4 2 0,00483
GO:0048812 neurite morphogenesis 157 21 0,00516
GO:0007169 transmembrane receptor protein tyrosine kinase 
 signaling pathway
222 14 0,00536
GO:0050769 positive regulation of neurogenesis 25 4 0,00542
GO:0006182 cGMP biosynthetic process 13 3 0,00556
GO:0009612 response to mechanical stimulus 13 3 0,00556
GO:0030198 extracellular matrix organization and biogenesis 57 6 0,00595
GO:0007422 peripheral nervous system development 26 4 0,00627
GO:0006690 icosanoid metabolic process 41 5 0,00633
GO:0007399 nervous system development 802 55 0,00751
GO:0008045 motor axon guidance 5 2 0,0079
GO:0048598 embryonic morphogenesis 142 10 0,00836
GO:0042490 mechanoreceptor differentiation 15 3 0,00848
GO:0016337 cell-cell adhesion 284 16 0,00879
GO:0045597 positive regulation of cell differentiation 45 5 0,0094
GO:0006928 cell motility 452 32 0,00976
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Table 2  List of the most significantly regulated GO-classes with p<0.01 for the three top-level 
branches “biological process”, cellular component and “molecular function”.
GO.ID Description An-
notated 
genes
Signi-
ficant 
genes
P-value
Cellular component
GO:0005578 extracellular matrix (sensu Metazoa) 337 30 2,20E-06
GO:0030424 axon 47 8 5,10E-05
GO:0008074 guanylate cyclase complex, soluble 4 3 9,20E-05
GO:0016021 integral to membrane 4503 164 0,00014
GO:0005615 extracellular space 540 29 0,00092
GO:0005581 collagen 51 6 0,00325
GO:0043005 neuron projection 87 13 0,0051
GO:0008021 synaptic vesicle 61 6 0,0079
GO:0005856 cytoskeleton 1060 44 0,00846
Molecular function
GO:0043121 neurotrophin binding 4 3 9,50E-05
GO:0005509 calcium ion binding 955 46 0,00049
GO:0008083 growth factor activity 176 14 0,00063
GO:0004714 transmembrane receptor protein tyrosine kinase activity 85 9 0,00079
GO:0004252 serine-type endopeptidase activity 160 13 0,00079
GO:0003851 2-hydroxyacylsphingosine 1-beta-galactosyltransferase 
activity
2 2 0,00084
GO:0008489 lactosylceramide synthase activity 2 2 0,00084
GO:0030246 carbohydrate binding 294 18 0,00241
GO:0004938 alpha2-adrenergic receptor activity 3 2 0,00247
GO:0004274 dipeptidyl-peptidase IV activity 10 3 0,0025
GO:0004383 guanylate cyclase activity 10 3 0,0025
GO:0005267 potassium channel activity 140 11 0,00256
GO:0004800 thyroxine 5’-deiodinase activity 4 2 0,00485
GO:0008260 3-oxoacid CoA-transferase activity 4 2 0,00485
GO:0004222 metalloendopeptidase activity 117 9 0,00701
GO:0030551 cyclic nucleotide binding 27 4 0,00722
GO:0004067 asparaginase activity 5 2 0,00792
GO:0004499 dimethylaniline monooxygenase (N-oxide-forming) 
activity
5 2 0,00792
GO:0004181 metallocarboxypeptidase activity 29 4 0,00934
GO:0005201 extracellular matrix structural constituent 123 9 0,00961
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Figure 3  Graphic representation of the 5 most significantly overrepresented GO-classes in the 
“Biological Process” branch and their position in the GO hierarchy (see table 2 for details on 
the most significant classes). 
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regulated, the level of expression was generally lower in neuroma tissue: tetraspanins 
and cadherins. Finally, there were several families of which some genes were up- and 
others downregulated. These families include the IgG superfamily of cell adhesion 
molecules, contactins (which are a subgroup of the IgG superfamily), matrix metal-
lopeptidases and the tyrosine kinase neurotrophin receptors.
Differentially expressed genes with a role in scar formation and modulation
 As the GO classes “cell adhesion” and “extracellular matrix” were significantly over-
represented and several members of the collagen, small leucine-rich repeat protein and 
proteoglycan (SLRP) and chondroitin sulphate proteoglycans (CSPG) gene families 
were predominantly upregulated, we searched the list of 722 differentially regulated 
genes for individual genes that may affect extracellular matrix (ECM) formation and 
modulation. These genes can be broadly divided in genes encoding structural ECM 
components and genes encoding proteins involved in the modulation of the ECM.
In general, the expression of structural ECM components appeared to be upregulated: 
the collagen family members COL11A1, COL12A1, COL5A2 and COL5A2 were up-
Figure 4  Graphic representation of the 5 most significantly overrepresented GO-classes in the 
“cellular component” branch and their position in the GO hierarchy (see table 2 for details on 
the most significant classes). 
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regulated, whereas COL8A2 was downregulated. Collagen formation, or fibrosis, has 
previously been shown to occur in the peripheral nerve neuroma and has been sug-
gested to impede regeneration 1,5. The expression of the structural component CSPG2 
(versican) was also upregulated. CSPGs are chemorepulsive constituents of central 
nervous system scars 58,88. Furthermore, they have also been implicated in peripheral 
regeneration 91. SLRPs are extracellular matrix molecules involved in the regulation 
of the assembly of fibrillar collagens and modulation of cell adhesion 92 The SLRPs 
BGN (biglycan), KERA (keratocan) OGN (osteoglycin) and ASPN (asporin) were all 
upregulated.
 In addition, several individual genes encoding proteins involved in ECM modula-
tion are differentially regulated. TGFB3 (transforming growth factor beta-3), which 
stimulates collagen production by fibroblasts of the peripheral nerve 93 was upregulat-
ed. ADAM12 (ADAM metallopeptidase domain 12), which regulates cell-extracellular 
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Figure 5  Graphic representation of the 5 most significantly overrepresented GO-classes in 
the “molecular function” branch and their position in the GO hierarchy (see table 2 for details 
on the most significant classes). Transmembr. recep. protein tyrosine kin.: transmembrane 
receptor protein tyrosine kinase.
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matrix interactions 94 and contributes to TGF-beta signaling 95 was also upregulated. 
POSTN (periostin) was strongly upregulated. POSTN is expressed in peripheral nerves 
96 and is necessary for the cross-linking of collagen 1, thereby mediating the biome-
chanical properties of fibrous connective tissue 97. LOXL-2 (lysyl oxidase-like 2) is 
required for the deposition of collagen by hepatocytes and was upregulated 98. MMP16 
(matrix metallopeptidase 16), a collagenolytic enzyme 99 that mediates cell migration 
98 was upregulated and MMP28 (matrix metallopeptidase 28), which modulates the 
axonal-glial extracellular microenvironment 100 was downregulated. 
Differentially expressed genes with a role in axon guidance and/or regeneration
Immunohistochemistry revealed that the neuroma contained regenerating axons and 
the distinct patterns of axonal outgrowth suggest that they are subject to guidance cues 
that are expressed in the neuroma. Furthermore, “axon guidance” was the second-
most significantly overrepresented GO-class in the “biological process” branch. We 
therefore searched for individual differentially expressed genes with a putative effect 
on axonal regeneration. Not all genes in the “axon guidance” class have a well defined 
role in the guidance of developing or regenerating peripheral nerve axons. Conversely, 
a literature search revealed additional differentially expressed genes that influence 
axon guidance that were not part of this particular GO-class. A combination of the 
relevant members of the “axon guidance” GO-class and a literature search resulted in 
a total of 18 genes (7 of which are members of the “axon guidance” GO-class) with a 
putative effect on peripheral nerve regeneration or axon guidance (table 3). Of these 
genes, 10 have been described as genes encoding genuine chemorepulsive proteins, 3 
as chemoattractive and 1 as both chemorepulsive and -attractive. Furthermore, 6 of 
these genes play a role in the fasciculation or defasciculation of developing axons and 
1 gene influences the interaction of regenerating axons with the surrounding glia.
 The expression of 8 of a total of 10 chemorepulsive proteins or receptors involved 
in chemorepulive signaling was upregulated: BOC (boc homolog) 101, CSPG2 (versi-
can) 88, 101, EPHB2 (EPH receptor B2, transcript variant 2) 102, ROBO1 (roundabout, 
axon guidance receptor, homolog 1) 102, SEMA5B (semaphorin 5B) 103,104, TNN (te-
nascin-N) 105, SLITRK 6 (SLIT and NTRK-like family, member 6) 106 and WNT5A 
(wingless-type MMTV integration site family, member 5A) 105. 
 The expression of two chemorepulsive proteins was downregulated: BMP7 (bone 
morphogenetic protein 7) 106 and MT3 (metallothionein 3) 107.
 The expression of all three chemoattractive proteins, CDH4 (cadherin 4) 107 , NTF3 
(neurotrophin 3) 108 and NRCAM (neuronal cell adhesion molecule) 109 was down-
regulated. 
 SPON1 (spondin 1) has been described both as chemorepulsive and as an outgrowth 
promoting protein. Spondin-1 is chemorepulsive to motor axons 110, but promotes 
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regeneration of peripheral sensory neurons 111. It was expressed significantly higher 
in the neuroma. 
 Of the 6 genes that have been described to affect fasciculation or defasciculation, the 
expression of 4 was upregulated: CSPG2 (versican) 76, POSTN (periostin, osteoblast 
specific factor) which is structurally similar to the Drosophila Fasciclin 96, ROBO1 102, 
and WNT5A 105. The expression of FEZ1 (fasciculation and elongation zeta 1/ zygin I), 
which induces fasciculation and elongation of developing neurons in C. elegans 112 
was downregulated. The expression of the defasciculation-inducing gene TLL1 (tol-
loid-like 1) 113, was upregulated.
 Finally, the expression of MMP-28, which is detectable along regenerating nerves be-
fore myelination during development and peripheral nerve regeneration, and is likely 
to modulate the axonal-glial extracellular microenvironment 100, was downregulated 
in the neuroma.
The extracellular matrix protein versican surrounds a number of mini-fascicles in 
the neuroma
The expression of the CSPG versican was significantly higher in the neuroma. Interest-
ingly, the enzymatic degradation of CSPGs enhances peripheral nerve regeneration 
across nerve gaps 91. Therefore, we performed an immunohistochemical staining to 
determine its location. No versican staining was detected in any of the nerve samples, 
but in neuroma sections it was present around a relatively small subset (<5%) of mini-
fascicles (figure 6). Versican is one of many CSPGs (e.g., aggrecan, neurocan, brevican, 
and phosphacan) 114 and the expression of none of these other CSPGs was significantly 
up- or downregulated in the neuroma. We therefore also performed a WFA staining 
on nerve and neuroma sections as a general marker for CSPGs. Strong WFA binding 
was present around virtually all axons in both nerve and neuroma sections (figure 6), 
indicating that CSPGs are indeed present in both nerve and neuroma tissue, but only 
versican is differentially expressed.
Discussion
We performed a genome-wide gene expression analysis of the superior trunk neuroma 
in continuity of OBPI infants and combined these data with immunohistochemical 
staining of axons to perform an in-depth analysis of the molecular characteristics 
of these lesions. In the absence of clinical signs of functional recovery, the neuroma 
contained a considerable number of regenerating axons. However, the density of axons 
appeared reduced and axonal routing was severely disturbed. At a molecular level, we 
identified a unique combination of differentially expressed genes that influence scar 
formation and axon guidance. Finally, versican, one of the differentially expressed che-
morepulsive proteins, was selectively expressed in the vicinity of regenerating axons. 
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The genes described in this paper may govern the disturbed axonal regeneration pro-
cess in neuroma tissue and can therefore form the starting point for the development of 
novel therapeutic intervention strategies aimed at promoting axonal regeneration.
Figure 6  Confocal laser scanning microscopy of nerve and neuroma sections stained with 
anti-versican (green), Wisteria floribunda agglutinin (WFA, green), anti-neurofilament (red) 
and topro (cell nuclei, blue). Versican is not detectable in the proximal nerve, but is specifically 
expressed in the vicinity of a small subset of mini-fascicles in the neuroma. In contrast, strong 
WFA binding, indicative of the presence of Chondroitin Sulphate Proteoglycans, surrounds 
virtually all axons in both nerve and neuroma tissue.
Scale bar: 20 µm.
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The disorganisation of axons in the neuroma: a negative effect on functional 
recovery?
The neuroma-in-continuity is generally considered to be an impediment to functional 
recovery 1,3. The present paper shows that it contains a considerable number of axons, 
although the density of axons appears to be lower than in the spinal nerve proximal to 
the lesion. The chaotic orientation of the majority of axons implies that the guidance 
that is normally provided by endoneurial tubes in intact nerve fascicles 8 is lost. The 
high degree of disorganisation of regenerating axons implies that many of these are ei-
ther trapped within the neuroma or are not present in their original distal endoneurial 
tubes, which leads to the reinnervation of inappropriate target organs. The misrouting 
of regenerating axons is a strong contributing factor to the lack of functional recovery 
in severe peripheral nerve injuries 8,115,116. In conclusion, our findings imply that the 
misrouting of regenerating axons in the neuroma in continuity is an important factor 
in the lack of functional recovery.
Formation and remodelling of the extracellular matrix in the neuroma
The current gene expression profile provides several indications that the neuroma is a 
highly dynamic environment. Firstly, gene ontology analysis shows that the GO-classes 
“cell adhesion” and “extracellular matrix” are the most significantly overrepresented 
GO-classes in the “biological process” and “cellular component” branches, respec-
tively. In general, the expression of structural ECM components (including collagen, 
SLRPs and versican) is upregulated. In addition, genes that promote collagen forma-
tion (TGFB3, ADAM12), are required for collagen deposition (LOXL2) or mediate 
collagen cross linking (POSTN) are also upregulated. Fibrosis has been shown before 
to be present in the peripheral nerve neuroma 1,6, but the present findings are the first 
to demonstrate the coordinated expression of a number of genes involved in collagen 
formation in neuroma tissue. Apparently, the formation and consolidation of the fi-
brotic scar is a process that continues up to 5 months after injury. Interestingly, several 
genes that influence the interaction between the ECM and regenerating axons are 
also differentially expressed. MMP16, a collagenolytic enzyme 99 was upregulated and 
could therefore aid the regeneration of axons across fibrous tissue. MMP28 displays 
proteolytic activity against myelin components and its expression is negatively cor-
related with the myelination of regenerating neurons. 100. The expression of MMP28 
was diminished in neuroma tissue and this may be necessary to allow remyelination 
of regenerating axons, but it could also result in inefficient breakdown of myelin com-
ponents in the neuroma, thereby impairing regeneration.
Axon guidance molecules are differentially regulated in the neuroma
The observed chaotic pattern of axons in the neuroma suggests that many axons are 
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Table 3  Differentially regulated genes in human neuroma tissue with a potential role on axon 
guidance. Expression: relative expression as a percentage of nerve control tissue (>100% indi-
cates upregulation in the neuroma, <100% indicates downregulation). P-values for differential 
expression between nerve and neuroma were corrected for multiple testing using the Bonferro-
ni correction algorithm. *Chondroitin sulphate proteglycans induce fasciculation, not versican 
specifically. ** Inhibition of neurite outgrowth is mediated by some splice variants of TNN.
Gene Description Expres-
sion %
Function Species
BMP7 bone morphogenetic 
protein 7
62 repulsive dorsoventral guidance of commissural 
axons 108
mouse
BOC boc homolog 316 dorsoventral guidance of commissural axons 99 mouse
CDH4 cadherin 4 66 promotes pioneer axon outgrowth 122 mouse
CSPG2 versican 207 scar-associated inhibitor CNS injury 87 rat
scar-associated inhibitor spinal cord injury 100 rat
   induces fasciculation 75* in vitro
EPHB2 EPH receptor B2,  
transcript variant 2
211 chemorepulsive, required for axon pathfinding 101 mouse
FEZ1 fasciculation and elonga-
tion zeta 1/ zygin I
70 fasciculation and elongation of developing 
neurons 114
C. elegans
   establishment of polarity in hippocampal  
neurons 123
rat
MMP28 matrix metallopeptidase 
28
61 modulates axonal-glial extracellular microenvi-
ronment 98
rat, mouse, 
frog
MT3 metallothionein 3 31 inhibits regeneration of the peripheral nerve 109 mouse
NTF3 neurotrophin 3 48 chemoattractive proprioceptive axon guidance 110 in vitro
NRCAM neuronal cell adhesion 
molecule
45 promotes axon extension, pathfinding of RGC 
axons 111
in vitro
POSTN periostin, osteoblast 
specific factor
257 structurally similar to Drosophila Fasciclin-1 93 drosophila
   regulates collagen I fibrillogenesis 94 mouse
ROBO1 roundabout, axon guid-
ance receptor, homolog 1
191 chemorepulsive, restricts defasciculation of optic 
tract neurons 102
zebrafish
SEMA5B semaphorin 5B 220 induces growth-cone collapse 104 in vitro
SLITRK 6 SLIT and NTRK-like 
family, member 6
768 inhibits neurite outgrowth 106 in vitro
SPON1 spondin 1 314 repulsive to developing motor axons 112 in vitro
   promotes regeneration of peripheral sensory 
neurons 113
rat
TNN tenascin-N 305 inhibits neurite outgrowth of hippocampal 
neurons 105**
in vitro
TLL1 tolloid-like 1 175 controls defasciculation of developing motoneu-
rons 105
drosophila
WNT5A wingless-type MMTV 
integration site family, 
member 5A
399 chemorepulsive axon guidance corpus callosum107 mouse
induces fasciculation 107 mouse
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misdirected and are likely to regenerate towards inappropriate target organs. How-
ever, several distinct phenomena, including fasciculation, defasciculation and turning 
events indicate that the regenerative path of these axons is not completely random. 
Instead, as they regenerate, they appear to be influenced by guidance cues in the extra-
cellular matrix of the neuroma tissue surrounding them. Indeed, the GO-class “axon 
guidance” was the second most significantly overrepresented class in the “biological 
process” branch and we identified a total of 18 genes with a potential guiding influence 
on regenerating axons in the peripheral nerve. 
Interestingly, the expression of the majority of outgrowth-inhibitory proteins (8 out of 
10) was upregulated, whereas all three differentially expressed outgrowth-promoting 
proteins were downregulated. The expression of NGF, which is upregulated in painful 
end-neuromas 86 was not differentially expressed in the neuroma in continuity. The same 
holds true for other well-known neurotrophic factors like brain-derived neurotrophic 
factor and glial cell-line derived neurotrophic factor (the only differentially expressed 
neurotrophin, NTF3, was downregulated), indicating that a possible initial increase in 
expression of these factors 77 appears to be normalised after 5 months. It thus appears 
that at the time of surgery, the balance between the expression of outgrowth-promoting 
and outgrowth-inhibitory genes in the neuroma has shifted towards the latter, resulting 
in a microenvironment that is unsupportive of regeneration. Chemorepulsive guid-
ance cues may have induced the observed turning of regenerating axons, causing some 
of them to become trapped in the neuroma and many others to become disorganised. 
 The majority of fasciculation-inducing proteins were upregulated. This finding may 
help to explain the presence of many mini-fascicles in the neuroma, although both 
the observed defasciculation of axons in neurofilament-stained sections and the up-
regulation of TLL1, a defasciculation-inducing gene, show that both fasciculation and 
defasciculation are mediated by proteins expressed by glial cells in the neuroma.
 Surprisingly, semaphorin3A, which we have recently shown to be expressed in the 
human neuroma 87, was not present in the list of significantly regulated genes in the 
present study, although there was indeed a trend towards higher semaphorin3A ex-
pression in the neuroma. Several factors may have contributed to this finding: first, the 
expression of semaphorin3A is relatively low and the qPCR method used in the previ-
ous study (which also contained more patient material) may have been more sensitive 
than the micro-array approach used here and a number of false-negative findings are 
to be expected in a micro-array approach. Second, different material was used in both 
studies: whereas the control tissue in the previous study was predominantly derived 
from proximal nerve stump C5, the control tissue in the present study was an even mix 
of C5 and C6 nerve tissue. Putative regional differences in semaphorin3A expression 
in the proximal nerve stumps may have therefore affected the measurement of the 
relative semaphorin3A expression in the neuroma.
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 The discovery of several new axon guidance proteins in this study may provide 
novel targets for future therapies aimed at improving regeneration after peripheral 
nerve injury. For instance, short interfering RNA mediated knockdown of inhibitory 
proteins, perhaps with the use of viral vectors 90, may cause enhanced regeneration 
across the fibrous nerve scar. Furthermore, the ability to reduce defasciculation of 
regenerating axons could help to reduce the chance of misrouting of regenerating 
axons and thereby improve functional recovery.
Versican and CSPGs surround nerve fibers 
Versican is a CSPG, and therefore a component of perineuronal nets that help stabilise 
neurons 114. CSPGs induce fasciculation in vitro 76 and their presence around mini-
fascicles in the neuroma may contribute to the fasciculation of regenerating axons. 
Although WFA staining was present around all axons in both nerve and neuroma 
sections, only the expression of versican was upregulated in the neuroma. This is 
surprising, as it was previously reported that versican is downregulated, albeit briefly, 
after peripheral nerve injury in the rat 117. However, there is evidence that versican is 
a component of newly formed perineuronal nets and plays a role in their maturation 
114,118,119. The presence of versican around a small subset of mini-fascicles in the neu-
roma therefore suggests that these are recently formed “immature” mini-fascicles that 
are in the process of being enveloped by a new perineuronal net. As they mature, the 
versican-content of these nets decreases. However, the fact that they can be stained 
with WFA suggests that they now contain other CSPGs. As virtually all axons in both 
nerve and neuroma are surrounded by WFA positive ECM, it is not surprising that 
the expression of these other CSPGs is not differentially regulated. Furthermore, in 
contrast to some other CSPGs, versican is expressed by glial cells, not neurons. The 
upregulation of versican, the presence of CSPGs in the vicinity of mini-fascicles, the 
role of CSPGs in both peripheral nerve regeneration 91 and fasciculation 76 and the fact 
that they can be degraded enzymatically 91, all make CSPGs a highly interesting target 
for experimental therapies aimed at the modulation and perhaps improvement of 
regeneration. However, there is a possibility that a degradation of CSPGs may induce 
defasciculation of regenerating axons, thereby increasing the chance that regenerating 
axons innervate inappropriate target organs.
Concluding remarks
The results described in this paper lead to the conclusion that the human neuroma in 
continuity contains a considerable number of highly disorganised axons, that misrout-
ing is a major contributing factor to the lack of functional recovery and that the regen-
erative paths of these axons appear to be influenced by a number of axon guidance cues 
that are differentially expressed by the glial cells of the peripheral nerve neuroma. 
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The discovery of a substantial number of axons should not be misconstrued as an 
argument against surgical repair of the injured nerve. In fact, the high degree of dis-
organisation of these axons in the neuroma makes it seem unlikely that functional 
recovery would occur without some kind of intervention. However, the purpose of 
reconstructive surgery could be redefined: the function of implanted autologous nerve 
grafts is to provide longitudinally aligned scaffolds that physically guide axons (as well 
as providing neurotrophic support) towards the appropriate distal nerve stump. The 
differentially regulated axon guidance molecules described in this paper could serve 
as targets for therapies aimed at influencing processes like fasciculation or defascicula-
tion of axons. However, these therapies will likely be applied in combination with, not 
instead of, reconstructive surgery. Viral vector mediated overexpression (or knock-
down) of therapeutic proteins is technically possible in human sural nerve grafts 90. 
Furthermore, the presence of CSPGs, specifically versican, in human neuroma tissue 
provides an additional argument for the therapeutic potential of enzymatic degrada-
tion of CSPGs 91,120 as a means to enhance peripheral nerve regeneration. These viral 
vector-based and enzymatic strategies may in the future provide a truly novel option 
to influence the functional outcome of surgery at a molecular level.
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Supplemental table 1  Complete list of all differentially regulated genes in human neuroma 
tissue (P<0.05). Expression: relative expression as a percentage of nerve control tissue (>100% 
indicates upregulation in the neuroma, <100% indicates downregulation). P-values for dif-
ferential expression between nerve and neuroma were corrected for multiple testing using the 
Bonferroni correction algorithm.
SLITRK6 SLIT and NTRK-like family, member 6 (SLITRK6), mRNA [NM_032229] 768 0.0076
DCX doublecortex; lissencephaly, X-linked (doublecortin) (DCX), transcript variant 1, mRNA [NM_000555] 653 0.0029
AL833005 mRNA; cDNA DKFZp666D074 (from clone DKFZp666D074) [AL833005] 589 0.0283
ASPN asporin (LRR class 1) (ASPN), mRNA [NM_017680] 553 0.0236
THC2271582 ALU5_HUMAN (P39192) Alu subfamily SC sequence contamination warning entry, partial (9%) 
[THC2271582]
548 0.0334
WNT5A wingless-type MMTV integration site family, member 5A (WNT5A), mRNA [NM_003392] 399 0.0442
LRRC38 full-length cDNA clone CS0DI025YD24 of Placenta Cot 25-normalized of (human). [CR622769] 373 0.0042
FNDC5 fibronectin type III domain containing 5 (FNDC5), mRNA [NM_153756] 367 0.0061
A_32_P171043 Unknown 353 0.0257
MXRA5 matrix-remodelling associated 5 (MXRA5), mRNA [NM_015419] 348 0.0247
GUCY1B3 guanylate cyclase 1, soluble, beta 3 (GUCY1B3), mRNA [NM_000857] 346 0.0053
AF119913 PRO3077 mRNA, complete cds. [AF119913] 344 0.0185
DKFZp434B1231 eEF1A2 binding protein (DKFZp434B1231), mRNA [NM_178275] 344 0.0217
ANGPTL1 angiopoietin-like 1 (ANGPTL1), mRNA [NM_004673] 337 0.0419
CPO carboxypeptidase O (CPO), mRNA [NM_173077] 335 0.0200
KLK8 kallikrein 8 (neuropsin/ovasin) (KLK8), transcript variant 2, mRNA [NM_144505] 334 0.0148
THC2277187 Q6PKF4 (Q6PKF4) C20orf77 protein (Fragment), partial (5%) [THC2277187] 331 0.0300
GUCY1A3 guanylate cyclase 1, soluble, alpha 3 (GUCY1A3), mRNA [NM_000856] 331 0.0283
THC2375612 HXAD_HUMAN (P31271) Homeobox protein Hox-A13 (Hox-1J), partial (9%) [THC2375612] 330 0.0156
THC2389705 Unknown 329 0.0268
SIX1 sine oculis homeobox homolog 1 (Drosophila) (SIX1), mRNA [NM_005982] 328 0.0356
C8orf57 mRNA; cDNA DKFZp761D112 (from clone DKFZp761D112). [AL136588] 326 0.0106
LECT2 leukocyte cell-derived chemotaxin 2 (LECT2), mRNA [NM_002302] 321 0.0145
CXCL13 chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant) (CXCL13), mRNA [NM_006419] 321 0.0092
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), transcript variant 2, mRNA [NM_181755] 318 0.0257
KLK11 kallikrein 11 (KLK11), transcript variant 2, mRNA [NM_144947] 317 0.0029
BOC Boc homolog (mouse) (BOC), mRNA [NM_033254] 316 0.0045
SPON1 spondin 1, extracellular matrix protein (SPON1), mRNA [NM_006108] 314 0.0333
BC039414 cDNA clone IMAGE:5302158. [BC039414] 313 0.0229
FLJ40125 hypothetical protein FLJ40125, mRNA (cDNA clone MGC:40208 IMAGE:5240955), complete cds. [BC028228] 311 0.0325
THBS4 thrombospondin 4 (THBS4), mRNA [NM_003248] 309 0.0243
TNN tenascin N (TNN), mRNA [NM_022093] 305 0.0257
KCNIP1 Kv channel interacting protein 1 (KCNIP1), transcript variant 2, mRNA [NM_014592] 303 0.0053
BC033590 Homo sapiens, clone IMAGE:4344826, mRNA. [BC033590] 301 0.0101
LOC388002 PREDICTED: hypothetical LOC388002 (LOC388002), mRNA [XM_373600] 300 0.0295
LOC284112 cDNA FLJ25640 fis, clone STM04823. [AK098506] 298 0.0036
A_32_P222241 Unknown 295 0.0133
COMP cartilage oligomeric matrix protein (COMP), mRNA [NM_000095] 295 0.0085
SPON2 spondin 2, extracellular matrix protein (SPON2), mRNA [NM_012445] 294 0.0156
C1orf92 chromosome 1 open reading frame 92 (C1orf92), mRNA [NM_144702] 292 0.0062
AY358804 clone DNA100312 VSSW1971 (UNQ1971) mRNA, complete cds. [AY358804] 291 0.0050
ENST00000278934 mRNA for KIAA1867 protein, partial cds. [AB058770] 287 0.0101
ENST00000380438 mRNA; cDNA DKFZp761O1810 (from clone DKFZp761O1810). [AL713706] 283 0.0068
ZCCHC5 zinc finger, CCHC domain containing 5 (ZCCHC5), mRNA [NM_152694] 283 0.0288
AK022045 cDNA FLJ11983 fis, clone HEMBB1001337. [AK022045] 282 0.0308
PTPRT protein tyrosine phosphatase, receptor type, T (PTPRT), transcript variant 1, mRNA [NM_133170] 281 0.0356
FAP fibroblast activation protein, alpha (FAP), mRNA [NM_004460] 280 0.0097
SFRP4 secreted frizzled-related protein 4 (SFRP4), mRNA [NM_003014] 279 0.0462
KERA keratocan (KERA), mRNA [NM_007035] 279 0.0054
HOXC9 homeobox C9 (HOXC9), mRNA [NM_006897] 277 0.0103
ITM2A integral membrane protein 2A (ITM2A), mRNA [NM_004867] 276 0.0275
Gene Description                                                                                                                                              Expr. (%) P-val.
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AK025975 cDNA: FLJ22322 fis, clone HRC05532. [AK025975] 265 0.0164
EYA1 eyes absent homolog 1 (Drosophila) (EYA1), transcript variant 3, mRNA [NM_000503] 263 0.0292
GSC goosecoid (GSC), mRNA [NM_173849] 261 0.0259
CN479762 CN479762 UI-H-EU0-azu-l-04-0-UI.s1 NCI_CGAP_Car1 cDNA clone UI-H-EU0-azu-l-04-0-UI 3’, mRNA 
sequence [CN479762]
261 0.0077
DIO2 deiodinase, iodothyronine, type II (DIO2), transcript variant 1, mRNA [NM_013989] 260 0.0149
AK124396 cDNA FLJ42405 fis, clone ASTRO3000474. [AK124396] 260 0.0439
ENST00000334770 cDNA FLJ16078 fis, clone NT2NE2003252, weakly  similar to Human putative serine/threonine protein kinase 
PRK (prk) mRNA. [AK122648]
259 0.0462
POSTN periostin, osteoblast specific factor (POSTN), mRNA [NM_006475] 257 0.0183
THC2317587 Unknown 256 0.0417
IGF1 insulin-like growth factor 1 (somatomedin C) (IGF1), mRNA [NM_000618] 255 0.0317
THC2357654 Unknown 253 0.0062
LRRC17 leucine rich repeat containing 17 (LRRC17), transcript variant 2, mRNA [NM_005824] 253 0.0192
ZMAT4 zinc finger, matrin type 4 (ZMAT4), mRNA [NM_024645] 251 0.0189
AW856073 AW856073 RC1-CT0286-060200-015-c06 CT0286 cDNA, mRNA sequence [AW856073] 250 0.0257
PPFIA2 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 2 (PP-
FIA2), mRNA [NM_003625]
249 0.0029
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 (SPOCK1), mRNA [NM_004598] 244 0.0384
ENST00000299694 cDNA FLJ31580 fis, clone NT2RI2002041. [AK056142] 244 0.0056
THC2269852 Q8TDP9 (Q8TDP9) 3-beta-hydroxysteroid dehydrogenase (Fragment), partial (38%) [THC2269852] 243 0.0236
PCDH19 protocadherin 19 (PCDH19), mRNA [NM_020766] 243 0.0051
HAS1 hyaluronan synthase 1 (HAS1), mRNA [NM_001523] 242 0.0283
WIT1 Wilms tumor upstream neighbor 1 (WIT1), mRNA [NM_015855] 242 0.0192
FGF19 fibroblast growth factor 19 (FGF19), mRNA [NM_005117] 239 0.0054
MRC2 mannose receptor, C type 2 (MRC2), mRNA [NM_006039] 239 0.0097
BFSP1 beaded filament structural protein 1, filensin (BFSP1), mRNA [NM_001195] 238 0.0152
COL11A1 collagen, type XI, alpha 1 (COL11A1), transcript variant B, mRNA [NM_080629] 238 0.0397
TGFB3 transforming growth factor, beta 3 (TGFB3), mRNA [NM_003239] 238 0.0203
CILP cartilage intermediate layer protein, nucleotide pyrophosphohydrolase (CILP), mRNA [NM_003613] 237 0.0187
FMO1 flavin containing monooxygenase 1 (FMO1), mRNA [NM_002021] 237 0.0417
C20orf102 chromosome 20 open reading frame 102 (C20orf102), mRNA [NM_080607] 237 0.0144
ENST00000343998 full-length cDNA clone CS0DF020YB12 of Fetal brain of (human). [CR618658] 236 0.0185
ENPEP glutamyl aminopeptidase (aminopeptidase A) (ENPEP), mRNA [NM_001977] 236 0.0029
KIAA1217 KIAA1217 (KIAA1217), mRNA [NM_019590] 236 0.0036
T52140 T52140 yb29h11.r1 Stratagene fetal spleen (#937205) cDNA clone IMAGE:72645 5’, mRNA sequence [T52140] 235 0.0162
KLK1 kallikrein 1, renal/pancreas/salivary (KLK1), mRNA [NM_002257] 234 0.0070
DAZL deleted in azoospermia-like (DAZL), mRNA [NM_001351] 234 0.0257
HSD3B1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 (HSD3B1), mRNA [NM_000862] 234 0.0291
ZFPM2 zinc finger protein, multitype 2 (ZFPM2), mRNA [NM_012082] 234 0.0145
TMEM133 transmembrane protein 133 (TMEM133), mRNA [NM_032021] 233 0.0100
KIAA1904 KIAA1904 protein (KIAA1904), mRNA [NM_052906] 232 0.0133
C1QTNF2 C1q and tumor necrosis factor related protein 2 (C1QTNF2), mRNA [NM_031908] 232 0.0421
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 (HS6ST2), mRNA [NM_147175] 231 0.0200
AA585242 AA585242 LTH022 HTCDL1 cDNA 5’/3’, mRNA sequence [AA585242] 230 0.0034
JAG1 jagged 1 (Alagille syndrome) (JAG1), mRNA [NM_000214] 230 0.0189
RGS5 regulator of G-protein signalling 5 (RGS5), mRNA [NM_003617] 228 0.0051
NOV nephroblastoma overexpressed gene (NOV), mRNA [NM_002514] 228 0.0381
CTHRC1 collagen triple helix repeat containing 1 (CTHRC1), mRNA [NM_138455] 227 0.0338
GEFT RAC/CDC42 exchange factor (GEFT), transcript variant 2, mRNA [NM_133483] 226 0.0439
EMILIN3 elastin microfibril interfacer 3 (EMILIN3), mRNA [NM_052846] 226 0.0359
PI16 peptidase inhibitor 16 (PI16), mRNA [NM_153370] 225 0.0247
KIAA1913 KIAA1913 (KIAA1913), mRNA [NM_052913] 225 0.0356
ENST00000261364 PR-domain zinc finger protein 6 isoform A (PRDM6) mRNA, partial cds; alternatively spliced. [AF272898] 225 0.0156
THC2339002 Q300_MOUSE (Q02722) Protein Q300, partial (17%) [THC2339002] 224 0.0288
ENST00000370548 cDNA FLJ11317 fis, clone PLACE1010261, moderately similar to SEGREGATION DISTORTER PROTEIN. 
[AK002179]
224 0.0283
COLEC12 collectin sub-family member 12 (COLEC12), transcript variant II, mRNA [NM_030781] 223 0.0288
PPIC peptidylprolyl isomerase C (cyclophilin C) (PPIC), mRNA [NM_000943] 222 0.0307
HEYL hairy/enhancer-of-split related with YRPW motif-like (HEYL), mRNA [NM_014571] 222 0.0062
SEMA5B sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 5B (SEMA5B), transcript variant 1, mRNA [NM_001031702]
220 0.0325
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GHR growth hormone receptor (GHR), mRNA [NM_000163] 220 0.0259
SLCO2A1 solute carrier organic anion transporter family, member 2A1 (SLCO2A1), mRNA [NM_005630] 219 0.0419
THC2442939 Unknown 218 0.0109
MGC16121 hypothetical protein MGC16121, mRNA (cDNA clone MGC:16121 IMAGE:3627113), complete cds. 
[BC007360]
216 0.0215
ENST00000373208 Q7QFH7 (Q7QFH7) ENSANGP00000019298 (Fragment), partial (7%) [THC2404711] 216 0.0317
BX115897 BX115897 BX115897 Soares_multiple_sclerosis_2NbHMSP cDNA clone IMAGp998J16611 ; IMAGE:276975, 
mRNA sequence [BX115897]
216 0.0156
PLCL2 phospholipase C-like 2 (PLCL2), mRNA [NM_015184] 216 0.0156
BX281073 BX281073 BX281073 NCI_CGAP_Lu24 cDNA clone IMAGp998O175628 ; IMAGE:2273128, mRNA sequence 
[BX281073]
215 0.0075
BQ897248 AGENCOURT_8122036 Lupski_dorsal_root_ganglion cDNA clone IMAGE:6179261 5’, mRNA sequence 
[BQ897248]
215 0.0406
BICC1 cDNA: FLJ22476 fis, clone HRC10682. [AK026129] 215 0.0246
RP11-301I17.1 proliferation-inducing protein 38 (PIG38), mRNA [NM_017993] 214 0.0308
OGN osteoglycin (osteoinductive factor, mimecan) (OGN), transcript variant 1, mRNA [NM_033014] 214 0.0257
BX648831 mRNA; cDNA DKFZp686J06116 (from clone DKFZp686J06116). [BX648831] 214 0.0132
METTL7A methyltransferase like 7A (METTL7A), mRNA [NM_014033] 214 0.0496
VIPR2 vasoactive intestinal peptide receptor 2 (VIPR2), mRNA [NM_003382] 213 0.0192
ENST00000380683 PREDICTED: hypothetical protein LOC646371 (LOC646371), mRNA [XM_933567] 213 0.0350
EPHB2 EPH receptor B2 (EPHB2), transcript variant 2, mRNA [NM_004442] 211 0.0283
NCALD neurocalcin delta (NCALD), transcript variant 8, mRNA [NM_032041] 211 0.0457
NGEF neuronal guanine nucleotide exchange factor (NGEF), mRNA [NM_019850] 211 0.0397
AK124281 cDNA FLJ42287 fis, clone TLIVE2005866. [AK124281] 210 0.0369
HMCN1 hemicentin 1 (HMCN1), mRNA [NM_031935] 210 0.0082
NMNAT2 nicotinamide nucleotide adenylyltransferase 2 (NMNAT2), transcript variant 1, mRNA [NM_015039] 210 0.0442
ENC1 ectodermal-neural cortex (with BTB-like domain) (ENC1), mRNA [NM_003633] 208 0.0064
CSPG2 chondroitin sulfate proteoglycan 2 (versican) (CSPG2), mRNA [NM_004385] 207 0.0194
CCBE1 collagen and calcium binding EGF domains 1 (CCBE1), mRNA [NM_133459] 207 0.0304
TSHZ2 teashirt family zinc finger 2 (TSHZ2), mRNA [NM_173485] 207 0.0042
THC2317900 Q9H2Q1 (Q9H2Q1) AD031, partial (69%) [THC2317900] 206 0.0163
AW015426 UI-H-BI0-aat-h-12-0-UI.s1 NCI_CGAP_Sub1 cDNA clone IMAGE:2710535 3’, mRNA sequence [AW015426] 206 0.0056
GRM1 glutamate receptor, metabotropic 1 (GRM1), mRNA [NM_000838] 205 0.0387
DFNB31 cDNA FLJ31628 fis, clone NT2RI2003344, weakly similar to PRESYNAPTIC PROTEIN SAP97. [AK056190] 205 0.0192
PTPN5 protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched) (PTPN5), transcript variant 2, mRNA 
[NM_032781]
204 0.0054
RNU12 RNA, U12 small nuclear (RNU12) on chromosome X [NR_000041] 203 0.0288
CR616003 full-length cDNA clone CS0DM012YB14 of Fetal liver of (human). [CR616003] 203 0.0265
TCF4 transcription factor 4 (TCF4), mRNA [NM_003199] 203 0.0202
C1orf54 chromosome 1 open reading frame 54 (C1orf54), mRNA [NM_024579] 203 0.0168
ENST00000256861 Unknown 202 0.0145
THC2339791 Unknown 202 0.0495
TMC4 transmembrane channel-like 4 (TMC4), mRNA [NM_144686] 202 0.0054
DAPK2 death-associated protein kinase 2 (DAPK2), mRNA [NM_014326] 202 0.0315
HTRA3 HtrA serine peptidase 3 (HTRA3), mRNA [NM_053044] 201 0.0466
WNT2B wingless-type MMTV integration site family, member 2B (WNT2B), transcript variant WNT-2B1, mRNA 
[NM_004185]
201 0.0231
BE835321 BE835321 RC5-FN0022-300600-022-G12 FN0022 cDNA, mRNA sequence [BE835321] 200 0.0401
CXCR4 chemokine (C-X-C motif) receptor 4 (CXCR4), transcript variant 1, mRNA [NM_001008540] 200 0.0229
A_32_P160388 Unknown 199 0.0103
SUSD4 sushi domain containing 4 (SUSD4), transcript variant 1, mRNA [NM_017982] 199 0.0257
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A), mRNA [NM_000621] 199 0.0076
AW138903 AW138903 UI-H-BI1-aeq-e-09-0-UI.s1 NCI_CGAP_Sub3 cDNA clone IMAGE:2720344 3’, mRNA sequence 
[AW138903]
198 0.0462
A_32_P219704 Unknown 198 0.0267
TK1 thymidine kinase 1, soluble (TK1), mRNA [NM_003258] 197 0.0229
KRT12 keratin 12 (Meesmann corneal dystrophy) (KRT12), mRNA [NM_000223] 197 0.0268
OSTalpha organic solute transporter alpha (OSTalpha), mRNA [NM_152672] 196 0.0342
AKR1C3 aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) (AKR1C3), mRNA 
[NM_003739]
195 0.0386
STEAP1 six transmembrane epithelial antigen of the prostate 1 (STEAP1), mRNA [NM_012449] 194 0.0462
GLI2 GLI-Kruppel family member GLI2 (GLI2), mRNA [NM_005270] 194 0.0318
VLDLR very low density lipoprotein receptor (VLDLR), transcript variant 1, mRNA [NM_003383] 193 0.0288
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SVEP1 cDNA FLJ14964 fis, clone PLACE4000581, moderately similar to FIBROPELLIN I PRECURSOR. [AK027870] 193 0.0149
SIX2 sine oculis homeobox homolog 2 (Drosophila) (SIX2), mRNA [NM_016932] 193 0.0409
AK001062 cDNA FLJ10200 fis, clone HEMBA1004863, highly similar to mRNA; cDNA DKFZp586M2022. [AK001062] 192 0.0257
PHACTR2 phosphatase and actin regulator 2 (PHACTR2), mRNA [NM_014721] 192 0.0114
C18orf4 chromosome 18 open reading frame 4 (C18orf4), mRNA [NM_032160] 192 0.0147
DAAM1 dishevelled associated activator of morphogenesis 1 (DAAM1), mRNA [NM_014992] 192 0.0259
CFI complement factor I (CFI), mRNA [NM_000204] 191 0.0097
THC2304714 Unknown 191 0.0272
ROBO1 roundabout, axon guidance receptor, homolog 1 (Drosophila) (ROBO1), transcript variant 2, mRNA 
[NM_133631]
191 0.0039
EBF2 early B-cell factor 2 (EBF2) mRNA, complete cds, alternatively spliced. [AY700779] 191 0.0101
PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), transcript variant 1, mRNA [NM_182943] 191 0.0201
ENST00000257897 mRNA for KIAA0167 gene, partial cds. [D79989] 191 0.0339
BAPX1 bagpipe homeobox homolog 1 (Drosophila) (BAPX1), mRNA [NM_001189] 191 0.0367
KIAA0101 KIAA0101 (KIAA0101), transcript variant 1, mRNA [NM_014736] 191 0.0205
JAM2 junctional adhesion molecule 2 (JAM2), mRNA [NM_021219] 190 0.0340
CAPN6 calpain 6 (CAPN6), mRNA [NM_014289] 190 0.0462
NTRK1 neurotrophic tyrosine kinase, receptor, type 1 (NTRK1), transcript variant 2, mRNA [NM_002529] 189 0.0308
MSC musculin (activated B-cell factor-1) (MSC), mRNA [NM_005098] 189 0.0330
TMEM26 transmembrane protein 26 (TMEM26), mRNA [NM_178505] 189 0.0229
CRABP2 cellular retinoic acid binding protein 2 (CRABP2), mRNA [NM_001878] 189 0.0330
THC2438512 Unknown 189 0.0142
TMEM100 transmembrane protein 100 (TMEM100), mRNA [NM_018286] 189 0.0185
ANKRD29 ankyrin repeat domain 29 (ANKRD29), mRNA [NM_173505] 188 0.0347
MYO10 cDNA clone MGC:131988 IMAGE:6164790, complete cds. [BC108736] 188 0.0141
ENST00000295549 hypothetical gene supported by BC013438, mRNA (cDNA clone IMAGE:3899073), partial cds. [BC013438] 188 0.0276
STXBP6 syntaxin binding protein 6 (amisyn) (STXBP6), mRNA [NM_014178] 187 0.0339
A_32_P9924 Unknown 187 0.0301
H19 H19, imprinted maternally expressed untranslated mRNA (H19) on chromosome 11 [NR_002196] 186 0.0205
BGN biglycan (BGN), mRNA [NM_001711] 185 0.0375
KIAA2002 cDNA FLJ34483 fis, clone HLUNG2004154. [AK091802] 184 0.0321
ECM2 extracellular matrix protein 2, female organ and adipocyte specific (ECM2), mRNA [NM_001393] 183 0.0163
DLST dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex) (DLST), mRNA 
[NM_001933]
182 0.0163
AK125961 cDNA FLJ43973 fis, clone TESTI4017984. [AK125961] 182 0.0283
ENST00000373886 cDNA FLJ26539 fis, clone KDN09310. [AK130049] 182 0.0286
HMMR hyaluronan-mediated motility receptor (RHAMM) (HMMR), transcript variant 1, mRNA [NM_012484] 181 0.0304
THC2287450 Unknown 181 0.0265
FAM83D family with sequence similarity 83, member D (FAM83D), mRNA [NM_030919] 181 0.0341
A_32_P19616 Unknown 181 0.0232
LOXL2 lysyl oxidase-like 2 (LOXL2), mRNA [NM_002318] 181 0.0194
IRF8 interferon regulatory factor 8 (IRF8), mRNA [NM_002163] 180 0.0257
COL6A2 collagen, type VI, alpha 2 (COL6A2), transcript variant 2C2, mRNA [NM_001849] 180 0.0292
CFB complement factor B (CFB), mRNA [NM_001710] 180 0.0472
A_24_P871726 Unknown 179 0.0077
FLJ16237 hypothetical protein LOC392636 (FLJ16237), mRNA [NM_001004320] 179 0.0166
CA421238 CA421238 UI-H-FG0-bct-h-02-0-UI.s1 NCI_CGAP_EN1_2 cDNA clone UI-H-FG0-bct-h-02-0-UI 3’, mRNA 
sequence [CA421238]
178 0.0317
A_24_P914669 Unknown 178 0.0325
RAB3IL1 RAB3A interacting protein (rabin3)-like 1 (RAB3IL1), mRNA [NM_013401] 178 0.0417
THC2406050 BX324349 BX324349 T CELLS (JURKAT CELL LINE) COT 10-NORMALIZED cDNA clone CS0DJ008YO15 
5-PRIME, mRNA sequence [BX324349]
178 0.0145
CTSK cathepsin K (pycnodysostosis) (CTSK), mRNA [NM_000396] 178 0.0468
KLK10 kallikrein 10 (KLK10), transcript variant 1, mRNA [NM_002776] 178 0.0283
ITIH5 inter-alpha (globulin) inhibitor H5 (ITIH5), transcript variant 1, mRNA [NM_030569] 177 0.0305
NOX4 NADPH oxidase 4 (NOX4), mRNA [NM_016931] 177 0.0311
GPR171 G protein-coupled receptor 171 (GPR171), mRNA [NM_013308] 177 0.0089
ADRA2A adrenergic, alpha-2A-, receptor (ADRA2A), mRNA [NM_000681] 177 0.0419
FLJ31485 cDNA FLJ31485 fis, clone NT2NE2001698. [AK056047] 177 0.0085
LOC651721 hypothetical protein LOC651721, mRNA (cDNA clone IMAGE:4430430), partial cds. [BC026225] 176 0.0284
ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) (ADAM12), transcript variant 1, mRNA [NM_003474] 176 0.0285
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ENST00000304372 potassium channel tetramerisation domain containing 19, mRNA (cDNA clone IMAGE:5268205). [BC070103] 176 0.0325
C14orf81 cDNA FLJ32169 fis, clone PLACE6000523. [AK056731] 176 0.0370
FMO3 flavin containing monooxygenase 3 (FMO3), transcript variant 2, mRNA [NM_001002294] 176 0.0295
DLG7 discs, large homolog 7 (Drosophila) (DLG7), mRNA [NM_014750] 176 0.0404
TOP2A topoisomerase (DNA) II alpha 170kDa (TOP2A), mRNA [NM_001067] 176 0.0191
CLEC1A C-type lectin domain family 1, member A (CLEC1A), mRNA [NM_016511] 176 0.0102
PLVAP plasmalemma vesicle associated protein (PLVAP), mRNA [NM_031310] 175 0.0359
MEST mesoderm specific transcript homolog (mouse) (MEST), transcript variant 1, mRNA [NM_002402] 175 0.0247
TLL1 tolloid-like 1 (TLL1), mRNA [NM_012464] 175 0.0061
THC2404912 Q7XXR9 (Q7XXR9) Katanin, partial (44%) [THC2404912] 174 0.0229
AK097130 cDNA FLJ39811 fis, clone SPLEN2009581. [AK097130] 174 0.0424
SOAT2 sterol O-acyltransferase 2 (SOAT2), mRNA [NM_003578] 174 0.0066
AL137560 mRNA; cDNA DKFZp434M0320 (from clone DKFZp434M0320). [AL137560] 174 0.0417
TMSL8 thymosin-like 8 (TMSL8), mRNA [NM_021992] 174 0.0288
BE716310 CM1-HT0761-010600-238-e06 HT0761 cDNA, mRNA sequence [BE716310] 174 0.0439
THC2363226 HLMITCSEQ Hylobates lar complete mitochondrial DNA sequence, partial (3%) [THC2363226] 174 0.0376
SART2 squamous cell carcinoma antigen recognized by T cells 2 (SART2), mRNA [NM_013352] 174 0.0275
THC2339566 Unknown 173 0.0399
PTGER4 prostaglandin E receptor 4 (subtype EP4) (PTGER4), mRNA [NM_000958] 173 0.0364
MAPK10 mitogen-activated protein kinase 10 (MAPK10), transcript variant 3, mRNA [NM_138980] 172 0.0220
CYP4F8 cytochrome P450, family 4, subfamily F, polypeptide 8 (CYP4F8), mRNA [NM_007253] 172 0.0474
PGF placental growth factor, vascular endothelial growth factor-related protein (PGF), mRNA [NM_002632] 171 0.0447
CNTN4 contactin 4 (CNTN4), transcript variant 1, mRNA [NM_175607] 171 0.0200
PLAGL1 pleiomorphic adenoma gene-like 1 (PLAGL1), transcript variant 2, mRNA [NM_006718] 171 0.0317
ENST00000371497 OVC10-2 mRNA, complete cds. [AF230201] 171 0.0210
TRA@ T cell receptor alpha locus, mRNA (cDNA clone MGC:71411 IMAGE:4853814), complete cds. [BC063385] 170 0.0060
THC2359080 Unknown 170 0.0305
CLEC11A C-type lectin domain family 11, member A (CLEC11A), mRNA [NM_002975] 170 0.0259
FAM20A family with sequence similarity 20, member A (FAM20A), mRNA [NM_017565] 170 0.0229
BC015449 Homo sapiens, clone IMAGE:4427279, mRNA. [BC015449] 170 0.0496
BC006419 cDNA clone IMAGE:3946309, complete cds. [BC006419] 170 0.0247
VCAM1 vascular cell adhesion molecule 1 (VCAM1), transcript variant 1, mRNA [NM_001078] 169 0.0434
CRTAC1 cartilage acidic protein 1 (CRTAC1), mRNA [NM_018058] 169 0.0434
U79293 Human clone 23948 mRNA sequence. [U79293] 169 0.0229
AK021606 cDNA FLJ11544 fis, clone HEMBA1002826. [AK021606] 169 0.0451
BFSP2 beaded filament structural protein 2, phakinin (BFSP2), mRNA [NM_003571] 169 0.0398
A_23_P208752 Unknown 169 0.0156
COL12A1 collagen, type XII, alpha 1 (COL12A1), transcript variant long, mRNA [NM_004370] 169 0.0061
FLJ35934 FLJ35934 protein (FLJ35934), mRNA [NM_207453] 168 0.0381
APOL6 apolipoprotein L, 6 (APOL6), mRNA [NM_030641] 168 0.0357
LPHN2 latrophilin 2 (LPHN2), mRNA [NM_012302] 168 0.0271
THC2268343 Unknown 168 0.0356
RAB23 RAB23, member RAS oncogene family (RAB23), transcript variant 1, mRNA [NM_016277] 168 0.0477
CACNB4 calcium channel, voltage-dependent, beta 4 subunit (CACNB4), transcript variant 1, mRNA [NM_001005747] 168 0.0240
BC013679 cDNA clone IMAGE:3857956, partial cds. [BC013679] 168 0.0207
TCF8 transcription factor 8 (represses interleukin 2 expression) (TCF8), mRNA [NM_030751] 167 0.0325
PBK PDZ binding kinase (PBK), mRNA [NM_018492] 167 0.0325
AF034187 clone 2.2H12 Ndr Ser/Thr kinase-like protein mRNA, partial cds. [AF034187] 166 0.0229
GAB2 GRB2-associated binding protein 2 (GAB2), transcript variant 2, mRNA [NM_012296] 166 0.0143
AK025323 cDNA: FLJ21670 fis, clone COL09010. [AK025323] 166 0.0267
AI093077 AI093077 qa96h02.x1 Soares_fetal_heart_NbHH19W cDNA clone IMAGE:1694643 3’, mRNA sequence 
[AI093077]
166 0.0417
PLXDC1 plexin domain containing 1 (PLXDC1), mRNA [NM_020405] 165 0.0454
ENST00000371079 cDNA FLJ20769 fis, clone COL06674. [AK000776] 165 0.0419
PLD1 cDNA FLJ34578 fis, clone KIDNE2008404, highly similar to PHOSPHOLIPASE D1 (EC 3.1.4.4). [AK091897] 165 0.0260
RNF144 ring finger protein 144 (RNF144), mRNA [NM_014746] 165 0.0204
SDSL serine dehydratase-like (SDSL), mRNA [NM_138432] 164 0.0232
THC2380706 Q6UXG1 (Q6UXG1) YVTM2421, partial (3%) [THC2380706] 164 0.0356
ENST00000292357 full-length cDNA clone CS0DC023YA11 of Neuroblastoma Cot 25-normalized of (human). [CR599082] 163 0.0389
LOC644242 hypothetical protein LOC644242, mRNA (cDNA clone IMAGE:4403366), partial cds. [BC015390] 163 0.0307
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A_23_P255111 Unknown 162 0.0318
NHS Nance-Horan syndrome (congenital cataracts and dental anomalies) (NHS), mRNA [NM_198270] 162 0.0496
TP53I3 tumor protein p53 inducible protein 3 (TP53I3), transcript variant 1, mRNA [NM_004881] 162 0.0133
OAF OAF homolog (Drosophila) (OAF), mRNA [NM_178507] 162 0.0311
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 (CDC42EP2), mRNA [NM_006779] 161 0.0333
ALOX12P2 arachidonate 12-lipoxygenase pseudogene 2 (ALOX12P2) on chromosome 17 [NR_002710] 161 0.0434
BY798288 BY798288 eye cDNA clone HE3347.seq 5’, mRNA sequence [BY798288] 161 0.0482
TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) (TPX2), mRNA [NM_012112] 160 0.0496
A_24_P401051 Unknown 160 0.0462
THC2442208 Unknown 160 0.0491
ANTXR1 anthrax toxin receptor 1 (ANTXR1), transcript variant 2, mRNA [NM_053034] 160 0.0365
CDC2 cell division cycle 2, G1 to S and G2 to M (CDC2), transcript variant 1, mRNA [NM_001786] 159 0.0419
THBS3 thrombospondin 3 (THBS3), mRNA [NM_007112] 159 0.0419
SLC16A12 cDNA FLJ42911 fis, clone BRHIP3024118, weakly  similar to Monocarboxylate transporter 4. [AK124901] 159 0.0485
DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 (DNAJC12), transcript variant 1, mRNA [NM_021800] 159 0.0215
sep-06 septin 6 (SEPT6), transcript variant V, mRNA [NM_145802] 159 0.0325
SPBC25 spindle pole body component 25 homolog (S. cerevisiae) (SPBC25), mRNA [NM_020675] 159 0.0283
ITGA1 integrin, alpha 1 (ITGA1), mRNA [NM_181501] 159 0.0356
HMGCLL1 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase-like 1 (HMGCLL1), transcript variant 1, mRNA 
[NM_019036]
159 0.0402
HSF4 heat shock transcription factor 4 (HSF4), transcript variant 1, mRNA [NM_001538] 159 0.0438
CPA1 carboxypeptidase A1 (pancreatic) (CPA1), mRNA [NM_001868] 158 0.0359
PFTK1 PFTAIRE protein kinase 1 (PFTK1), mRNA [NM_012395] 156 0.0288
AK094929 cDNA FLJ37610 fis, clone BRCOC2011398. [AK094929] 156 0.0328
ROR1 receptor tyrosine kinase-like orphan receptor 1 (ROR1), mRNA [NM_005012] 155 0.0429
KLK13 kallikrein 13 (KLK13), mRNA [NM_015596] 155 0.0192
RAB6B RAB6B, member RAS oncogene family (RAB6B), mRNA [NM_016577] 154 0.0375
CHST1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 (CHST1), mRNA [NM_003654] 154 0.0171
LYPD1 LY6/PLAUR domain containing 1 (LYPD1), mRNA [NM_144586] 154 0.0434
MMP16 matrix metallopeptidase 16 (membrane-inserted) (MMP16), transcript variant 2, mRNA [NM_022564] 154 0.0231
MGC26647 hypothetical protein MGC26647 (MGC26647), mRNA [NM_152706] 153 0.0381
A_32_P183519 Unknown 153 0.0454
AI263220 AI263220 qz36f10.x1 NCI_CGAP_Kid11 cDNA clone IMAGE:2029003 3’ similar to TR:Q14041 Q14041 COL-
LAGEN VI ALPHA-1 N-TERMINAL GLOBULAR DOMAIN PRECURSOR ;, mRNA sequence [AI263220]
153 0.0419
CHMP4B chromatin modifying protein 4B (CHMP4B), mRNA [NM_176812] 152 0.0308
SLC22A16 solute carrier family 22 (organic cation transporter), member 16 (SLC22A16), mRNA [NM_033125] 152 0.0427
KCNK2 potassium channel, subfamily K, member 2 (KCNK2), transcript variant 1, mRNA [NM_001017424] 152 0.0317
NXN nucleoredoxin (NXN), mRNA [NM_022463] 151 0.0308
MLLT4 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 4 (MLLT4), 
transcript variant 3, mRNA [NM_005936]
150 0.0294
KATNAL2 katanin p60 subunit A-like 2 (KATNAL2), mRNA [NM_031303] 150 0.0236
MCM4 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) (MCM4), transcript variant 1, mRNA 
[NM_005914]
150 0.0321
TCN2 transcobalamin II; macrocytic anemia (TCN2), mRNA [NM_000355] 150 0.0328
RASSF2 Ras association (RalGDS/AF-6) domain family 2 (RASSF2), transcript variant 1, mRNA [NM_014737] 150 0.0236
A_32_P190334 Unknown 150 0.0435
COL5A2 collagen, type V, alpha 2 (COL5A2), mRNA [NM_000393] 150 0.0192
SAMD3 sterile alpha motif domain containing 3 (SAMD3), transcript variant 1, mRNA [NM_001017373] 149 0.0357
ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit (ATP5D), nuclear gene encoding mito-
chondrial protein, transcript variant 2, mRNA [NM_001001975]
149 0.0430
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1), mRNA [NM_004095] 149 0.0417
A_24_P552131 Unknown 148 0.0402
M74720 Human SEF2-1D protein (SEF2-1D) mRNA, partial cds. [M74720] 148 0.0188
PLA2R1 phospholipase A2 receptor 1, 180kDa (PLA2R1), transcript variant 1, mRNA [NM_007366] 148 0.0363
GALNTL4 clone 25215 mRNA sequence, partial cds. [AF131852] 148 0.0290
DDR2 discoidin domain receptor family, member 2 (DDR2), transcript variant 1, mRNA [NM_001014796] 147 0.0499
THC2279352 Q8NH31 (Q8NH31) Seven transmembrane helix receptor, partial (5%) [THC2279352] 147 0.0317
A_24_P178784 Unknown 147 0.0339
ETV5 ets variant gene 5 (ets-related molecule) (ETV5), mRNA [NM_004454] 146 0.0435
CR621923 full-length cDNA clone CS0DC010YA19 of Neuroblastoma Cot 25-normalized of (human). [CR621923] 145 0.0381
CR612178 full-length cDNA clone CS0DI015YM13 of Placenta Cot 25-normalized of (human). [CR612178] 145 0.0365
A_24_P255509 Unknown 145 0.0356
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CDKN3 cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase) (CDKN3), mRNA 
[NM_005192]
144 0.0419
HNRPLL heterogeneous nuclear ribonucleoprotein L-like, mRNA (cDNA clone MGC:5437 IMAGE:3449607), complete 
cds. [BC008217]
144 0.0283
AF146694 clone IMAGE:121412 mRNA sequence. [AF146694] 143 0.0308
FOXP1 forkhead box P1 (FOXP1), transcript variant 1, mRNA [NM_032682] 143 0.0370
SULT1A2 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 (SULT1A2), transcript variant 2, mRNA 
[NM_177528]
143 0.0288
DKFZp762E1312 hypothetical protein DKFZp762E1312 (DKFZp762E1312), mRNA [NM_018410] 141 0.0434
A_24_P118336 Unknown 141 0.0321
LOC57228 small trans-membrane and glycosylated protein (LOC57228), transcript variant 1, mRNA [NM_001031628] 140 0.0375
A_24_P913629 Unknown 140 0.0464
L3MBTL3 l(3)mbt-like 3 (Drosophila) (L3MBTL3), transcript variant 1, mRNA [NM_032438] 138 0.0483
FLJ38482 hypothetical protein FLJ38482 (FLJ38482), mRNA [NM_152681] 75 0.0417
ENST00000377411 cDNA: FLJ23230 fis, clone CAE07143. [AK026883] 75 0.0434
TIMP3 TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory) (TIMP3), mRNA 
[NM_000362]
75 0.0483
CTSL2 cathepsin L2 (CTSL2), mRNA [NM_001333] 74 0.0421
MGC16385 hypothetical protein MGC16385 (MGC16385), mRNA [NM_145039] 74 0.0436
LOC402573 hypothetical LOC402573 (LOC402573), mRNA [NM_001004323] 74 0.0387
FRMD1 FERM domain containing 1 (FRMD1), mRNA [NM_024919] 74 0.0399
AK096991 cDNA FLJ39672 fis, clone SMINT2009233. [AK096991] 73 0.0492
TMEM1 transmembrane protein 1 (TMEM1), transcript variant 1, mRNA [NM_003274] 73 0.0316
FDPS farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltran-
stransferase) (FDPS), mRNA [NM_002004]
73 0.0435
UST uronyl-2-sulfotransferase (UST), mRNA [NM_005715] 73 0.0359
AK023472 cDNA FLJ13410 fis, clone PLACE1001720. [AK023472] 73 0.0349
BQ424374 AGENCOURT_7892842 NIH_MGC_72 cDNA clone IMAGE:6157378 5’, mRNA sequence [BQ424374] 73 0.0339
LINCR likely ortholog of mouse lung-inducible Neutralized-related C3HC4 RING domain protein, mRNA (cDNA clone 
MGC:15646 IMAGE:3346442), complete cds. [BC012317]
72 0.0439
AGA aspartylglucosaminidase (AGA), mRNA [NM_000027] 72 0.0283
LRP8 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor (LRP8), transcript variant 2, mRNA 
[NM_033300]
72 0.0494
FKBP1B FK506 binding protein 1B, 12.6 kDa (FKBP1B), transcript variant 2, mRNA [NM_054033] 72 0.0283
BQ019626 BQ019626 UI-H-ED0-axd-f-18-0-UI.s1 NCI_CGAP_ED0 cDNA clone IMAGE:5827217 3’, mRNA sequence 
[BQ019626]
72 0.0215
ENST00000342275 RST6901 Athersys RAGE Library cDNA, mRNA sequence [BG187898] 72 0.0229
STON1 stonin 1 (STON1), mRNA [NM_006873] 72 0.0485
BU661610 cl74d04.z1 Hembase; Erythroid Precursor Cells (LCB:cl library) cDNA clone cl74d04 5’, mRNA sequence 
[BU661610]
72 0.0401
KNDC1 kinase non-catalytic C-lobe domain (KIND) containing 1 (KNDC1), transcript variant 1, mRNA [NM_152643] 72 0.0356
TEKT3 tektin 3 (TEKT3), mRNA [NM_031898] 71 0.0327
OCIAD2 OCIA domain containing 2 (OCIAD2), transcript variant 1, mRNA [NM_001014446] 71 0.0267
FTHL12 ferritin, heavy polypeptide-like 12 (FTHL12) on chromosome 9 [NR_002205] 71 0.0419
SHMT1 serine hydroxymethyltransferase 1 (soluble) (SHMT1), transcript variant 1, mRNA [NM_004169] 71 0.0288
AL049443 mRNA; cDNA DKFZp586N2020 (from clone DKFZp586N2020). [AL049443] 70 0.0387
ENST00000256367 tetratricopeptide repeat domain 9, mRNA (cDNA clone IMAGE:5763935), partial cds. [BC047950] 70 0.0302
FEZ1 fasciculation and elongation protein zeta 1 (zygin I) (FEZ1), transcript variant 1, mRNA [NM_005103] 70 0.0451
A_32_P35031 Unknown 70 0.0259
ASRGL1 asparaginase like 1, mRNA (cDNA clone IMAGE:3952485), complete cds. [BC006267] 70 0.0325
ENST00000320378 cDNA FLJ39084 fis, clone NT2RP7018871. [AK096403] 70 0.0351
LHPP phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP), mRNA [NM_022126] 70 0.0260
AK095986 cDNA FLJ38667 fis, clone HLUNG2006843. [AK095986] 70 0.0451
LOC283481 hypothetical protein LOC283481, mRNA (cDNA clone IMAGE:5296747). [BC033993] 70 0.0259
ANKS1B ankyrin repeat and sterile alpha motif domain containing 1B (ANKS1B), transcript variant 2, mRNA 
[NM_181670]
70 0.0339
GNAZ guanine nucleotide binding protein (G protein), alpha z polypeptide (GNAZ), mRNA [NM_002073] 69 0.0166
BC030102 cDNA clone IMAGE:4796690. [BC030102] 69 0.0156
C6orf194 chromosome 6 open reading frame 194 (C6orf194), mRNA [NM_001007531] 69 0.0434
ENST00000343149 Unknown 69 0.0419
HRASLS2 HRAS-like suppressor 2 (HRASLS2), mRNA [NM_017878] 69 0.0344
A_32_P190864 Unknown 69 0.0319
EMP2 epithelial membrane protein 2 (EMP2), mRNA [NM_001424] 69 0.0492
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THC2281336 Unknown 69 0.0359
LOC388114 cDNA clone IMAGE:4798730. [BC036424] 69 0.0436
K-ALPHA-1 alpha tubulin (K-ALPHA-1), mRNA [NM_006082] 69 0.0257
SCD stearoyl-CoA desaturase (delta-9-desaturase) (SCD), mRNA [NM_005063] 69 0.0467
GAS7 growth arrest-specific 7 (GAS7), transcript variant c, mRNA [NM_201433] 68 0.0305
BM045853 603624848F1 NIH_MGC_40 cDNA clone IMAGE:5451514 5’, mRNA sequence [BM045853] 68 0.0462
SNTG2 syntrophin, gamma 2 (SNTG2), mRNA [NM_018968] 68 0.0149
BG943680 BG943680 ax40g03.x1 Hembase; Erythroid Progenitor Cells (LCB:ax library) cDNA clone ax40g03 random, 
mRNA sequence [BG943680]
68 0.0308
MRPS6 mitochondrial ribosomal protein S6 (MRPS6), nuclear gene encoding mitochondrial protein, mRNA 
[NM_032476]
68 0.0457
AK054684 cDNA FLJ30122 fis, clone BRACE1000087. [AK054684] 68 0.0331
HCA112 hepatocellular carcinoma-associated antigen 112 (HCA112), mRNA [NM_018487] 68 0.0435
C6orf1 chromosome 6 open reading frame 1 (C6orf1), transcript variant 1, mRNA [NM_178508] 68 0.0451
OXCT2 mRNA for FLJ00030 protein, partial cds. [AK024440] 68 0.0439
CXorf6 chromosome X open reading frame 6 (CXorf6), mRNA [NM_005491] 68 0.0192
ENST00000377492 Q99KF9 (Q99KF9) Lrpprc protein, partial (39%) [THC2336834] 68 0.0130
SCCPDH saccharopine dehydrogenase (putative) (SCCPDH), mRNA [NM_016002] 68 0.0359
BM955917 EST0854 HEV PCR-select cDNA clone HEV#2788 similar to olfactory receptor OR7E15P pseudogene, mRNA 
sequence [BM955917]
68 0.0229
KIAA0232 KIAA0232 gene product (KIAA0232), mRNA [NM_014743] 68 0.0231
C9orf165 chromosome 9 open reading frame 165 (C9orf165), mRNA [NM_198573] 67 0.0307
ZSWIM3 zinc finger, SWIM-type containing 3 (ZSWIM3), mRNA [NM_080752] 67 0.0330
LGI3 leucine-rich repeat LGI family, member 3 (LGI3), mRNA [NM_139278] 67 0.0209
TNNI3K TNNI3 interacting kinase (TNNI3K), mRNA [NM_015978] 67 0.0406
AA348270 AA348270 EST54713 Hippocampus I cDNA 3’ end similar to EST containing Alu repeat, mRNA sequence 
[AA348270]
67 0.0451
FDFT1 farnesyl-diphosphate farnesyltransferase 1 (FDFT1), mRNA [NM_004462] 67 0.0307
MFSD2 major facilitator superfamily domain containing 2 (MFSD2), mRNA [NM_032793] 67 0.0267
THC2315973 Unknown 67 0.0130
ENST00000374395 Down syndrome critical region gene 1-like 2, mRNA (cDNA clone MGC:46109 IMAGE:5770066), complete cds. 
[BC035854]
67 0.0229
TMEM139 transmembrane protein 139 (TMEM139), mRNA [NM_153345] 67 0.0488
KIAA1026 kazrin (KIAA1026), transcript variant B, mRNA [NM_001018000] 67 0.0243
INPP5F inositol polyphosphate-5-phosphatase F (INPP5F), transcript variant 1, mRNA [NM_014937] 67 0.0339
MLLT11 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11 (MLLT11), 
mRNA [NM_006818]
67 0.0401
THC2344033 Unknown 67 0.0436
DHCR7 7-dehydrocholesterol reductase (DHCR7), mRNA [NM_001360] 66 0.0356
AK026697 cDNA: FLJ23044 fis, clone LNG02454. [AK026697] 66 0.0413
TMEM155 transmembrane protein 155 (TMEM155), mRNA [NM_152399] 66 0.0316
FZD8 frizzled homolog 8 (Drosophila) (FZD8), mRNA [NM_031866] 66 0.0182
A_23_P120606 Unknown 66 0.0441
LIPC lipase, hepatic (LIPC), mRNA [NM_000236] 66 0.0183
LRRC4C leucine rich repeat containing 4C (LRRC4C), mRNA [NM_020929] 66 0.0439
ANKRD43 ankyrin repeat domain 43 (ANKRD43), mRNA [NM_175873] 66 0.0417
SNX24 sorting nexing 24 (SNX24), mRNA [NM_014035] 66 0.0259
PDZD2 PDZ domain containing 2 (PDZD2), mRNA [NM_178140] 66 0.0356
ENST00000277575 mRNA for KIAA0019 protein, partial cds. [D13644] 66 0.0257
SLC20A2 solute carrier family 20 (phosphate transporter), member 2 (SLC20A2), mRNA [NM_006749] 66 0.0297
THC2302865 FABE_HUMAN (Q01469) Fatty acid-binding protein, epidermal (E-FABP) (Psoriasis-associated fatty acid-bind-
ing protein homolog) (PA-FABP), partial (53%) [THC2302865]
66 0.0434
STAG3 stromal antigen 3 (STAG3), mRNA [NM_012447] 65 0.0441
RASEF RAS and EF-hand domain containing (RASEF), mRNA [NM_152573] 65 0.0242
CDH4 cDNA: FLJ22202 fis, clone HRC01333. [AK025855] 65 0.0381
NLK nemo-like kinase (NLK), mRNA [NM_016231] 65 0.0338
RAB37 RAB37, member RAS oncogene family (RAB37), transcript variant 3, mRNA [NM_175738] 65 0.0205
PCSK6 proprotein convertase subtilisin/kexin type 6 (PCSK6), transcript variant 1, mRNA [NM_002570] 65 0.0201
ARHGAP22 Rho GTPase activating protein 22 (ARHGAP22), mRNA [NM_021226] 65 0.0407
HSPA2 heat shock 70kDa protein 2 (HSPA2), mRNA [NM_021979] 65 0.0182
AQP11 aquaporin 11 (AQP11), mRNA [NM_173039] 65 0.0202
THC2270160 Unknown 65 0.0491
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FAM19A5 family with sequence similarity 19 (chemokine (C-C motif)-like), member A5 (FAM19A5), mRNA 
[NM_015381]
65 0.0384
CD9 CD9 molecule (CD9), mRNA [NM_001769] 65 0.0457
BG216262 RST35951 Athersys RAGE Library cDNA, mRNA sequence [BG216262] 65 0.0258
MCOLN2 mucolipin 2 (MCOLN2), mRNA [NM_153259] 65 0.0376
CMTM6 CKLF-like MARVEL transmembrane domain containing 6 (CMTM6), mRNA [NM_017801] 65 0.0259
CMTM7 CKLF-like MARVEL transmembrane domain containing 7 (CMTM7), transcript variant 1, mRNA 
[NM_138410]
65 0.0413
CPXM2 carboxypeptidase X (M14 family), member 2 (CPXM2), mRNA [NM_198148] 64 0.0229
A_24_P255836 Unknown 64 0.0082
A_23_P113762 Unknown 64 0.0146
SORD sorbitol dehydrogenase (SORD), mRNA [NM_003104] 64 0.0350
STMN4 stathmin-like 4 (STMN4), mRNA [NM_030795] 64 0.0229
SAMHD1 SAM domain and HD domain 1 (SAMHD1), mRNA [NM_015474] 64 0.0275
C10orf125 chromosome 10 open reading frame 125 (C10orf125), mRNA [NM_198472] 64 0.0192
CR608907 full-length cDNA clone CS0DM002YA18 of Fetal liver of (human). [CR608907] 64 0.0098
KLF15 Kruppel-like factor 15 (KLF15), mRNA [NM_014079] 64 0.0164
C10orf13 chromosome 10 open reading frame 13 (C10orf13), mRNA [NM_152429] 64 0.0283
TSGA2 testis specific A2 homolog (mouse) (TSGA2), mRNA [NM_080860] 64 0.0197
BZRAP1 benzodiazapine receptor (peripheral) associated protein 1 (BZRAP1), mRNA [NM_004758] 64 0.0499
A_23_P140454 Unknown 64 0.0121
ARHGAP24 Rho GTPase activating protein 24 (ARHGAP24), mRNA [NM_031305] 64 0.0240
RAB38 RAB38, member RAS oncogene family (RAB38), mRNA [NM_022337] 64 0.0077
RDH10 retinol dehydrogenase 10 (all-trans) (RDH10), mRNA [NM_172037] 64 0.0307
FLJ25530 hepatocyte cell adhesion molecule (FLJ25530), mRNA [NM_152722] 64 0.0101
TESK2 testis-specific kinase 2 (TESK2), mRNA [NM_007170] 63 0.0229
Ells1 hypothetical protein Ells1 (Ells1), mRNA [NM_152793] 63 0.0186
HPS5 Hermansky-Pudlak syndrome 5 (HPS5), transcript variant 1, mRNA [NM_181507] 63 0.0260
GDF1 growth differentiation factor 1 (GDF1), mRNA [NM_001492] 63 0.0229
C9orf50 chromosome 9 open reading frame 50 (C9orf50), mRNA [NM_199350] 63 0.0171
MPP6 membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) (MPP6), mRNA [NM_016447] 63 0.0295
C9orf58 chromosome 9 open reading frame 58 (C9orf58), transcript variant 2, mRNA [NM_001002260] 63 0.0259
SYT1 synaptotagmin I (SYT1), mRNA [NM_005639] 63 0.0257
WFIKKN2 WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 (WFIKKN2), mRNA 
[NM_175575]
63 0.0073
GLDC glycine dehydrogenase (decarboxylating) (GLDC), mRNA [NM_000170] 63 0.0386
LOC439914 cDNA FLJ37045 fis, clone BRACE2012185. [AK094364] 63 0.0054
MMD2 monocyte to macrophage differentiation-associated 2 (MMD2), mRNA [NM_198403] 63 0.0379
ENTHD1 ENTH domain containing 1 (ENTHD1), mRNA [NM_152512] 63 0.0292
BF803942 BF803942 CM2-CI0135-021100-477-g08 CI0135 cDNA, mRNA sequence [BF803942] 63 0.0180
FRMD3 FERM domain containing 3 (FRMD3), mRNA [NM_174938] 63 0.0168
AK5 adenylate kinase 5 (AK5), transcript variant 1, mRNA [NM_174858] 63 0.0152
CYFIP2 cytoplasmic FMR1 interacting protein 2 (CYFIP2), transcript variant 3, mRNA [NM_014376] 63 0.0317
THC2404004 Q9GZC7 (Q9GZC7) RNA binding protein RGGm, partial (7%) [THC2404004] 62 0.0232
PCDH10 protocadherin 10 (PCDH10), transcript variant 1, mRNA [NM_032961] 62 0.0318
TSPAN13 tetraspanin 13 (TSPAN13), mRNA [NM_014399] 62 0.0361
KIF13B kinesin family member 13B (KIF13B), mRNA [NM_015254] 62 0.0130
KIAA1688 KIAA1688 protein (KIAA1688), mRNA [NM_025251] 62 0.0215
BDKRB2 bradykinin receptor B2 (BDKRB2), mRNA [NM_000623] 62 0.0435
IGSF4C immunoglobulin superfamily, member 4C (IGSF4C), mRNA [NM_145296] 62 0.0327
PEG10 paternally expressed 10 (PEG10), transcript variant 2, mRNA [NM_001040152] 62 0.0334
AF132203 PRO1933 mRNA, complete cds. [AF132203] 62 0.0313
FAM83F family with sequence similarity 83, member F (FAM83F), mRNA [NM_138435] 62 0.0156
BMP7 bone morphogenetic protein 7 (osteogenic protein 1) (BMP7), mRNA [NM_001719] 62 0.0311
KIAA1576 KIAA1576 protein (KIAA1576), mRNA [NM_020927] 61 0.0256
THC2438994 Unknown 61 0.0308
EYA2 eyes absent homolog 2 (Drosophila) (EYA2), transcript variant 2, mRNA [NM_172113] 61 0.0373
TCBA1 T-cell lymphoma breakpoint associated target 1 (TCBA1), mRNA [NM_001040214] 61 0.0341
ADARB2 adenosine deaminase, RNA-specific, B2 (RED2 homolog rat) (ADARB2), mRNA [NM_018702] 61 0.0185
PARD6B par-6 partitioning defective 6 homolog beta (C. elegans) (PARD6B), mRNA [NM_032521] 61 0.0429
MMP28 matrix metallopeptidase 28 (MMP28), transcript variant 1, mRNA [NM_024302] 61 0.0144
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RAP1GDS1 RAP1, GTP-GDP dissociation stimulator 1 (RAP1GDS1), mRNA [NM_021159] 61 0.0196
MIA melanoma inhibitory activity (MIA), mRNA [NM_006533] 61 0.0294
OR7E24 olfactory receptor, family 7, subfamily E, member 24 (OR7E24) on chromosome 19 [NR_002146] 61 0.0077
ENST00000368025 Unknown 61 0.0419
EHBP1 EH domain binding protein 1 (EHBP1), mRNA [NM_015252] 61 0.0334
GLOXD1 glyoxalase domain containing 1 (GLOXD1), mRNA [NM_032756] 61 0.0049
MLPH melanophilin (MLPH), transcript variant 1, mRNA [NM_024101] 60 0.0076
KHDRBS3 KH domain containing, RNA binding, signal transduction associated 3 (KHDRBS3), mRNA [NM_006558] 60 0.0439
BC034319 cDNA clone IMAGE:4837650. [BC034319] 60 0.0130
TMC7 transmembrane channel-like 7 (TMC7), mRNA [NM_024847] 60 0.0090
ENST00000357776 cDNA FLJ13094 fis, clone NT2RP3002163. [AK023156] 60 0.0149
METRNL meteorin, glial cell differentiation regulator-like (METRNL), mRNA [NM_001004431] 60 0.0485
T15787 T15787 IB1893 Infant brain, Bento Soares cDNA 3’end, mRNA sequence [T15787] 60 0.0491
NEGR1 neuronal growth regulator 1 (NEGR1), mRNA [NM_173808] 60 0.0283
AP1S3 adaptor-related protein complex 1, sigma 3 subunit (AP1S3), mRNA [NM_001039569] 60 0.0417
PLLP transmembrane 4 superfamily member 11 (plasmolipin) (TM4SF11), mRNA [NM_015993] 60 0.0093
THC2412859 Unknown 60 0.0362
FLJ30428 cDNA FLJ30428 fis, clone BRACE2008941. [AK054990] 60 0.0088
KIF5A mRNA for KIF5A variant protein, partial cds, clone: ph00435. [AB210045] 60 0.0179
ENST00000322839 cDNA FLJ32334 fis, clone PROST2005426. [AK056896] 60 0.0317
B3GAT1 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) (B3GAT1), transcript variant 1, mRNA 
[NM_018644]
60 0.0259
KRT16 keratin 16 (focal non-epidermolytic palmoplantar keratoderma) (KRT16), mRNA [NM_005557] 60 0.0456
ENST00000374851 cDNA FLJ37094 fis, clone BRACE2018337. [AK094413] 59 0.0356
KCNK12 potassium channel, subfamily K, member 12 (KCNK12), mRNA [NM_022055] 59 0.0161
A_24_P533142 Unknown 59 0.0097
LY75 lymphocyte antigen 75 (LY75), mRNA [NM_002349] 59 0.0200
BMP8B bone morphogenetic protein 8b (osteogenic protein 2) (BMP8B), mRNA [NM_001720] 59 0.0173
ROM1 retinal outer segment membrane protein 1 (ROM1), mRNA [NM_000327] 59 0.0092
NRXN1 neurexin 1 (NRXN1), transcript variant alpha, mRNA [NM_004801] 59 0.0296
THC2434739 GP27_HUMAN (Q9NS67) Probable G protein-coupled receptor 27 (Super conserved receptor expressed in 
brain 1), complete [THC2434739]
59 0.0276
SC4MOL sterol-C4-methyl oxidase-like (SC4MOL), transcript variant 1, mRNA [NM_006745] 59 0.0296
SPTBN5 spectrin, beta, non-erythrocytic 5 (SPTBN5), mRNA [NM_016642] 59 0.0375
PRPH peripherin (PRPH), mRNA [NM_006262] 59 0.0359
IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3), mRNA [NM_006547] 59 0.0343
AK090670 cDNA FLJ33351 fis, clone BRACE2005063. [AK090670] 59 0.0077
C9orf125 chromosome 9 open reading frame 125 (C9orf125), mRNA [NM_032342] 59 0.0317
A_24_P110201 Unknown 59 0.0050
BIRC7 baculoviral IAP repeat-containing 7 (livin) (BIRC7), transcript variant 2, mRNA [NM_022161] 59 0.0408
OR7E156P olfactory receptor, family 7, subfamily E, member 156 pseudogene (OR7E156P) on chromosome 13 
[NR_002171]
59 0.0050
HEPN1 associated with liver cancer (HEPN1), mRNA [NM_001037558] 59 0.0339
AK125371 cDNA FLJ43381 fis, clone OCBBF2005428. [AK125371] 58 0.0340
FADS1 fatty acid desaturase 1 (FADS1), mRNA [NM_013402] 58 0.0097
DB534761 DB534761 RIKEN full-length enriched human cDNA library, hippocampus cDNA clone H023029H14 3’, mRNA 
sequence [DB534761]
58 0.0156
KCTD11 potassium channel tetramerisation domain containing 11 (KCTD11), mRNA [NM_001002914] 58 0.0230
OR2W3 olfactory receptor, family 2, subfamily W, member 3 (OR2W3), mRNA [NM_001001957] 58 0.0200
BG216229 BG216229 RST35803 Athersys RAGE Library cDNA, mRNA sequence [BG216229] 58 0.0279
UGT8 Human ceramide UDPgalactosyltransferase mRNA, complete cds. [U62899] 58 0.0192
NLGN4X neuroligin 4, X-linked (NLGN4X), transcript variant 1, mRNA [NM_020742] 58 0.0146
C20orf46 chromosome 20 open reading frame 46 (C20orf46), mRNA [NM_018354] 58 0.0205
THC2272949 Unknown 58 0.0259
BX100088 BX100088 BX100088 Soares_testis_NHT cDNA clone IMAGp998K133560 ; IMAGE:1409412, mRNA sequence 
[BX100088]
58 0.0258
THC2283645 Q71UK0 (Q71UK0) Growth factor receptor (Fragment), partial (20%) [THC2283645] 58 0.0178
THC2444209 Unknown 58 0.0229
ABAT 4-aminobutyrate aminotransferase (ABAT), nuclear gene encoding mitochondrial protein, transcript variant 1, 
mRNA [NM_020686]
58 0.0042
AK026984 cDNA: FLJ23331 fis, clone HEP12664. [AK026984] 57 0.0457
MET met proto-oncogene (hepatocyte growth factor receptor) (MET), mRNA [NM_000245] 57 0.0317
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C20orf100 chromosome 20 open reading frame 100 (C20orf100), mRNA [NM_032883] 57 0.0387
C2orf39 chromosome 2 open reading frame 39 (C2orf39), mRNA [NM_145038] 57 0.0156
ENST00000251170 KIAA0420 mRNA, complete cds. [AB007880] 57 0.0356
COL8A2 collagen, type VIII, alpha 2 (COL8A2), mRNA [NM_005202] 57 0.0061
SNCA synuclein, alpha (non A4 component of amyloid precursor) (SNCA), transcript variant NACP112, mRNA 
[NM_007308]
57 0.0229
WFDC2 WAP four-disulfide core domain 2 (WFDC2), transcript variant 4, mRNA [NM_080734] 57 0.0166
UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) (UCHL1), mRNA [NM_004181] 57 0.0095
ADRA2C adrenergic, alpha-2C-, receptor (ADRA2C), mRNA [NM_000683] 57 0.0465
THC2339102 BU616603 UI-H-FH1-bfi-p-18-0-UI.s1 NCI_CGAP_FH1 cDNA clone UI-H-FH1-bfi-p-18-0-UI 3’, mRNA 
sequence [BU616603]
57 0.0256
MFAP3L microfibrillar-associated protein 3-like (MFAP3L), transcript variant 2, mRNA [NM_001009554] 57 0.0356
TMEM132B transmembrane protein 132B (TMEM132B), mRNA [NM_052907] 57 0.0304
C10orf35 chromosome 10 open reading frame 35 (C10orf35), mRNA [NM_145306] 57 0.0283
THC2426594 Unknown 57 0.0243
AJ002788 mRNA for protein kinase C beta 1, 3’ UTR; fetal brain cDNA ICRFp507K04156. [AJ002788] 56 0.0404
KIAA0408 KIAA0408 (KIAA0408), mRNA [NM_014702] 56 0.0347
PRX periaxin (PRX), transcript variant 1, mRNA [NM_020956] 56 0.0054
EPPK1 epiplakin 1 (EPPK1), mRNA [NM_031308] 56 0.0073
ENST00000370599 fibroblast growth factor homologous factor 2 isoform 1Z+1Y (FHF-2) mRNA, partial cds. [AF199613] 56 0.0267
RASAL1 RAS protein activator like 1 (GAP1 like) (RASAL1), mRNA [NM_004658] 56 0.0081
BAMBI BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) (BAMBI), mRNA [NM_012342] 56 0.0060
AL564305 AL564305 AL564305 FETAL LIVER cDNA clone CS0DM004YC01 3-PRIME, mRNA sequence [AL564305] 56 0.0363
PRKCB1 protein kinase C, beta 1 (PRKCB1), transcript variant 2, mRNA [NM_002738] 56 0.0259
SIPA1L2 signal-induced proliferation-associated 1 like 2 (SIPA1L2), mRNA [NM_020808] 56 0.0255
CDH1 cadherin 1, type 1, E-cadherin (epithelial) (CDH1), mRNA [NM_004360] 56 0.0304
AK092450 cDNA FLJ35131 fis, clone PLACE6008824. [AK092450] 56 0.0231
NRIP2 nuclear receptor interacting protein 2 (NRIP2), mRNA [NM_031474] 56 0.0054
CNTN1 contactin 1 (CNTN1), transcript variant 1, mRNA [NM_001843] 56 0.0159
ENST00000382496 clone FBD8 Cri-du-chat critical region mRNA. [AF056434] 56 0.0054
CYP51A1 cytochrome P450, family 51, subfamily A, polypeptide 1 (CYP51A1), mRNA [NM_000786] 56 0.0283
LOC645904 PREDICTED: similar to Mitotic spindle assembly checkpoint protein MAD1 (Mitotic arrest deficient-like 
protein 1) (MAD1-like 1) (Mitotic checkpoint MAD1 protein-homolog) (HsMAD1) (hMAD1) (Tax-binding 
protein 181) (LOC645904), mRNA [XM_928876]
55 0.0084
RP11-35N6.1 plasticity related gene 3 (PRG-3), transcript variant 1, mRNA [NM_207299] 55 0.0098
GATM glycine amidinotransferase (L-arginine:glycine amidinotransferase) (GATM), mRNA [NM_001482] 55 0.0210
PLAT plasminogen activator, tissue (PLAT), transcript variant 1, mRNA [NM_000930] 55 0.0339
ENST00000309874 cDNA FLJ33063 fis, clone TRACH2000047. [AK057625] 55 0.0210
DHCR24 24-dehydrocholesterol reductase (DHCR24), mRNA [NM_014762] 55 0.0189
ATOH8 atonal homolog 8 (Drosophila) (ATOH8), mRNA [NM_032827] 55 0.0308
S100B S100 calcium binding protein, beta (neural) (S100B), mRNA [NM_006272] 55 0.0405
PCDH9 protocadherin 9 (PCDH9), transcript variant 1, mRNA [NM_203487] 55 0.0325
ENST00000330640 Homo sapiens, clone IMAGE:2899977, mRNA, partial cds. [BC022980] 55 0.0283
TUBB2B tubulin, beta 2B (TUBB2B), mRNA [NM_178012] 55 0.0362
THC2318057 Unknown 55 0.0341
C10orf82 chromosome 10 open reading frame 82 (C10orf82), mRNA [NM_144661] 54 0.0282
DRP2 dystrophin related protein 2 (DRP2), mRNA [NM_001939] 54 0.0054
THC2348985 T32824 EST54797 Human Brain cDNA 3’ end similar to None., mRNA sequence [T32824] 54 0.0183
TRIM58 tripartite motif-containing 58 (TRIM58), mRNA [NM_015431] 54 0.0156
FMN2 formin 2 (FMN2), mRNA [NM_020066] 54 0.0405
CHEK2 CHK2 checkpoint homolog (S. pombe) (CHEK2), transcript variant 3, mRNA [NM_001005735] 54 0.0036
AK094995 cDNA FLJ37676 fis, clone BRHIP2012627. [AK094995] 54 0.0334
NDP Norrie disease (pseudoglioma) (NDP), mRNA [NM_000266] 54 0.0036
EDN1 endothelin 1 (EDN1), mRNA [NM_001955] 54 0.0344
ENST00000360099 contactin 1, mRNA (cDNA clone MGC:41894 IMAGE:5273941), complete cds. [BC036569] 54 0.0256
BX338933 BX338933 BX338933 PLACENTA COT 25-NORMALIZED cDNA clone CS0DI065YH21 3-PRIME, mRNA 
sequence [BX338933]
53 0.0183
LRRIQ1 leucine-rich repeats and IQ motif containing 1 (LRRIQ1), mRNA [NM_032165] 53 0.0340
PEX5L peroxisomal biogenesis factor 5-like (PEX5L), mRNA [NM_016559] 53 0.0383
SOX2 SRY (sex determining region Y)-box 2 (SOX2), mRNA [NM_003106] 53 0.0093
PKP2 plakophilin 2 (PKP2), transcript variant 2b, mRNA [NM_004572] 53 0.0201
CNTN2 contactin 2 (axonal) (CNTN2), mRNA [NM_005076] 53 0.0091
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ACAT2 acetyl-Coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme A thiolase), mRNA (cDNA clone MGC:8573 
IMAGE:2823036), complete cds. [BC000408]
53 0.0257
BC039411 cDNA clone IMAGE:5301690. [BC039411] 53 0.0436
CHST2 carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 (CHST2), mRNA [NM_004267] 53 0.0229
MGC102966 similar to Keratin, type I cytoskeletal 16 (Cytokeratin-16) (CK-16) (Keratin-16) (K16), mRNA (cDNA clone 
MGC:102966 IMAGE:4752428), complete cds. [BC110641]
52 0.0119
BF836076 QV4-HT1018-171100-551-b09 HT1018 cDNA, mRNA sequence [BF836076] 52 0.0029
PAQR6 progestin and adipoQ receptor family member VI (PAQR6), transcript variant 1, mRNA [NM_024897] 52 0.0259
SLC13A3 solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 (SLC13A3), transcript variant 
2, mRNA [NM_001011554]
52 0.0235
KCNMB4 potassium large conductance calcium-activated channel, subfamily M, beta member 4 (KCNMB4), mRNA 
[NM_014505]
52 0.0062
CNGA1 cyclic nucleotide gated channel alpha 1 (CNGA1), mRNA [NM_000087] 52 0.0125
THC2409530 Unknown 52 0.0039
TSPAN5 cDNA FLJ31097 fis, clone IMR321000210. [AK055659] 52 0.0491
HPR haptoglobin-related protein (HPR), mRNA [NM_020995] 52 0.0375
RASL11B RAS-like, family 11, member B (RASL11B), mRNA [NM_023940] 51 0.0149
HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR), mRNA [NM_000859] 51 0.0321
AL137342 mRNA; cDNA DKFZp761G1111 (from clone DKFZp761G1111). [AL137342] 51 0.0210
CHL1 cell adhesion molecule with homology to L1CAM (close homolog of L1) (CHL1), mRNA [NM_006614] 51 0.0268
BQ188373 UI-E-EJ1-ajw-m-11-0-UI.r1 UI-E-EJ1 cDNA clone UI-E-EJ1-ajw-m-11-0-UI 5’, mRNA sequence [BQ188373] 51 0.0056
HRASLS3 HRAS-like suppressor 3 (HRASLS3), mRNA [NM_007069] 51 0.0318
AK124939 cDNA FLJ42949 fis, clone BRSTN2006583. [AK124939] 51 0.0304
CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1 (CYP26B1), mRNA [NM_019885] 51 0.0304
BU537617 BU537617 AGENCOURT_10224860 NIH_MGC_126 cDNA clone IMAGE:6567892 5’, mRNA sequence 
[BU537617]
51 0.0029
ARSI arylsulfatase family, member I, mRNA (cDNA clone IMAGE:5750037). [BC111002] 51 0.0062
LOC440421 PREDICTED: similar to keratin 17, transcript variant 1 (LOC440421), mRNA [XM_496202] 50 0.0153
HCN1 hyperpolarization activated cyclic nucleotide-gated potassium channel 1 (HCN1), mRNA [NM_021072] 50 0.0045
THC2377128 Unknown 50 0.0401
THC2401542 Unknown 50 0.0429
CYB5R2 cytochrome b5 reductase 2 (CYB5R2), mRNA [NM_016229] 50 0.0062
AW268902 AW268902 xv48h10.x1 Soares_NFL_T_GBC_S1 cDNA clone IMAGE:2816419 3’, mRNA sequence [AW268902]50 0.0127
THC2343678 Q6E5T4 (Q6E5T4) Claudin 2, partial (5%) [THC2343678] 50 0.0416
UTS2 urotensin 2 (UTS2), transcript variant 1, mRNA [NM_021995] 50 0.0247
PNLIPRP2 pancreatic lipase-related protein 2 (PNLIPRP2), mRNA [NM_005396] 50 0.0143
OPCML opioid binding protein/cell adhesion molecule-like (OPCML), transcript variant 2, mRNA [NM_001012393] 50 0.0257
THC2338229 Unknown 50 0.0086
STK32A serine/threonine kinase 32A (STK32A), mRNA [NM_145001] 50 0.0090
A_23_P7719 Unknown 50 0.0042
IL17B interleukin 17B (IL17B), mRNA [NM_014443] 49 0.0054
CYP2J2 cytochrome P450, family 2, subfamily J, polypeptide 2 (CYP2J2), mRNA [NM_000775] 49 0.0171
SCRN1 secernin 1 (SCRN1), mRNA [NM_014766] 49 0.0051
ENST00000311208 MGC5.2.1.1.1.B03.F.1 NIH_MGC_331 cDNA clone MGC5.2.1.1.1.B03, mRNA sequence [DR007925] 49 0.0061
OR7E47P olfactory receptor, family 7, subfamily E, member 47 pseudogene, mRNA (cDNA clone IMAGE:5590288). 
[BC042060]
49 0.0029
LOC63928 hepatocellular carcinoma antigen gene 520 (LOC63928), mRNA [NM_022097] 49 0.0304
NTF3 neurotrophin 3 (NTF3), mRNA [NM_002527] 48 0.0029
CR1L PREDICTED: complement component (3b/4b) receptor 1-like, transcript variant 3 (CR1L), mRNA 
[XM_931256]
48 0.0146
FA2H fatty acid 2-hydroxylase (FA2H), mRNA [NM_024306] 48 0.0077
A_32_P100830 Unknown 48 0.0210
BCAS1 breast carcinoma amplified sequence 1 (BCAS1), mRNA [NM_003657] 48 0.0054
ENST00000370306 BX089019 Soares_testis_NHT cDNA clone IMAGp998K243513 ; IMAGE:1391375, mRNA sequence 
[BX089019]
48 0.0036
FOLH1 folate hydrolase (prostate-specific membrane antigen) 1 (FOLH1), transcript variant 1, mRNA [NM_004476] 48 0.0053
ENST00000321925 cDNA FLJ41687 fis, clone HCASM2006632, highly  similar to UREA TRANSPORTER, ERYTHROCYTE. 
[AK123681]
48 0.0462
C6orf142 chromosome 6 open reading frame 142 (C6orf142), mRNA [NM_138569] 47 0.0220
ALDOC aldolase C, fructose-bisphosphate (ALDOC), mRNA [NM_005165] 47 0.0036
AL110257 mRNA; cDNA DKFZp566P2346 (from clone DKFZp566P2346). [AL110257] 47 0.0039
KRT17 keratin 17 (KRT17), mRNA [NM_000422] 47 0.0061
CR597597 full-length cDNA clone CS0DI013YN06 of Placenta Cot 25-normalized of (human). [CR597597] 47 0.0101
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LOC153328 similar to CG4995 gene product, mRNA (cDNA clone MGC:35539 IMAGE:5200129), complete cds. [BC025747]47 0.0039
A_24_P408449 Unknown 47 0.0130
RGS9 regulator of G-protein signalling 9 (RGS9), mRNA [NM_003835] 47 0.0434
THC2373072 CB243285 UI-CF-FN0-agc-l-12-0-UI.s1 UI-CF-FN0 cDNA clone UI-CF-FN0-agc-l-12-0-UI 3’, mRNA sequence 
[CB243285]
46 0.0029
EB386378 nbj15e01.y1 Human optic nerve. Unnormalized (nbj) cDNA clone nbj15e01 5’, mRNA sequence [EB386378] 46 0.0180
RTN1 reticulon 1 (RTN1), transcript variant 1, mRNA [NM_021136] 46 0.0054
TLL2 tolloid-like 2 (TLL2), mRNA [NM_012465] 46 0.0029
FAM81A family with sequence similarity 81, member A (FAM81A), mRNA [NM_152450] 46 0.0045
FLJ41603 FLJ41603 protein (FLJ41603), mRNA [NM_001001669] 46 0.0106
NRCAM neuronal cell adhesion molecule (NRCAM), transcript variant 2, mRNA [NM_005010] 45 0.0419
KRT14 keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner) (KRT14), mRNA [NM_000526] 45 0.0045
ELOVL7 ELOVL family member 7, elongation of long chain fatty acids (yeast) (ELOVL7), mRNA [NM_024930] 45 0.0168
THC2406238 Q8DHD4 (Q8DHD4) Tlr2025 protein, partial (10%) [THC2406238] 45 0.0259
GDPD2 glycerophosphodiester phosphodiesterase domain containing 2 (GDPD2), mRNA [NM_017711] 45 0.0045
SHRM shroom (SHRM), mRNA [NM_020859] 44 0.0188
ENST00000382108 mRNA; cDNA DKFZp686N20108 (from clone DKFZp686N20108). [BX648244] 44 0.0229
SV2B synaptic vesicle glycoprotein 2B (SV2B), mRNA [NM_014848] 44 0.0205
SOX2OT SOX2 overlapping transcript (non-coding RNA) (SOX2OT) on chromosome 3 [NR_002810] 44 0.0065
DKFZp313A2432 mRNA; cDNA DKFZp313A2432 (from clone DKFZp313A2432). [AL833119] 44 0.0215
CRLF1 cytokine receptor-like factor 1 (CRLF1), mRNA [NM_004750] 43 0.0404
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 (NTRK2), transcript variant b, mRNA [NM_001007097] 43 0.0029
MAL mal, T-cell differentiation protein (MAL), transcript variant a, mRNA [NM_002371] 43 0.0045
BC040293 cDNA clone IMAGE:4820330. [BC040293] 43 0.0192
RASGEF1A RasGEF domain family, member 1A (RASGEF1A), mRNA [NM_145313] 42 0.0034
PSMAL growth-inhibiting protein 26 (PSMAL), mRNA [NM_153696] 42 0.0080
THC2442514 Q9V4T7 (Q9V4T7) CG8694-PA (RE63163p), partial (4%) [THC2442514] 42 0.0029
SLC17A6 solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6 (SLC17A6), mRNA 
[NM_020346]
41 0.0168
GFAP glial fibrillary acidic protein (GFAP), mRNA [NM_002055] 41 0.0142
THC2342207 Unknown 41 0.0121
BQ717813 AGENCOURT_8229426 Lupski_dorsal_root_ganglion cDNA clone IMAGE:6184804 5’, mRNA sequence 
[BQ717813]
41 0.0050
THC2442021 Unknown 41 0.0039
AW950828 AW950828 EST362898 MAGE resequences, MAGA cDNA, mRNA sequence [AW950828] 39 0.0029
C20orf39 chromosome 20 open reading frame 39 (C20orf39), mRNA [NM_024893] 39 0.0029
DKFZP586H2123 regeneration associated muscle protease (DKFZP586H2123), transcript variant 1, mRNA [NM_015430] 38 0.0095
PPP2R2B protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform (PPP2R2B), transcript variant 
1, mRNA [NM_004576]
38 0.0050
ABCA13 ATP-binding cassette, sub-family A (ABC1), member 13 (ABCA13), mRNA [NM_152701] 36 0.0092
AK094523 cDNA FLJ37204 fis, clone BRALZ2006976. [AK094523] 35 0.0029
RGS22 regulator of G-protein signalling 22 (RGS22), mRNA [NM_015668] 34 0.0029
CP ceruloplasmin (ferroxidase) (CP), mRNA [NM_000096] 34 0.0077
KSP37 Ksp37 protein (KSP37), mRNA [NM_031950] 32 0.0029
GAP43 growth associated protein 43 (GAP43), mRNA [NM_002045] 31 0.0133
FBXO2 F-box protein 2 (FBXO2), mRNA [NM_012168] 31 0.0035
MT3 metallothionein 3 (growth inhibitory factor (neurotrophic)) (MT3), mRNA [NM_005954] 31 0.0029
ENST00000333722 chromosome 12 open reading frame 56, mRNA (cDNA clone IMAGE:3685952). [BC015121] 31 0.0036
GPM6A glycoprotein M6A (GPM6A), transcript variant 2, mRNA [NM_201591] 30 0.0033
SLC27A6 solute carrier family 27 (fatty acid transporter), member 6 (SLC27A6), transcript variant 2, mRNA [NM_
001017372]
30 0.0029
NKX6-2 NK6 transcription factor related, locus 2 (Drosophila) (NKX6-2), mRNA [NM_177400] 29 0.0036
KIF5C mRNA for KIAA0531 protein, partial cds. [AB011103] 29 0.0029
ANGPTL7 angiopoietin-like 7 (ANGPTL7), mRNA [NM_021146] 28 0.0035
IGSF4D immunoglobulin superfamily, member 4D (IGSF4D), mRNA [NM_153184] 27 0.0049
TSPAN8 tetraspanin 8 (TSPAN8), mRNA [NM_004616] 27 0.0136
SORCS3 sortilin-related VPS10 domain containing receptor 3 (SORCS3), mRNA [NM_014978] 27 0.0029
PCP4 Purkinje cell protein 4 (PCP4), mRNA [NM_006198] 27 0.0037
Gene Description                                                                                                                                              Expr. (%) P-val.
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Chapter 4
Genetic modification of human sural nerve segments by a lentiviral vector 
encoding nerve growth factor
Martijn R Tannemaat, Gerard J Boer, Joost Verhaagen, Martijn J Malessy 
Neurosurgery. 2007 Dec;61(6):1286-94; discussion 1294-6
Abstract 
objective Autologous nerve grafts are used to treat severe peripheral nerve injury, 
but recovery of nerve function after grafting is rarely complete. Exogenous applica-
tion of neurotrophic factors may enhance regeneration, but thus far the application 
of neurotrophic factors has been hampered by fast degradation following local ap-
plication and unwanted side effects following systemic application. These problems 
may be overcome with the use of lentiviral (LV) vectors which direct sustained local 
transgene expression in cells. 
methods Human sural nerve segments were either submerged in or injected with 
LV vectors encoding green fluorescent protein (GFP) and cultured in vitro. Produc-
tion of nerve growth factor (NGF) by nerve segments after injection of LV-NGF was 
quantified. The effect of NGF produced by LV-transduced fibroblasts derived from 
human sural nerve segments was assessed on neurite outgrowth in vitro.
results Injection of vector into nerve segments is a more effective way to deliver the 
vector than submersion of the nerve in vector-containing medium, leading to large 
numbers of transduced fibroblasts over a significant extent inside the nerve. The injec-
tion of LV-NGF leads to a gradual increase of NGF production, reaching a plateau after 
4 days. LV-NGF-transduced human fibroblasts promote neurite outgrowth in vitro. 
conclusion We have developed a method to transduce cells in human sural nerve 
segments with LV vector. This approach holds promise as a powerful novel adjuvant 
therapy for peripheral nerve surgery and can be performed without changing the 
routine practice of nerve grafting.
Objective
In patients with a complete transection of a peripheral nerve, surgical repair is neces-
sary to allow regeneration of the nerve and the return of nerve function. When ten-
sion-free direct coaptation of the proximal and distal nerve stumps is not possible, 
an autologous nerve is used as a graft to bridge the gap 1. The most commonly used 
nerve for this purpose is the sural nerve. 
 Two major functions of the nerve graft can be distinguished: physical guidance 
78
chapter 4
and trophic support. The transplanted nerve gives physical guidance to regenerating 
axons by the longitudinally oriented endoneurial tubes that act as scaffolds for the 
regenerating axons 7. The trophic support for regenerating axons comes mainly from 
the Schwann cells inside the nerve graft. After the graft is dissected from the donor 
site, activated Schwann cells start secreting a wide range of neurotrophic proteins such 
as nerve growth factor (NGF) 9. In spite of the axon-guiding and outgrowth-support-
ing properties of these nerve grafts, the functional outcome of nerve grafting is often 
limited, especially when long nerve grafts have to be used1.
 It is widely believed that surgical repair of the peripheral nerve by autologous grafts 
has reached optimal technical refinement and that new concepts are needed to en-
hance functional outcome2. Research has focused on the development of artificial 
nerve guides as an alternative, sometimes seeded with naïve Schwann cells122, Schwann 
cells genetically modified to secrete neurotrophic factors28 or engineered to release 
neurotrophic factors 121. A wide range of artificial tubes has been investigated, but so 
far, none has been shown unambiguously to possess better nerve outgrowth-support-
ing properties than the autologous nerve graft122. Theoretical advantages of artificial 
nerve tubes are the off-the-shelf availability and the absence of donor site morbidity. 
However, to ensure continuous trophic support to regenerating neurites, the addition 
of autologous Schwann cells seems unavoidable, but this will inherently compromise 
the aforementioned advantages.
 We therefore believe that enhancing the outgrowth-supporting properties of the 
autologous nerve graft itself is another alternative which should be explored in order 
to improve the functional results of nerve grafting. One way to achieve this may be 
the application of viral vectors to induce overexpression of therapeutic proteins.
 The application of first generation viral vectors such as herpes simplex viral vectors 
and adenoviral vectors was hampered by a vector-mediated immune response, loss 
of transgene expression and direct neurotoxicity of these vectors123. These problems 
have been overcome with the development of adeno-associated viral (AAV)126 and 
lentiviral (LV) vectors42, which have a favourable toxicity profile, infect dividing and 
non-dividing cells and direct long term transgene expression in the nervous system. 
Currently, the vesicular stomatitis virus G glycoprotein (VSV-G) pseudotyped LV has 
an advantage over AAV as it infects a wide range of cells, whereas AAV serotype 2 
predominantly infects neurons32. Although this may change with the ongoing develop-
ment of different AAV serotypes 124, for this study we applied LV vectors to transduce 
the non-neuronal cells in nerve segments.
 The application of viral vectors has potential as an adjuvant therapy as it does not 
have to interfere with the clinical routine. We chose, therefore, as a first necessary step 
towards clinical application, to investigate whether cells in the human peripheral nerve 
can be transduced ex vivo. 
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Methods
Lentiviral vector preparation
The production of self-inactivating LV vectors has been described in detail previ-
ously42. The plasmids needed for the production of GFP-encoding LV vector were 
generously provided by Dr L Tamagnone and Dr L Naldini (Institute for Cancer Re-
search, University of Torino, Italy). For the production of LV-NGF, cDNA coding for 
rat NGF was ligated into the transfer vector pRRLsinPPTh-WPRE.
 Vector stocks were generated by as described previously 125. All stocks were stored 
in 0.1 M sodium phosphate buffered saline pH 7.4 (PBS) at -800C. For LV-GFP, the 
concentration of vector particles was defined by infecting HEK 293T cells and count-
ing the number of GFP-expressing cells after 48 h. Recombinant stock titers were 
expressed as transducing units per ml (TUHEK293T/ml) and ranged from 109 to 1010.
 For LV-NGF, the vector titer was determined with an HIV-p24 core profile ELISA kit 
(Perkin Elmer Life Sciences). HIV-p24 ELISA on an LV-GFP stock with a known concen-
tration in TUHEK293T /ml was performed simultaneously so that the titer of LV-NGF could 
be calculated on the same basis as LV-GFP. The concentration of the currently used LV-
NGF stocks was subsequently estimated to range from 1.7x109 to 8x109 TUHEK293T /ml.
Culture and transduction of human sural nerve segments
Residual segments of human sural nerve applied for reconstructive surgery from adult 
patients with a traumatic brachial plexus lesion or infants with an obstetrical brachial 
plexus lesion were used. These reconstructions were performed at the Department 
of Neurosurgery, Leiden University Medical Center. Prior to surgery, consent from 
patients or their guardians was obtained for the use of residual segments of sural 
nerve for research purposes. Sural nerve segments that would otherwise have been 
discarded were transferred to Isocove’s modified Dulbecco culture medium, contain-
ing 10% fetal bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin and 2 mM 
Glutamax (Sigma) (this will subsequently be referred to as “culture medium”) at room 
temperature and as soon as possible, but always within 24 h, cut to a standard length 
of 15 mm before infection with LV vector. Two methods of transducing the cells in 
the nerve segments with LV vector were tested: direct injection and submersion for 
up to 16 h under in vitro culture conditions.
 For direct injection, the nerve was gently stretched and attached with two metal pins 
to a plate containing dental wax. A glass capillary with an 80 μm tip diameter was at-
tached to a Hamilton syringe and filled with PBS containing LV-GFP as well as 0.1% 
Fast Green to visualize fluid during injection. The injection volume was 2 μl (except 
for three trials with 5-6 μl; see table 1) with vector titers ranging from 1.5x109 to 1010 
TU/ml. To be able to study the number and spread of transduced cells resulting from 
a single injection of vector we chose not to apply multiple injections. The vector was 
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injected through the epineurium in the center of the nerve, by slowly applying manual 
pressure to the plunger of the Hamilton syringe. 
 For submersion, nerve segments were incubated in 250 μl culture medium, just 
enough to keep the segments moist, that contained LV-GFP in concentrations rang-
ing from 3x106 to 108 TU/ml. Incubation time was either 4 or 16 h under 5% CO2 in 
a humidified incubator at 37°C. 
 After nerves were exposed to the viral vector, they were further cultured free float-
ing for 3 days in 2 ml culture medium at 37°C in a humidified incubator in 5% CO2 
to allow for GFP to accumulate inside the cell. A total number of 21 nerve segments 
from 12 different patients were used for transduction with LV-GFP (Table 1). 
Tissue preparation and histology
Three days after infection, the nerve segments were gently stretched and fixed with 
4% paraformaldehyde in 0.1 M phosphate buffer pH 7.4 overnight, followed by 24 
h incubation in 25% sucrose in phosphate buffer for cryoprotection and stored at 
-80°C before 4-8 series of alternative longitudinal 20 μm thick cryostat sections were 
mounted on Superfrost Plus glass slides. 
 The efficacy of viral transduction was assessed by observing the distribution of 
GFP-containing cells with a fluorescence microscope on glycerol-Mowiol-embedded 
sections of the nerve. For each nerve, photomicrographs were made of the section 
containing the highest number of GFP positive cells. Scoring was performed by 2 
independent observers that were blinded to the method of vector application. Nerve 
segments without GFP positive cells were scored 0, nerve segments with an estimated 
maximum of 10 GFP positive cells on a single section were scored +, 10-100 GFP 
positive cells ++, 100-1000 GFP positive cells +++ and nerve segments with more 
than 1000 GFP-positive cells on a single section were scored ++++. The maximal 
longitudinal distance of the area of GFP positive cells within one section was measured 
using ImagePro software (Media Cybernetics, Silver Spring, USA), as an indication of 
the spatial distribution of transduced cells. Routine thionine staining of sections was 
performed to visualize cell nuclei and to asses the structural integrity of the nerve seg-
ments after 4 days of culture. A special effort was made to identify the site of injection 
in order to assess possible damage to the endoneurial tubes.
Table 1  Overview of GFP expression in LV-GFP transduced human sural nerve segments.
* From some patients, several segments were used. Nerve segments from the same patient can 
be identified by corresponding numbers in the Patient # column. ** GFP expression is quanti-
fied as follows: - no GFP positive cells, + 0-10 GFP positive cells, ++ 10-100 GFP positive cells, 
+++ 100-1000 GFP positive cells, ++++ >1000 GFP positive cells on a representative section 
of the nerve. *** Distance between two outmost transduced cells in a section as a percentage 
of the length of the nerve segment (15 mm). **** Injection volume 5 or 6 μl instead of 2 μl.
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 For immunocytochemistry, sections were washed three times in 0.1 M Tris/HCl-
buffered saline pH 7.4 (TBS). To enhance antibody tissue penetration and to block 
unspecific antibody binding sites, sections were incubated in TBS containing 0.3% 
Triton X-100 and 5% fetal bovine serum for 1 h. Subsequently, sections were exposed 
to primary antibodies against S100 to stain Schwann cells (1:200; Dako, #Z0311, and 
against raldh2 (1:500; rabbit polyclonal; a gift from Dr. P. McCaffery, E. Kennedy 
Shriver Center, University of Massachusetts Medical School, Boston, USA)126 and 
fibronectin (1:400; mouse monoclonal FN-3E2, Sigma) to stain fibroblasts. Primary 
antibody incubations were performed overnight at 4°C. The next day, sections were 
washed three times in TBS and incubated with fluorophore-conjugated secondary 
antibodies for 2 h. Depending on the desired staining, DαR-Cy3 or DαM-Cy3 were 
used (1:400; Jackson ImmunoReagents). Finally, the sections were washed in TBS, 
mounted in Moviol and coverslipped.
Transduction of co-cultured Schwann cells and fibroblasts
Co-cultures of human Schwann cells and fibroblasts were created using the serial ex-
plant method developed by Morrissey et al.127. Schwann cells from human sural nerve 
segments were isolated by placing small nerve segments in culture and allowing the 
faster migrating fibroblasts to move out. When migrated cells reached a monolayer, 
the explants were placed in new dishes until the monolayer showed equal densities of 
Schwann cells and fibroblasts. At that point, the cells were trypsinized (0.25% in PBS 
for 2 min), taken up in culture medium and plated out at 50% confluency on poly-
L-lysine-coated glass coverslips. The next day, LV-GFP was added at a multiplicity of 
infection (MOI) of 1, 10 or 50 and culture continued for 48 h under 5% CO2 condi-
tions in a humidified incubator at 37°C to allow transgene expression. Subsequently 
cells were fixed with 4% parformaldehyde in PBS for 30 min and stained with the 
fibronectin and S100 antibodies as described above. 
 Images were made with a confocal laser scanning microscope from random fields 
from 3 separate cultures per MOI. The number of GFP positive (fibronectin positive) 
fibroblasts and GFP positive (S100 positive) Schwann cells were counted manually per 
image and the relative amount of transduced cells per cell type calculated. Statistical 
analysis of these results was performed using a two-tailed Student’s T-test assuming 
unequal variances. 
Transduction with LV-NGF and quantification of NGF production
Three 15 mm nerve segments from one patient were transduced by injection of 2.5x107 
TU LV-NGF in 3 μl PBS. An additional three segments from another patient were 
injected with 107 TU LV-NGF in 6 μl PBS. For each transduced nerve segment, a 15 
mm segment from the same patient served as non-transduced control. Segments from 
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the first patient were cultured for 7 days and segments from the second patient were 
cultured for 11 days. The culture medium was refreshed every 24 h, and the condi-
tioned medium stored at -20°C for the measurement of the NGF concentration using 
an NGF ELISA kit (#G7630; Promega, Madison, USA). This kit detects both human 
(endogenous)and rat (transgenic) NGF.
Effect of overexpression of NGF on rat neurite outgrowth in vitro
The biological activity of NGF produced by LV-NGF-transduced fibroblasts was de-
termined with an outgrowth assay on cultured embryonic rat dorsal root ganglia 
(DRGs) (16). To create fibroblast cultures from small segments of human sural nerve, 
fibroblasts were allowed to migrate out of cultured nerve segments (which were sub-
sequently removed) and proliferate further. To achieve optimal transduction, LV-NGF 
was added at an MOI of 50 when cultured fibroblasts were 50-75% confluent, using 
non-transduced cultures as controls. The cells were cultured in 2 ml for 72 h to allow 
NGF to accumulate in the medium, after which it was harvested and stored at -20°C 
for bioassays.
 The bioassay was performed as described previously by Niclou et al. 128 on DRGs 
isolated from E15 rat embryos that were plated as whole explants on laminin-coated 
glass coverslips (n=6 per condition). In short, after culturing for 48 h in either a) fresh 
culture medium, b) culture medium conditioned from cultured but non-transfected 
fibroblasts, c) culture medium conditioned from cultured fibroblasts transduced with 
LV-NGF, or d) culture medium to which 20 ng/ml recombinant NGF was added 
(#1014331, Roche, Bazel, Switzerland), the DRGs were fixed for 30 min with 4% 
paraformaldehyde in PBS and neurite growth visualized by neurofilament antibody 
staining (2H3 ascites 1:1000; Dev. Stud. Hybridoma Bank, University of Iowa, Iowa, 
USA) using Cy3 as chromogen in the second antibody step. Fluorescence photographs 
were taken with the same intensity settings for all DRGs. Neurite outgrowth was then 
quantified as the total area of neurofilament-stained structures outside the DRG bor-
ders using ImagePro software. Statistical evaluation was performed with two-tailed 
Student’s T-tests assuming unequal variances. 
Results
Injection of vector is the most effective method to transduce cells in a human 
sural nerve graft
Twelve nerve segments were transduced by direct injection of LV-GFP and compared 
to 9 nerve segments that were submerged in LV-GFP medium for either 4 (n=4) or 
16 h (n=5). Thionine nuclear staining of both the injected and submerged nerve seg-
ments showed that after 4 days in culture the cytoarchitecture of the nerve segments 
remained intact. Occasionally a small disruption of the epineurium, likely due to the 
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damage of the injection needle, could be observed, but generally no disruption of 
the nerve fascicles was visible. The majority of cells were S100 positive Schwann cells 
that aligned within the nerve fascicles. Staining for macrophages inside the nerve seg-
ments was negative (data not presented). In general, most cells appeared to be intact, 
although signs of necrosis of cells could sometimes be observed in small areas, usually 
at the center of the nerve segment (data not shown).
 After a single direct injection of LV-GFP numerous GFP positive cells could be ob-
served in 11 out of 12 nerve segments (table 1). Transduced cells were usually located 
in a distinct pattern in the epineurium surrounding the longitudinally oriented nerve 
fascicles (figure 1a). Only very rarely could a GFP positive cell be observed inside 
nerve fascicles. The number of transduced cells in a nerve segment was highly variable, 
with estimates ranging between 10 and more than a 1000 on a representative section 
Figure 1 In vitro transduction of human sural nerve after injection or immersion with LV-
GFP. For clarity, images have been inverted so that the fluorescent signal from transduced cells 
appears dark on a light background.
a) Overview after injection of 2x107 TU LV-GFP in 2 μl shows numerous GFP positive cells 
surrounding the fascicles (subject #6 in table 1).
b) Overview after submersion in 250 μl containing 4x108 TU LV-GFP shows less transduced 
cells that are mainly located on the outer edges of the nerve (subject #12 in table 1). 
c) and d) High magnification of boxed areas in a) revealing a dense transduction level. 
e) and f) High magnification of boxed areas in b) revealing some transduced cells on the outer 
edges of the nerve.
Scale bar indicates 0.5 mm.
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through the middle of the nerve (figure 1c and 1d). The average distance over which 
transduction could be seen was 5.5 mm, slightly more than 1/3 of the nerve, but in 
some nerve segments transgene expression was observed along the entire length of 
the nerve. After submersion in vector medium, low numbers of GFP positive cells were 
found in 5 out of 9 nerve segments (table 1), but primarily located near the ends of 
the nerve and outside the epineurium over the entire length (figure 1bef). The single 
nerve with the highest number of transduced cells was a segment that appeared to 
have a partially disrupted epineurium (data not shown). Submersion in higher con-
centrations of vector tended to increase numbers of transduced cells (table 1), but 
application of even larger amounts of vector is not easily feasible with the current LV 
vector stock concentrations. Increasing the incubation time from 4 to 16 h did not 
increase the number of transduced cells. No difference was observed in transduction 
efficiency for segments from adults or neonates with either injection or submersion.
The majority of transduced cells are fibroblasts
Immunohistochemical staining showed that more than 95% of transduced cells was 
not S100 positive. S100 positive cells were found inside the nerve fascicles, whereas 
most GFP positive cells were found in the epineurium surrounding the nerve fascicles 
(figure 2a). Although S100 staining did occasionally show a GFP positive Schwann 
cell, these were usually Schwann cells on the outer boundary of the nerve fascicles 
(figure 2b). Fibronectin (figure 2c) or raldh2 (figure 2d) immunofluorescent staining 
indicated that the majority of GFP-containing cells were fibroblasts, all located outside 
the nerve fascicles.
LV-GFP transduces co-cultured fibroblasts and Schwann cells with similar 
efficacy
Since the majority of transduced cells inside the human sural nerve were fibroblasts, 
we determined whether there is a difference in the intrinsic capability of LV to infect 
and transduce Schwann cells and fibroblasts. Cultured Schwann cells could easily 
be distinguished from fibroblasts because they showed an intense staining for S100, 
whereas fibroblasts stained brighter for fibronectin than Schwann cells. 
I n vitro application of increasing amounts of LV-GFP to co-cultures (n=3) led to 
increasing numbers of GFP positive cells. At MOI=1 only an occasionally transduced 
cell was found, whereas at MOI=10 and 50 respectively 12% and 21%, and 66% and 
59% of fibroblasts and Schwann cells were transduced with no statistically significant 
differences between the cell types (figure 3). This indicates that the LV vector is capable 
of transducing both cell types with similar efficacy when applied in culture, i.e., in the 
absence of potential physical obstacles.
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Injection of LV-NGF leads to an increase in NGF production
LV-NGF-transduced nerve segments secrete NGF into the culture medium at levels 
high enough to be detectable with ELISA. Segments either injected with 2.5x107 TU 
LV-NGF in 3 μl (patient 1 samples) or 107 TU in 6 μl (patient 2 samples) strikingly 
produced similar amounts over time despite the 2.5x higher LV-NGF TUs applied in 
nerve segments from the first patient (figure 4). Culture medium harvested before, or 
Figure 2 Identification of the LV-GFP-transduced cells of the human sural nerve in vitro. 
a) GFP positive cells are  found outside  the areas of S100 positive cells,  that  is not  inside 
Schwann cell-containing nerve fascicles. 
b) Occasionally a GFP and S100 positive cell could be seen on the edge of the nerve fascicle 
(arrow). 
c) Many fibronectin-labelled fibroblasts express GFP 
d) Raldh2-labelled fibroblasts expressing GFP. 
Scale bar indicates 0.5 mm in a) and 0.1 mm in b), c) and d).
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1 day after LV-NGF application did not contain detectable amounts of NGF. NGF pro-
duction subsequently increased and reached a plateau between 4 and 6 days ranging 
between 1.0 and 4.5 ng/day after which a slight decline took place up to 11 days. One 
nerve sample receiving a 107 TU/6 μl injection appeared the exception and daily NGF 
production from this sample was roughly 2-fold higher over the entire time period. 
The evaluation of time points later than 11 days was not possible due to slow disinte-
gration of the nerve segments. Non-transduced control nerve segments secreted no 
significant amounts of NGF (highest value 0.057 ng/day at an ELISA detection level of 
0.008 ng/day), indicating that endogenous production of NGF was virtually absent.
LV-NGF-transduced fibroblasts stimulate neurite outgrowth in vitro
 The biological activity of NGF produced by LV-NGF-transduced and non-trans-
duced fibroblasts was evaluated on in vitro E15 rat DRGs with negative (DRGs cul-
tured in control medium) and positive controls (recombinant NGF). 
 Neurite outgrowth from DRGs, visualized by neurofilament staining, was slightly 
increased in conditioned medium from non-transduced fibroblasts over that of fresh 
medium, although this difference was not significant (p=0.16) (figure 5). DRGs cul-
tured in medium harvested from fibroblasts transduced with LV-NGF showed robust 
neurite outgrowth that was fourfold higher than that upon use of conditioned medium 
from non-transduced human fibroblasts (p=0.01) and similar to the outgrowth from 
DRGs in 20 ng/ml recombinant NGF. 
 Human fibroblasts are thus capable of producing and secreting NGF that stimulates 
neurite outgrowth in vitro.
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Figure 3 Efficacy of LV-GFP transduction of human fibroblasts and Schwann cells in co-cul-
ture. Graph indicates that with increasing MOI of LV-GFP both cell types showed a comparable 
transduction rate. Bars indicate average ± SEM for n=3.
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Discussion
Injection of LV vector is the method of choice to transduce sural nerve segments
Direct injection of the LV vector is a faster and more efficient method to deliver the 
transgene than submersion of the nerve in vector-containing medium. A single in-
jection into the middle of a 15 mm nerve segment generally leads to a high number 
of transduced cells over a significant distance, but usually not over the entire length. 
The transduction of longer sural nerve grafts – for instance needed in human brachial 
plexus repair surgery129 - will therefore require multiple injections. The observed vari-
ability in the number of transduced cells after injection may pose a potential problem 
for clinical application, but may decrease with multiple injections.
 Transduction by submersion of the nerve segment in a vector-containing medium 
was limited to the boundaries of the nerve segment even at high LV vector concentra-
tions. The greater efficacy of injection is therefore likely the result of the forced flow 
of vector particles through the nerve. 
The physical properties of the nerve apparently lead to preferential transduction 
of fibroblasts in the epineurium 
Most GFP positive cells were localized outside the S100 positive nerve fascicles and 
were immuno-positive for fibronectin or raldh2. Although not all GFP positive cells 
Figure 4 NGF production by nerve segments injected with 2.5x107 TU LV-NGF in 3 μl (patient 
1 samples) or 107 TU in 6 μl (patient 2 samples). 
Both the levels of NGF and the temporal pattern of production are remarkably similar in 5 of 
the 6 injected nerve segments, reaching a plateau in NGF production between 4 and 6 days, 
after which a slight decline occurs.
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were positive for the extracellular matrix protein fibronectin and the presence of raldh2 
has so far only been described in fibroblasts of meningeal origin(4)), the absence of 
S100 in the transduced cells, their cell morphology and location support a conclusion 
that the predominant cell type that was transduced were fibroblasts. 
 We hypothesize that the physical properties of the human peripheral nerve lead to 
this result. After injection, the flow of viral vector particles will naturally follow a path 
of least resistance, resulting in a buildup of vector particles in the loose epineurial 
tissue surrounding the fascicles but not in the dense, highly myelinated fascicle itself. 
The spreading of viral vector along anatomical boundaries following injection in the 
central and peripheral nervous system has also been described following the use of 
adenoviral vectors130. This conclusion is further supported by the fact that LV-GFP 
was capable of transducing both fibroblasts and Schwann cells with similar efficiency 
when co-cultured on coated coverslips (i.e., in the absence of physical obstacles for 
vector particles). 
 
Continuous production of NGF by LV-NGF-transduced nerve segments
One attractive feature of viral vector-mediated transduction of cells is that a single 
application leads to long term production of a potential therapeutic protein. LV-
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Figure 5 Neurite outgrowth of rat E15 dorsal root ganglion (DRG) cells with conditioned 
medium of cultured LV-NGF-transduced human fibroblasts. A robust 4-fold higher neurite 
outgrowth was observed compared to the use of conditioned medium from non-transduced 
human fibroblasts (p=0.01) which was comparable to the neurite outgrowth from DRGs in 20 
ng/ml recombinant NGF. Neurite area of DRGs cultured in recombinant NGF is set at 100%. 
Bars indicate average ± SEM for n=3.
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NGF injected in the nerve resulted in NGF secretion for at least 11 days. LV vectors 
have previously been reported to give continuous transgene expression in vivo for 
months43,131. All present nerve segments showed a strikingly similar temporal pattern 
of NGF production, except for one that had a 2-fold higher production. This was one 
sample out of three from the same donor. This variation between segments from one 
patient may have been caused in part by technical difficulties involving the injection 
of a volume of 6 μl in a sural nerve segment which in itself has a volume of 15-20 μl, 
possibly leading to some leakage of vector containing fluid. Ideally our experiments 
should be repeated using tissue from the same donor with different concentrations of 
vector in varying volumes, but this approach requires large lengths of sural nerve that 
rarely become available in the clinical setting of nerve grafting.
Transducing nerve grafts as a novel concept to enhance regeneration of the 
peripheral nerve
LV vector-mediated transduction of cells inside sural nerve segments to induce con-
tinuous secretion of neurite outgrowth-promoting factors opens up an entirely novel 
possibility to enhance regeneration after peripheral nerve grafting. Nerve repair sur-
gery is often performed several months after the initial trauma65, but chronic denerva-
tion of the distal nerve stump is deleterious to the results132. This may in part be due to 
a progressive decline22 in initially enhanced levels9 of neurotrophic factors in the distal 
nerve stump after transection. LV vector-mediated overexpression makes it possible 
to reconstitute neurotrophin levels. Moreover, it can be performed in minutes and 
can therefore be potentially included in the clinical practice of nerve grafting without 
major interference with the current routine.
 NGF may be a good candidate for LV vector-mediated gene transfer to the nerve, as 
NGF applied exogenously for 4-12 weeks through diffusion from a daily filled silicon 
reservoir has already been shown to increase the number of sensory neurites that cross 
the lesion site after nerve transection133. Furthermore, the addition of NGF to fibrin 
sealant gave a significant improvement of functional outcome after nerve transection18. 
These latter approaches, however, required multiple daily injections of NGF to fill the 
silicon reservoir133 or consisted of only one single application with limited effective 
exposure time18. The protocol described in this study could result in a stronger effect 
on regeneration, as injection of LV vector led to long term production of the desired 
protein inside the nerve. 
 A possible disadvantage of the use of NGF may be related to its possible role in 
the pathogenesis of pain10. However, the endogenous production of NGF distal to 
a peripheral nerve lesion9 does not lead to pain1. A major advantage of viral vector-
mediated overexpression of NGF in this respect may be that the location, production 
and release of NGF closely mimic the physiological situation. Furthermore, other neu-
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rotrophic factors have also shown promising effects on regeneration of the peripheral 
nerve, including BDNF21,22, NT-3134, NT-419 and GDNF21,121. LV-mediated overexpres-
sion of CNTF in peripheral nerve transplants has positive effects on regeneration of 
the optic nerve137. 
 An important finding in this study is that cells outside the nerve fascicles, and not 
Schwann cells are transduced. A higher concentration of NGF may attract regenerating 
neurons to grow outside the fascicle, perhaps making it harder for them to be directed 
towards the proper end organs. On the other hand NGF produced by transduced 
fibroblasts in the central nervous system has been shown to diffuse 1-2 mm into the 
brain parenchyma135, a distance greater than the average diameter of a peripheral nerve 
fascicle. 
 To investigate whether viral vector-mediated overexpression of NGF or other neu-
rotrophic factors will actually improve functional regeneration of the peripheral nerve, 
more extensive studies with transduced nerve grafts in a relevant animal model, e.g., 
a rat sciatic nerve lesion are needed34. If extensive functional testing of hind limb 
function and histological quantification of regeneration including retrograde tracing 
show a favorable effect of the application of LV-NGF then this would be an important 
step towards clinical application. The present results, the established safety and clinical 
applicability of LV vectors43, as well as the promising results obtained previously with 
NGF in other studies18,133, warrant such investigations. 
Conclusion
LV vector-mediated transduction of human sural nerve grafts is technically feasible 
and can potentially be performed without changing the routine clinical practice of 
nerve grafting in PNS repair. Large numbers of fibroblasts inside the nerve, but outside 
the nerve fascicles can be transduced and following the use of LV-NGF significant 
amounts of biologically active NGF are released. The acquired knowledge forms the 
basis for the further development of a novel approach to enhance regeneration after 
surgical peripheral nerve reconstruction.
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Neuroregenerative effects of lentiviral vector-mediated GDNF expression in 
reimplanted ventral roots
Ruben Eggers, William T Hendriks, Martijn R Tannemaat, Joop J van Heerikhuize, Chris W Pool, Thomas 
P Carlstedt, Arnaud Zaldumbide, Rob C Hoeben, Gerard J Boer, Joost Verhaagen
Molecular and Cellular Neuroscience. 2008 Sep;39(1):105-17
Abstract
Traumatic avulsion of spinal nerve roots causes complete paralysis of the affected limb. 
Reimplantation of avulsed roots results in only limited functional recovery in humans, 
specifically of distal targets. Therefore, root avulsion causes serious and permanent 
disability. Here, we show in a rat model that lentiviral vector-mediated overexpres-
sion of glial cell line-derived neurotrophic factor (GDNF) in reimplanted nerve roots 
completely prevents motoneuron atrophy after ventral root avulsion and stimulates 
regeneration of axons into reimplanted roots. However, over the course of 16 weeks 
neuroma-like structures are formed in the reimplanted roots, and regenerating axons 
are trapped at sites with high levels of GDNF expression. A high local concentration 
of GDNF therefore impairs long-distance regeneration. These observations show the 
feasibility of combining neurosurgical repair of avulsed roots with gene-therapeutic 
approaches. Our data also point to the importance of developing viral vectors that 
allow regulated expression of neurotrophic factors.
Introduction
Traumatic avulsion of nerve roots from the spinal cord is a devastating event that 
usually occurs in the brachial plexus of either young adults during motor vehicle or 
sports accidents or in newborn children during difficult childbirth 136. Three surgical 
strategies to restore motor function after ventral root avulsion have been explored 
in human subjects: 1) reimplantation of the avulsed roots into the spinal cord 137, 2) 
implantation of autologous nerve grafts that are connected distally to the avulsed 
roots 137,138 and 3) rerouting of healthy nonessential nerves towards the distal targets 
of the avulsed roots 139.
 Without treatment, ventral root avulsion leads to progressive atrophy of motoneu-
rons, whereas reimplantation of a ventral root results in rescue of approximately 70% 
of motoneurons in experimental animals 140-142. Reimplantation can result in some 
clinical signs of motoneuron regeneration in humans, but long distance regenera-
tion and functional reinnervation of more distally located targets such as the hand 
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is extremely rare 137,143-145. Hence, even with the currently available surgical options, 
root avulsion remains a condition that leads to serious and permanent disability. 
To re-establish nerve function after root reimplantation, 4 successive goals have to 
be achieved: 1) prevention of motoneuron atrophy after avulsion, 2) regeneration 
of axons through the outgrowth-inhibitory environment of the scarred spinal cord 
into the nerve root, 3) sustained axonal growth through the peripheral nerve to cre-
ate functional connections with target organs and 4) preservation of target organs 
including muscles. 
 The survival of motoneurons following root avulsion and reimplantation in the rat 
can be enhanced with the application of glial cell line-derived neurotrophic factor 
(GDNF) 146-148, a combination of riluzole and GDNF 149 and with viral vector-medi-
ated overexpression of brain-derived neurotrophic factor (BDNF) or GDNF in the 
spinal cord 24. Although motoneuron survival was achieved in the latter study, axonal 
outgrowth into the reimplanted nerve root was not improved and regenerating axons 
appeared to be trapped in the ventral spinal cord.
 Here, we combined neurosurgical reimplantation of avulsed ventral spinal roots 
with lentiviral (LV) vector-mediated expression of BDNF or GDNF in the reimplanted 
roots. We hypothesized that this approach would create a neurotrophic factor gradient 
from the reimplanted roots to the ventral spinal cord that would attract motor axons 
toward the root. We examined whether enhanced expression of these neurotrophic 
factors by the implanted spinal roots can prevent the severe lesion-induced atrophy 
of motoneurons and promote the regeneration of motor axons into the roots. We also 
assessed the ability of motor axons to regenerate over long distances into the sciatic 
nerve and the functional recovery of the denervated hind limb.
 
Results
Characterisation of LV vectors
The titers of the LV stocks are provided in figure 1. To determine if BDNF and GDNF 
produced by LV vector-mediated transduced cells are biologically active, their effect on 
neurite outgrowth from E14 rat embryonic DRG explants was quantified following the 
method of Niclou et al. 128. Conditioned medium from LV-BDNF- and LV-GDNF-in-
fected 293T cells significantly increased the neurite growth of DRG explants (p<0.002 
for LV-BDNF, p< 0.0001 for LV-GDNF,) compared to LV-GArGFP-conditioned media 
(figure 2). This shows that LV-BDNF and LV-GDNF direct the expression of biologi-
cally active BDNF and GDNF protein. 
Injection of LV vector leads to long term transgene expression in the nerve root
In the LV-GArGFP-injected control group, GFP positive cells were observed in the 
avulsed and reimplanted nerve root throughout the 16 weeks post-lesion period (fig-
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ure 3A). LV vector-mediated expression of BDNF and GDNF in the nerve roots was 
established by in situ hybridisation. In all animals numerous cells expressing high 
levels of BDNF (figure 3B) and GDNF mRNA (figure 3C) were present in nerve roots 
at 16 weeks post-lesion. Transduced cells were only found within the nerve root, close 
to regenerating axons, had a Schwann cell-like morphology and stained positive for 
S100 (figure 3A). In vivo transduction efficiency was further quantified on sections 
of LV-GArGFP injected animals at 4 weeks by measuring the distance between the 
two outermost transduced cells. The average longitudinal spread of transduced cells 
was 2.3 ± 0.43 mm. In the center of the transduced area, an average of 17 ± 4.5% of 
Schwann cell nuclei was positive for GArGFP. Transduced cells did not migrate into 
Figure 1  Schematic representation of surgical procedures (ventral root avulsion, vector injec-
tion and root implantation) and overview of experimental groups. 
A) Schematic representation of a cross section of the intact spinal cord and its dorsal (DR) and 
ventral root (VR) on one side. 
B) After ventral root avulsion, the root is either directly reimplanted in the spinal cord just 
above the avulsion site or reimplanted after an injection with 1 µl of a viral vector.
C) Overview of experimental series, treatment groups, amount of vector injected (transducing 
units, TU) and survival times. Some animals were lost during the experiment due to autotomy. 
The number in parentheses in the “# animals” column indicates the final number of animals 
used for all functional and histological analyses.
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the spinal cord. A single injection of 1 µl containing 1-2x106 TU LV vector thus leads 
to long term transgene expression, similar to what has been described previously 150.
LV vector- mediated expression of GDNF in reimplanted ventral roots completely 
prevents motor neuron atrophy.
Atrophy of motoneurons was assessed on spinal cord sections 16 weeks after avulsion 
and implantation (figure 4). Motoneurons on the contralateral side appeared unaf-
fected in all groups and had a normal morphology (figure 4A). Many motoneurons 
displayed considerable atrophy in both control groups (figure 4B), as well as in the 
LV-BDNF-treated group (figure 4C). In the LV-GDNF-treated animals, most moto-
neurons appeared to be the same size as the contralateral side (figure 4D), while some 
motoneurons appeared to be slightly larger with a rounder shape, possibly indicating 
Figure 2 Biological activity of neurotrophic factors produced by LV vector-transduced cells. 
A) Examples of in vitro neurite outgrowth of E14 rat embryonic dorsal root ganglia after 48 h 
in conditioned medium derived from LV-GArGFP, LV-BDNF or LV-GDNF transduced 293T 
cells. Scale bar 750 μm.
B) Quantification of neurite outgrowth as percentage of the value of mock controls. Medium 
from LV-GArGFP-infected cells does not affect outgrowth, whereas medium from LV-BDNF- 
and LV-GDNF-infected cells increases neurite outgrowth 9- and 11-fold respectively. Under 
these conditions 25 ng/ml recombinant BDNF or GDNF both increase neurite outgrowth 
approximately 6-fold. Error bars indicate SEM for n=8 per group. *p < 0.05; ***p < 0.001; 
one-way ANOVA followed by Bonferroni’s post hoc testing. 
Figure 3 Immunohistochemistry and in situ hybridization at 16 weeks demonstrates that injec-
tion of LV vector leads to long-term transgene expression in Schwann cells in the reimplanted 
ventral root.
A) GArGFP (green) is present in the nuclei of numerous S100 positive Schwann cells (blue) in 
close proximity to NF positive axons (red). Cells containing BDNF (B) or GDNF (C) mRNA 
(blue, arrows) close to ChAT positive motoneuron fibers (brown) in the ventral root.
Scale bar 50 μm.
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hypertrophy (figure 4D). Motoneuron atrophy was quantified by calculating the total 
volume of the motoneuron pool as a percentage of the contralateral motoneuron pool 
(figure 4E). In the two control groups, implant and LV-GArGFP, the total volume of 
ChAT positive motoneurons on the side of the avulsed roots was ~30% smaller as 
compared to their contralateral side (p<0.001 implant, p<0.03 LV-GArGFP). In the 
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Figure 4 The effect of long term LV vector-mediated overexpression of BDNF and GDNF in 
the avulsed/reimplanted root on motoneuron soma size in the rat spinal cord.
A) Representative high magnification of intact motoneurons stained for ChAT showing normal 
motoneuron morphology. At 16 weeks, motoneurons on the root avulsion side of the spinal 
cord of LV-GArGFP, (B) and LV-BDNF-treated animals, (C) display atrophied motoneurons 
(arrowheads). In contrast, motoneurons in the LV-GDNF group (D) display many motoneu-
rons with a round hypertrophic morphology (arrows). Scale bar 50 μm.
E) Quantification of total motoneuron (MN) volume displays complete rescue of motoneuron 
volume in LV-GDNF-treated animals and no statistically significant effects in the other groups 
when compared to the values of the contralateral unaffected side.
 *** p < 0.001; one-way ANOVA followed by Bonferroni’s post hoc testing. 
F) Frequency distribution of motoneuron size, showing that avulsion and reimplantation leads 
to shift in soma size distribution resulting in fewer big structures (>600µm2) and more smaller 
structures (<300 µm2) in control groups (white and light grey), compared to unaffected mo-
toneuron distribution (dotted lines). The application of LV-GDNF leads to restoration of the 
normal distribution, and even some hypertrophy, as indicated by the increased number of very 
large structures (900-1800 µm2).
LV-BDNF group the motoneuron volume had decreased by ~20%, as compared to 
the contralateral side, comparable to the control groups (p< 0.004). In contrast, in 
LV-GDNF-treated animals, the total volume of the affected motoneurons was similar 
to the control side (105%, p=0.2), and the volume of the affected side as a percentage 
of the contralateral side was significantly higher than all other groups (P<0.0001). 
Quantitative analysis of individual motoneuron profiles (figure 4F) revealed a signifi-
cant shift towards relatively smaller profiles and a reduction of large structures when 
compared to the distribution of intact motoneurons (dotted lines) and to motoneurons 
after avulsion and reimplantation (white bars). In LV-GDNF treated animals a nor-
malisation of soma size distribution was observed (black bars). Moreover, LV-GDNF 
treatment results in a small but significant proportion of hypertrophic motoneurons, 
as indicated by the relative increase of motor neuron profiles larger then 900 µm2. 
These findings indicate that LV vector-mediated expression of GDNF in reimplanted 
ventral nerve roots completely prevents the atrophy of axotomized motoneurons at 
16 weeks after avulsion and reimplantation of the ventral root. 
LV vector-mediated expression of GDNF stimulates outgrowth into the 
reimplanted root, but also coiling of axons
Regeneration of ChAT positive motoneurons into reimplanted roots could be observed 
as early as 4 weeks after avulsion and nerve root reimplantation (figure 5AB). Thin 
ChAT positive axons traversed the spinal cord white matter and entered the root at 
the site of implantation. The regenerated fibers have a clear longitudinal orientation 
within the root, although they are thinner and follow a more undulating path than 
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axons in the intact root (figure 5CD). In the LV-BDNF group, comparable patterns 
of neurite outgrowth were seen as in control animals (data not shown). In contrast, 
LV vector-mediated expression of GDNF appeared to stimulate more axons growing 
into the nerve root (figure 5E). The density of axons entering the implanted root was 
quantified by counting the number of axons crossing a reference line perpendicular to 
the implanted root, just distal from its implantation site in the spinal cord at 4 weeks. 
The application of LV-GDNF led to a significant increase in axon density compared 
to LV-GArGFP (p=0.016; figure 5F). The fiber density in LV-GDNF treated animals 
was comparable to that in the non-avulsed control root.
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 Apart from the density, both the longitudinal orientation and distribution of axons 
distal from the spinal cord (scored blindly at 4, 10 and 16 weeks post-lesion) in LV-
GDNF-treated animals differed considerably from LV-GArGFP-injected control ani-
mals. The most striking observation was the presence of specific areas with a high 
density of axons with a considerably coiled appearance in ventral roots with transgenic 
GDNF expression. This phenomenon was present almost exclusively in the LV-GDNF-
treated group and already apparent 4 weeks after the intervention (figure 6). At that 
stage, in the majority of animals (72%) these nerve fibers were still oriented longitu-
dinally within the nerve root and appeared to be grouped together in thick strands 
(figures 5E and 6A), but in one animal (14%), small areas were seen in which axons 
appeared to have lost their longitudinal orientation completely. After 10 weeks, areas 
with coiled axons were observed in 83% of the LV-GDNF-injected animals (p<0.02 
compared to LV-GArGFP, figure 6B). Moreover, these areas were larger than those 
observed at 4 weeks. After 16 weeks of GDNF overexpression, extreme coiling of large 
numbers of axons was seen in all animals (p<0.001, figure 6CD). By then, entire nerve 
roots were filled with thick coils of ChAT positive axons and only a minority of axons 
(the fibers outside the clusters) had a longitudinal orientation (figures 6D and 7I). The 
increased numbers of nerve fibers were accompanied by an increase in the diameter of 
the injected nerve roots, occasionally to such an extent that the spinal cord was slightly 
displaced by the implanted nerve roots (figure 6D). Coiling of axons was not observed 
in any of the control LV-GArGFP-injected animals at any time point, and not seen at 
16 weeks in the ‘implant’ group and in only one animal of the LV-BDNF group (14%). 
Figure 5 ChAT positive neurite outgrowth from the spinal cord into the implanted ventral 
root 4 weeks after avulsion and reimplantation. 
A) Representative image at the site of implantation in a control LV-GArGFP-injected root 
showing a few fibers (arrowheads) traversing from motoneuron pool (left) towards the im-
planted root (right). 
B) The implantation site in an LV-GDNF-treated animal displays a similar pattern as in A).  
Insets show higher magnification of boxed areas in (AB) Dotted white lines in (AB) show 
boundary of implanted root.
C) Typical ChAT staining of motor axons in the intact ventral root displays thick, longitudi-
nally oriented fibers. 
D) The ventral roots of a LV-GArGFP-treated rat distal from the implantation site shows several 
thin regenerating fibers.
E). A distinctly higher density of motor axons is present in the roots of LV-GDNF-treated 
animals. 
F) Quantification of the axon density in the reimplanted root just distal from the implantation 
site. LV-GDNF significantly increases axon density compared to LV-GArGFP. **p < 0.016; 
Kruskal-Wallis followed by Mann-Whitney U test.
Dotted gray line indicates axon density of unavulsed root. 
Scale bars A-B 100 μm; C-E 50 μm.
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 Immunohistochemical staining for GDNF showed that the levels of GDNF protein 
were locally elevated within the LV-GDNF transduced nerve root at 4 (supplemen-
tal figure 1) and 10 weeks (figure 7). A gradient of GDNF from the spinal cord to 
the implanted root is thus continuously maintained after LV-mediated transduction. 
GDNF protein could not be detected by immunohistochemistry in non-avulsed roots 
(figure 7A) or in avulsed LV-GArGFP-injected and reimplanted roots (figure 7C, 
supplemental figure 1). Staining of adjacent sections for GDNF and ChAT in the LV-
GDNF-treated group at 10 weeks showed that the increased numbers of nerve fibers 
co-localised with the presence of GDNF protein (figure 7). Double staining for GDNF 
and NF revealed a high density of NF positive fibers in GDNF positive areas, whereas 
ChAT staining on adjacent sections revealed that these nerve fibers were indeed axons 
of motoneurons (figures 7EF and 7GH). Consequently, the increased density of axons 
appears to be caused by the high local concentrations of GDNF after injection of LV-
GDNF (figure 7I). 
LV-GDNF increases the density of Schwann cells in the implanted nerve root
Because Schwann cells express the GDNF receptor GFRα-1 151, we studied the effect 
of LV-BDNF and LV-GDNF on cell density in the implanted root. Longitudinal spinal 
cord sections containing unavulsed control roots or implanted roots were stained 
for NF (figure 8A), S100 and Hoechst and manually outlined using the NF signal. 
In LV-GDNF treated animals, coils were outlined and measured separately (figure 
8C). S100 staining confirmed that the majority of measured cells within the nerve 
root were Schwann cells (data not shown). The S100 staining could, however, not be 
used to reliably identify and quantify individual Schwann cells since the S100-positive 
Schwann cells are closely packed together and the S100 signal filled the whole cell. 
Therefore Hoechst staining was used to quantify the cells in the nerve root. To this end 
Figure 6 ChAT staining of LV-GDNF-injected nerve roots up to 16 weeks showing the devel-
opment and changing morphology of fiber coils over time.
A) At 4 weeks, numerous areas with an increased fiber density (strands) are present (72%). 
These areas are relatively small and fibers primarily have a longitudinal orientation. Incidentally 
coiled fibergrowth is observed (14%). Scale bar 50 μm.
B) At 10 weeks, the areas with a high fiber density are larger. Many of them have a strong 
chaotic, coiled morphology. Scale bar 50 μm.
C) At 16 weeks, extremely large coils of axons fill up the entire nerve root. Scale bar 50 μm.
D) An overview of the spinal cord and nerve root at 16 weeks displays the local but large coil 
formation of ChAT positive fibers, resulting in an increase of root diameter and slight compres-
sion to the spinal cord. Scale bar 500 μm.
E) Presence of coil formation was quantified at all time points and expressed as percentage of 
presence or absence in the number of animals. *p < 0.05; ***p < 0.001; Pearson Chi-Square 
test. n.d.= not determined.
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Figure 7 Immunohistochemistry at 10 weeks shows that GDNF overexpression in the reim-
planted ventral root colocalizes with dense ChAT positive motor axon fiber coils. 
A-B) Immunohistochemistry on consecutive sections of a normal, non-avulsed root double-
immunolabeled for GDNF and NF (A) and immunostained for ChAT (B). No GDNF staining 
is visible, whereas the staining pattern of NF and ChAT is similar. 
C-D) Similar stainings of control LV-GArGFP-injected ventral roots display no GDNF signal, 
and thin regenerating fibers. 
E-H) Strong GDNF staining is observed in the LV-GDNF-injected ventral roots (cf. boxes in 
the overview of I), in which consecutive sections show dense coils of ChAT positive fibers in 
the area of high GDNF expression. 
I) Overlay of adjacent sections (GDNF/ChAT) displays strong colocalisation between GDNF 
protein and coil location which is prominently seen in the overlay picture of GDNF (green) 
and ChAT signal (black) from consecutive sections at lower magnification. 
Scale bars A-H 50 μm; I 100 μm.
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the area covered by Hoechst-labelled nuclei was calculated automatically (figure 8BD) 
as a proportion of the outlined area to create a measure of Schwann cell density. This 
quantification showed that cell density increases strongly (13-fold) after root avulsion 
and reimplantation alone compared to non-avulsed roots. Importantly, the applica-
tion LV-GDNF led to a trend towards a higher cell density to 1.32 fold compared to 
“implant” (p < 0.09 vs “implant”) and cell density was significantly higher within the 
nerve coils that contain the highest levels of GDNF (p < 0.003 vs “implant”).
 The measured density of nuclei could not be used to generate absolute cell counts, 
due to the high number of overlapping nuclei (figure 8D). However, it can be estimated 
that the observed densities correspond to approximately 1200, 16.000, 18.000 and 
20.000 cells/mm2 in non-avulsed, “implant”, LV-GDNF nerve roots and LV-GDNF 
coils, respectively. It should be noted that in sections with higher cell densities, this 
calculation likely underestimates the actual number of cells due to overlapping nuclei. 
S100 staining confirmed that the majority of measured cells within the nerve root were 
Schwann cells (data not shown).
Local high levels of GDNF prevent more distal neurite outgrowth
Long distance regeneration was quantified by counting the number of ChAT positive 
nerve fibers in the sciatic nerve, 7 cm distal to the site of reimplantation in the 16 week 
survival groups. Equal numbers of axons were present at this level in the sciatic nerve 
with or without the injection of LV-GArGFP (figure 9A). The application of LV-BDNF 
did not lead to an increase in the number of nerve fibers. Surprisingly, despite the high 
density of ChAT positive fibers in the ventral root, the application of LV-GDNF did not 
result in more, but significantly less regenerated axons distally, compared to ‘implant’ 
(p<0.014) and LV-BDNF (p<0.005) (figure 9BC). A frequency distribution of the 
diameters of axons in the sciatic showed that the reduction in total number of ChAT 
positive fibers in the distal sciatic of LV-GDNF-treated animals was predominantly 
the result of a significant decrease in the number of small diameter axons (figure 9D) 
(p<0.005 compared to ‘implant’ and LV-BDNF, p<0.05 compared to LV-GArGFP) 
and to a lesser extent in medium-sized fibers ( p<0.05 compared to “implant”). This 
suggests that LV vector-mediated expression of GDNF in the reimplanted nerve roots 
prevents sustained long distance regeneration of motor axons into the sciatic nerve.
Transduction of reimplanted nerve roots with LV-BDNF or LV-GDNF does not 
affect recovery of hind limb function
Avulsion of the L4, 5 and 6 roots leads to a substantial loss of hind limb function. In 
the implant control group, the average modified BBB score dropped from 14 to 2.4, re-
covering to 5.3 at 4 weeks and remaining at this plateau up to 13 weeks. The LV-BDNF- 
and LV-GDNF-treated groups had an identical pattern of recovery; no differences in 
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the modified BBB score between groups were observed at any time point. The score 
per animal was generally the result of some movement in the hip, knee and ankle. No 
voluntary stepping, toe clearance or weight support of the affected limb was observed 
in any animal at any time point. No correlation was found between the number of re-
generated axons in the sciatic nerve and recovery of hind limb function, either within 
the control groups or when analysing all animals together (data not shown). Severe 
muscle atrophy of the denervated hind limb was present in all animals.
Discussion
In the present study we show that LV vector-mediated overexpression of GDNF in 
avulsed and reimplanted ventral nerve roots completely prevents motoneuron atrophy 
and leads to a significant increase in regenerating axons in the reimplanted roots. 
In LV-GDNF-treated animals neuroma-like structures were formed at sites of high 
levels of GDNF expression. The number of fibers that had regenerated to the level of 
the sciatic nerve was significantly lower in LV-GDNF treated animals. A local high 
concentration of GDNF thus appears to trap regenerating axons.
Transduction of reimplanted nerve roots with LV-GDNF prevents motoneuron 
atrophy
A loss of neurotrophic support after root avulsion and the inability of motoneuron 
axons to regenerate leads to severe atrophy and virtual disappearance of 80-90% of 
affected motoneurons over a course of several weeks 142,152. The automated quantifi-
cation of the total volume of all ChAT positive structures used in the present study 
allowed for a comprehensive and accurate measurement of the total volume of the 
affected motoneuron pool. This method avoids the potential pitfall of mistaking se-
vere motoneuron atrophy for cell death 153. Furthermore, unlike retrograde tracing, 
it does not exclude the 20-35% of motoneurons that survive without regenerating 
into the implanted root 154,155. Reimplantation of the avulsed root by itself partially 
prevents atrophy of motoneurons, but this neuroprotective effect is not sufficient for 
complete long term survival at longer time points 142,149,156. In this paper we describe 
a similar, significant 30% decline of the volume of the motoneuron pool at 16 weeks 
after reimplantation. 
 Axotomized motoneurons are sensitive to a number of neurotrophic factors 9. 
Motoneuron death after ventral root avulsion can be prevented with BDNF 157,158 or 
GDNF 146. However, a single application of BDNF and/or ciliary neurotrophic factor 
(CNTF) does not have a notable effect 159, and long term infusion of neurotrophic fac-
tors is problematic 160. Viral vector-mediated overexpression is thus a very promising 
method for long term expression of therapeutic genes. Adeno-associated virus (AAV) 
vector-mediated overexpression of BDNF or GDNF in the spinal cord does indeed 
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promote motoneuron survival after ventral root avulsion and reimplantation 24. Here, 
we show that expression of GDNF distal from the affected motoneuron pool, i.e., in 
the reimplanted nerve root, is sufficient to prevent atrophy after axotomy and causes 
a slight hypertrophy of motoneurons, similar to previous publications 146,161,162. 
LV vector-mediated expression of BDNF in the implanted nerve root has a limited 
effect
In contrast to GDNF, the continuous overexpression of BDNF has no significant effect 
on motoneuron survival at 16 weeks. A similar difference between these neurotrophic 
factors was also observed after a single application of recombinant BDNF or GDNF 
after root avulsion 146 and after AAV vector-mediated transduction of the spinal cord 
24, although BDNF did have a modest effect in the latter and other 163 studies. The 
GDNF and BDNF receptors are expressed differentially in injured motoneurons. The 
expression of the receptors for GDNF, GFRα-1 and c-RET, is increased up to 300% 
after avulsion, whereas TrkB, the high affinity receptor for BDNF is downregulated 
after ventral root avulsion 164. 
 This difference, combined with the application of LV-GDNF in the nerve root may 
explain the lack of effect of BDNF as found in the current experiments.
Application of LV-GDNF stimulates axonal outgrowth into the reimplanted root
Besides preventing cell atrophy, the second goal of a treatment strategy should be to 
increase the number of axons entering the implanted root 155. This requires axonal 
regeneration across the outgrowth-inhibitory environment of the spinal cord 57,61 and 
was achieved previously with a combination of GDNF and riluzole 149 or with the en-
zymatic degradation of inhibitory molecules in the spinal cord 165. Our results show 
that LV vector-mediated overexpression of GDNF significantly increases the density of 
axons entering the LV-GDNF-injected nerve roots. This could be caused by an increase 
in the number of motoneurons that project an axon into the implanted root and/or by 
branching of motor axons at sites of elevated GDNF expression.
Long term local production of GDNF negatively affects long distance 
regeneration
Continuously elevated levels of GDNF results in the progressive occurrence of extreme 
coiling of axons within the nerve root and appear to impair long distance regeneration. 
After 4 weeks of transgene expression, the majority of axons still have a longitudinal 
alignment. The density and coiling of nerve fibers subsequently increase over the 
course of several weeks. After 16 weeks of transgene expression, the majority of axons 
are coiled in GDNF-rich areas in an extremely chaotic pattern that is reminiscent of 
peripheral nerve neuromas 1, implying a strong neurotropic role for GDNF. This effect 
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has been described previously with motor axons failing to enter the reimplanted root 
after AAV-mediated overexpression in the spinal cord 24. Our experiments are the 
first to provide a detailed temporal and spatial analysis of the growth of regenerating 
axons in relation to transgenic GDNF expression in reimplanted nerve roots. The 
formation of neuroma-like structures is probably caused by a direct effect of GDNF 
on axons, which express GFRα-1 and c-RET 164. We also show that in areas of high 
GDNF expression the density of cells is increased and that the majority of these cells 
are Schwann cells. This may be the result of a direct effect on Schwann cells, which 
also express GFRα-1 151 since the exogenous systemic application of GDNF causes 
Schwann cell proliferation and myelination of nerve fibers 166. However, the observed 
high density of Schwann cells could also be the indirect result of the increased number 
of axons present in these areas. These two mechanisms can not be distinguished in 
this in vivo model where both axons and Schwann cells are affected by overexpres-
sion of GNDF. Nonetheless, Schwann cell proliferation in nerve coils is a factor that 
could contribute to the increased diameter of nerve roots that was observed after the 
application of LV-GDNF.
Long distance regeneration is one of the prerequisites to enhance recovery of 
function
The final goal of any experimental intervention to treat root avulsion injuries is to 
stimulate long distance regeneration and enhance recovery of function after nerve 
root avulsion and reimplantation. Although regenerating axons were observed the 
reimplanted nerve roots in all groups in the present study, only small numbers of 
ChAT positive fibers had regenerated to mid-thigh level of the sciatic nerve at 16 
weeks and we did not observe a significant recovery of function in any treatment 
Figure 8  Quantification of the density of cell nuclei based on Hoechst labelling and immuno-
histochemistry for Neurofilament (NF) shows an increased cellular density in the LV-GDNF 
treated roots at 16 weeks compared to controls.
AB) An outline in a non-avulsed ventral root was drawn using the NF signal (A). The surface 
area of Hoechst-labelled nuclei was measured with an automated filter algorithm (red) and 
expressed as a proportion of the outlined area (B).
CD) In LV-GDNF treated animals, dense NF positive areas (C) were used to separately outline 
coils and the surrounding root, resulting in specific measurement of the density of nuclei in 
these coils (D). Similar measurements were also made outside the coil in LV-GDNF or LV-
BDNF injected roots and on implanted control roots (images not shown).
E) The area covered by cell nuclei as a proportion of the total outlined area (cell density) 
strongly increases after avulsion and reimplantation. Cell density is significantly increased in 
coils of LV-GDNF treated animals compared to “implant” *p <0.003; one-way ANOVA fol-
lowed by Bonferroni’s post hoc testing.
Scale bar 250 μm. 
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group. Functional recovery has been described in root avulsion models which involve 
regeneration over shorter distances, i.e. towards the front paw after cervical nerve root 
avulsion 167 or towards the bladder sphincter 168. In the present study, reinnervation of 
hind limb muscles requires regeneration over approximately twice this distance. The 
decline over time in the levels of neurotrophic factors produced by denervated distal 
Schwann cells 9 may contribute to the observed lack of regeneration over long distances 
as shown in our study. Furthermore, recovery of function depends on more factors 
than axonal outgrowth, including correct routing of regenerated fibers 8. Enhanced 
hind limb function has been observed with the combined application of GDNF and 
riluzole after ventral root avulsion and reimplantation, but according to the authors, 
this was not the result of increased numbers of regenerated motoneurons in the re-
implanted root 149, emphasizing that the recovery of certain functional modalities can 
occur irrespective of long-distance axonal regeneration and may perhaps be related 
to enhancing plasticity at the level of the spinal cord 57,120.
Concluding remarks
Our results highlight that trapping of axons in areas with continuously elevated levels 
of neurotrophic factor poses a new challenge for the application of viral vector-medi-
ated delivery of these factors in a ventral root reimplantation model. A possible solu-
tion for this problem lies in the application of viral vectors with regulatable expression 
50,51. It has been shown recently that in a spinal cord lesion model, trapping could be 
avoided by transient local expression of neurotrophic factors with such a vector 52. 
Our results suggest that transient expression of GDNF for 4 weeks is sufficient to at-
tract vast numbers of regenerating axons into the reimplanted nerve root. We predict 
that cessation of GDNF expression at this post-lesion time point will result in signifi-
cantly more axons growing towards target organs. An alternative approach to prevent 
trapping of axons may consist of the transplantation of GDNF overexpressing cells 
Figure 9  LV-GDNF impairs long distance outgrowth of ChAT positive fibers in the reim-
planted ventral root.
A) Representative photographs of ChAT-stained motor axons (arrowheads) in the transverse 
sciatic nerve, 7 cm distal from reimplantation site in a control ‘implant’ animal.
B) Similar to A) in an LV-GDNF-treated animal, showing a reduction in ChAT positive fibers. 
Scale bar 20 μm.
C) Quantification of the total number of ChAT positive fibers in the 4 experimental groups 
displays an significant decrease in total fiber number in the LV-GDNF-treated group. ** p < 
0.01; one-way ANOVA followed by Bonferroni’s post hoc testing.
D) Frequency distribution of fiber diameter shows that the LV-GDNF-treated group had a 
significant reduction of small diameter motor axons, usually associated with regeneration. *p 
< 0.05, ***p < 0.001; Kruskal-Wallis followed by Mann-Whitney U test.
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169 or the application of LV-transduced peripheral nerve grafts 87,149. As transplanted 
cells are likely to migrate, expression levels of neurotrophic factors could be more 
homogenously distributed within the nerve using this approach. Nonetheless, the 
number of axons entering the implanted root is only one aspect that influences the 
recovery of function in humans and future therapeutic strategies will likely need to 
address other problems (including chronic denervation and subsequent target organ 
atrophy) as well 11.
Materials and Methods
Lentiviral vector production
Plasmids used for the production of the LV vectors have been described previously 
42. The LV-GArGFP control vector was generated by fusing the Gly-Ala repeat (GAr) 
domain of the Epstein-Barr nuclear antigen-1 as described by Hendriks et al. 150 to the 
N-term part of the green fluorescent protein (GFP). As described previously 170, by 
interfering with the proteasome, the long alanine stretch of the GAr domain reduces 
the generation of antigen-linked MHC-I peptide and prevents a GFP-mediated cyto-
toxic T-lymphocyte immune response.
 Lentiviral vectors encoding BDNF and GDNF were generated as follows using the 
pRRLsin-PPThCMV vector containing the Woodchuck posttranscriptional regulatory 
element 171. The BamHI/XhoI BDNF cDNA excised from pc5-BDNF 24 was introduced 
into a BamHI/SalI opened LV transfer vector. The HindIII/XbaI excised GDNF cDNA 
(pBlue-GDNF 24) was cloned into its respective site into a pAG-3 vector. Subsequently, 
the GDNF fragment was excised from pAG-3-GDNF with XbaI and cloned into an 
Xba1 opened LV transfer vector. Both cDNA were under the control of the human 
cytomegalovirus (CMV) promoter. LV vectors were sequenced to verify the sequence 
and orientation of the inserts.
 Lentiviral vectors were generated as described previously 42. pRRLsin-PPThCMV-
wpre, encoding either GArGFP, BDNF or GDNF (20 µg), the VSV-G envelope pro-
tein vector pMD.G.2 (7 µg) and the viral core-packaging construct pCMVdeltaR8.74 
(13 µg) were co-transfected in 293T cells with Isocove’s Modified Dulbecco’s Medium 
(IMDM) containing 10% foetal calf serum (FCS), 100 U/ml penicillin/streptomy-
cin (PS) and 2 mM glutamine. The next day, medium was refreshed and cells were 
incubated for another 24 h. Medium was harvested, spun at 176xg, the supernatant 
cleared through a 0.22 µm cellulose acetate filter and centrifuged at 80,000xg for 
2.5 h. The pellet was resuspended in 0.1 M sodium phosphate buffer pH 7.4 in saline 
(PBS), aliquoted and stored at – 80 ºC. The titer of the LV-GArGFP vector stock was 
evaluated by infecting 293T cells upon serial dilution and determining the number 
of transducing units per ml (TU/ml), which was in the order of 109 TU/ml. In addi-
tion, viral vector stocks were titered by assay of p24 content (ng/ml) with an ELISA 
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(Perkin Elmer Nederland BV). The ratio between the TU/ml and p24 content of the 
LV-GArGFP stock was used to calculate relative TU/ml titers for the LV-BDNF and 
LV-GDNF stocks.
Biological activity of LV vector-derived neurotrophic factors
The biological activity of BDNF and GDNF derived from LV vector-mediated trans-
duced cells was assessed with a dorsal root ganglion (DRG) assay 128. DRG neurite 
outgrowth of conditioned medium from LV-GArGFP-, LV-BDNF- and LV-GDNF-
infected cells was expressed as percentage of control conditioned medium from mock-
infected 293T cells.
Experimental animals and surgical procedure
A total of 66 female Wistar rats (200-250 g; Harlan, Horst, the Netherlands) were 
used in this experiment. Animals were housed under standard conditions in a 12:12 
h light/dark cycle with food and water ad libitum. Experimental handling and postop-
erative care were in accordance with the guidelines of the local committee for labora-
tory animal welfare and experimentation. Animals underwent a left-sided unilateral 
avulsion of three lumbar ventral roots (L4- L6) as described in detail previously 150. 
Briefly, rats were anaesthetized using Hypnorm (Fentanyl/ Fluanisone; 0.08 ml/100 g 
body weight, i.m.; Janssen Pharmaceuticals, Beerse, Belgium) and Dormicum (Mid-
azolam; 0.05 ml/100 g body weight s.c.; Roche, Almere, the Netherlands). Access to 
the ventral roots was obtained via a dorsal laminectomy (T12-L1) and opening of the 
dura mater. Ventral root attachment sites were used for final positive identification 
of L4, L5 and L6. By applying slight lateral traction with a pair of fine forceps on the 
root at the spinal cord exit site, avulsions were obtained directly at the surface of the 
spinal cord. The avulsed roots were either immediately reimplanted in the spinal cord 
or prior to reimplantation injected with 1 µl of LV-GArGFP (106 TU), LV-BDNF (2 x 
106 TU) or LV-GDNF (2 x 106 TU) using a glass capillary with a 80 µm diameter tip 
attached to a 10 µl Hamilton syringe. For reimplantation a small pocket was made 
into the lateral spinal cord using the tip of a glass capillary approximately 1 mm above 
the L4, L5 and L6 avulsion sites. The three reimplanted roots were fixed in place with 
2 µl fibrin glue (TissueCol; Baxter B.V., Utrecht, the Netherlands) and covered by a 
piece of autologous fat tissue to prevent adhesion to the surrounding tissue. Paraspi-
nous muscles and skin were closed in separate layers, animals were kept at 37ºC until 
recovered and received Temgesic (buprenorphine 0.03 ml/100 g body weight s.c., 
Schering-Plough B.V., Maarssen, the Netherlands) for post-operative analgesia. This 
study was performed in two separate experimental series. The first series comprised 4 
groups of 10 animals (implant, LV-GArGFP, LV-BDNF, and LV-GDNF; see figure 1C) 
of which functional recovery was evaluated during the 16 week survival time. At this 
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post-lesion time point, animals were sacrificed to study transgene expression as well 
as spinal motoneuron atrophy, motor axon re-innervation into the reimplanted roots 
and long distance regeneration to the sciatic nerve using in situ hybridization and im-
munohistochemistry. In a second series, the effect of LV-GDNF on axonal outgrowth 
and (motor) axon trapping was studied in more detail at 4 and 10 weeks survival times 
with LV-GArGFP-injected animals serving as controls (n=8 and 5 per time point for 
LV-GDNF and LV-GArGFP respectively). 
 After surgery, joints of the affected hind limb were manipulated daily to prevent 
contractures. Animals that displayed severe damage of the hind limb due to autotomy 
were promptly sacrificed; all remaining animals were included in each functional and 
histological analysis. Figure 1 provides a schematic overview of surgical procedures, 
treatment groups (including the number of animals per group) and survival times of 
the two experimental series.
Assessment of recovery of hind limb function
Avulsion of the lumbar ventral roots L4-6 results in a complete loss of left-sided spon-
taneous hind limb movement. After a two-week pre-operative training period, recov-
ery of function was assessed at 4, 7, 9, 11 and 13 weeks post-operative with elements 
of the BBB open field test 172 that are relevant to the root avulsion model. Voluntary 
movement of the hip, knee and ankle joint was scored with 0, 1 or 2 for “no”, “slight” 
or “extensive” movement in each joint. Stepping and toe clearance were assessed and 
0, 1, 2 or 3 points were scored if this occurred “never”, “occasionally”, “frequently” or 
“consistently”, respectively. Additional single points were given if plantar paw place-
ment and weight support were observed, leading to a maximum cumulative score of 
14 points for intact animals.
Tissue processing and staining 
After 4, 10 or 16 weeks, animals were deeply anesthetized with sodium pentobarbital 
(Sanofi Sante, Maassluis, the Netherlands) and perfused transcardially with ice cold 
saline, followed by 4% PFA in PBS. The left sciatic nerve was dissected between the 
sciatic notch and the bifurcation into tibial and peroneal branches (7 cm distal from 
the implantation site). Segments of the lumbar spinal cords containing the implanta-
tion area were then dissected out under a microscope. Both nerves and spinal cords 
were post-fixed overnight in PFA/PBS at 4˚C. Spinal cords were then incubated over-
night in 250 mM EDTA in PBS to soften possible residual bone debris. All tissue was 
finally cryoprotected in 25% sucrose in PBS at 4˚C for 3 days followed by embedding 
in OCT Compound 4583 (Tissue-Tek; Sakura, Zoeterwoude, the Netherlands), snap-
freezing in 2-methylbutane and storage at -80˚C. Five series of 20 µm horizontal 
longitudinal spinal cord sections and transverse sciatic nerve sections were cut on a 
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cryostat, mounted on Superfrost Plus slides (Menzel-Gläser, Braunsweig, Germany) 
and stored at -80˚C. 
In situ hybridization
Standard in situ hybridization was performed with digoxygenin(DIG)-labeled cRNA 
probes for BDNF or GDNF mRNA as described previously 173 on spinal cord tissue 
16 weeks after surgery. Briefly, sections were post-fixed with 4% PFA in PBS for 20 
min followed by acetylation and overnight incubation at 60˚C using 200 ng/ml heat-
denatured DIG-labeled cRNA probe in hybridization solution [5x standard saline 
citrate (SSC), 50% formamide, 5x Denhardt’s, 125 mg/ml bakers yeast tRNA (Sigma, 
Zwijndrecht, the Netherlands]. After stringency washes (5 min 5x SSC, 1 min 2x SSC, 
30 min 0.2x SSC in 50% formamide all at 60˚C and 5 min 0.2x SSC at room tempera-
ture) and blocking for 1 h in blocking reagent (Roche Nederland B.V., Almere, the 
Netherlands), sections were incubated with alkaline phosphatase-conjugated anti-DIG 
antibody (1:3000, Roche, Almere, the Netherlands) in TBS for 3 h. Enzyme activity 
was then visualized by overnight incubation with 300 µg/ml nitroblue-tetrazolium and 
170 µg/ml 5-bromo-4-chloro-indolyl phosphate in detection buffer (100 mM NaCl, 5 
mM MgCl2, 100 mM Tris/HCl pH 9.5), resulting in a dark purple precipitate. Sections 
were mounted in Aquamount solution (BDH Laboratory Supplies, Poole, England).
In vivo transduction efficiency
Transduction efficiency was determined by capturing tiled fluorescence images of 
longitudinal sections of LV-GArGFP injected root at 4 weeks. The distance between 
the most proximal and distal GArGFP transduced cells was subsequently measured 
using Image Pro Plus software. High magnification images were collected with a 40x 
objective from the center of the transduced area and the percentage of GArGFP posi-
tive nuclei was determined.
GDNF, S100 and NF immunostaining
Fluorescent double labelling to further analyze transgene protein expression was per-
formed on nerve roots transduced with LV- GArGFP or LV-GDNF at 4, 10 and 16 
weeks. Sections were washed three times in PBS and blocked in blocking buffer (PBS 
containing 5% FCS and 0.3% Triton X-100) for 1 h. Sections were then incubated over-
night at 4˚C in blocking buffer containing primary antibodies against GDNF (1:500; 
R&D systems, Minneapolis, MN, USA), against S100 to visualise Schwann cells (1:200; 
Dako, Glostrup, Denmark) or against NF(1:1000; α-2H3; Developmental Studies Hy-
bridoma bank, University of Iowa). The next day, sections were washed three times 
for 10 min in PBS and incubated for 2 h with biotin-conjugated or Cy3-conjugated 
secondary antibodies (1:400; Jackson ImmunoResearch Europe Ltd., Newmarket, 
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Suffolk, UK) in blocking buffer. Subsequently, sections were washed three times 10 
min in PBS and incubated with Cy2-conjugated streptavidin and/or Hoechst (1 μg/ml; 
BioRad, Hercules CA) in blocking buffer for 30 min. After 3 washes in PBS, sections 
were mounted in Vectashield (Vector Laboratories, Burlingame, CA, USA). Specific-
ity of the GDNF antibody was confirmed by absence of staining 1) on contralateral, 
non-injected nerve roots in a spinal cord section, 2) on LV-GArGFP injected roots, 
and 3) by omission of the primary antibody.
ChAT motoneuron staining. 
Although choline acetyl transferase (ChAT) is temporarily downregulated, it stains 
motoneurons reliably when used beyond 4 weeks after root avulsion 168. Therefore, 
ChAT immunohistochemical staining was performed to label motoneurons and their 
axons on spinal cords and sciatic nerve sections according to Blits et al. 24. This staining 
protocol starts with a 10 min 0.1% Triton-X100 and 0.01mg/ml proteinase K in PBS 
treatment and an overnight 50% formamide treatment at 55˚C for antigen retrieval 
followed by standard immunohistochemistry as described above with primary anti 
ChAT (1:200; ChAT pAb, AB144P, Chemicon, Hampshire, UK). For spinal cord sec-
tions, the primary antibody incubation was followed by biotinylated horse anti-goat 
1:300, stained with 0.035% 3, 3’-diaminobenzamidine tetrahydrochloride (DAB) in 
TBS containing 0.01% H2O2 and 0.2 mg/ml (NH4)2.SO4.NiSO4, resulting in a dark 
purple precipitate. Sections were dehydrated in graded series of ethanol, cleared in 
xylene and embedded in Entallan for quantitative light microscopic analysis. For sci-
atic nerve sections, the primary antibody was followed by Cy3-conjugated donkey anti 
goat 1:400 (Jackson ImmunoResearch Europe Ltd.) and embedding in Aquamount 
solution for fluorescent quantification of axons.
Quantification of total motoneuron volume and soma size distribution
Severe atrophy of motoneurons can hamper the accurate quantification of surviv-
ing motoneurons (e.g., when nuclear condensation clouds the presence of nucleoli). 
Whereas some authors discard structures with a diameter <30 µm when counting 
motoneurons 174, others show that motoneurons that have seemingly died can re-ap-
pear after a second axotomy, indicating that severe atrophy can easily be mistaken 
for cell death 153. To avoid this issue and to quantify the atrophy of motoneurons 
objectively and systematically, we used automated quantification of all ChAT positive 
structures (≈3000 structures per animal) to calculate the total volume of the affected 
motoneuron pool. 
 To this end, high-resolution tiled digital images were captured of a series of ChAT-
stained spinal cord sections at an interval of 200 µm. These images were imported in 
Image Pro Plus software and the entire motoneuron pools (i.e., areas containing ChAT 
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positive cells) of the root avulsion-affected side and contralateral (control) side were 
manually outlined. The motoneurons inside the motoneuron pool were then automati-
cally segmented with a filter algorithm. The total volume of both the affected and the 
contralateral motoneuron pool was calculated for each animal by interpolating the 
total measured surface area per section to the distance between sections (200 µm). 
This volume was expressed as a percentage of the contralateral side. The soma sizes 
on both sides of the spinal cord were pooled for all animals in an experimental group 
and the frequency histogram calculated in area intervals of 300 μm2.
Evaluation of ChAT fiber appearance and density in implanted ventral roots
The implanted ventral roots were studied on ChAT stained sections at 4, 10 and 16 
weeks by an observer blinded to treatment group. At 4 weeks, the density of axons 
entering the implanted root was quantified in non-avulsed, LV-GArGFP injected and 
LV-GDNF injected roots (n=5 per group). Three high resolution tiled images per ani-
mal were collected spanning the width of the root directly distal to the implantation 
site. A reference-line was drawn in Image Pro Plus software perpendicular to the im-
planted root. All axons crossing this line were counted manually by two investigators 
blinded to treatment. Furthermore, the temporal occurrence of aberrant fiber growth 
was studied. The presence or absence of specific areas with a high density of fibers with 
a longitudinal orientation (“strands”) and areas with a large number of fibers with a 
circular orientation (“coils”) was scored within each treatment group.
Evaluation of Schwann cell density in nerve roots
Schwann cell density was calculated in nerve roots from the “implant”, LV-BDNF and 
LV-GDNF groups at 16 weeks. Sections were stained for NF, S100 and Hoechst as 
described above. The root was outlined and if nerve coils were present (in LV-GDNF 
treated animals), these coils were outlined separately based on NF immunohisto-
chemical staining. The area covered by Hoechst-labelled nuclei was calculated as a 
proportion of the outlined area to create a measure of cell density with an ImagePro 
filter algorithm based on Hoechst signal.
Quantification of motor axon number and diameter in the sciatic nerve
To quantify the number of motor axons 7 cm distal from the implantation site, images 
of ChAT immunofluorescence-stained transversal sciatic nerve sections were captured 
using an LSM410 Zeiss confocal laser scanning microscope. Equal settings for detec-
tor gain, offset and pinhole were used to acquire each image. The surface area of the 
sciatic nerve was calculated using a 10x objective. Subsequently, 4 random samples 
in this surface area were captured with a 40x objective, covering approximately 50% 
of the total surface area. These were used to determine the total motor axon number 
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and diameter with a custom-made segmentation tool on Image Pro Plus software. 
Finally, distribution histograms of axon diameter were made with diameter intervals 
of 0.25 μm. 
Statistical analysis
Analysis for statistical difference between groups was performed using SPSS software 
(version 12.0; SPSS, Chicago, IL). One-way analysis of variance (ANOVA) followed 
by post-hoc Bonferroni test was performed on DRG outgrowth, motoneuron soma 
volume, Schwann cell density and total sciatic nerve fibers. Nonparametric analysis 
was performed on fiber density in implanted roots, motoneuron volume and sciatic 
fiber distributions using Kruskal-Wallis followed by Mann-Whitney U test. Coil for-
mation in the ventral root was examined using a Pearson Chi-Square test. Data were 
considered statistically significant if p<0.05.
Supplemental figure 1  GDNF is present in LV-GDNF transduced roots at 4 weeks, but not in 
LV-GArGFP injected or intact roots.
Immunohistochemistry for GDNF (green) and NF (red) on longitudinal spinal cord sections 
at the site of root reimplantation (arrows) for LV-GAr-GFP (A) and LV-GDNF (B) injected 
roots. No GDNF staining is visible in the LV-GAr-GFP injected root, whereas the injection of 
LV-GDNF leads to diffuse, strong GDNF staining in the entire root. 
CD) High magnification images of boxed areas in (A) and (B). Numerous fluorescent green 
nuclei are present in the LV-GAr-GFP injected nerve roots (arrowheads) (C), but diffuse GDNF 
staining is absent. Strong, diffuse GDNF staining is present in a LV-GDNF injected root (D) 
and is closely associated with regenerating nerve fibers (red)
E) Overview of the spinal cord of a LV-GDNF injected animal. GDNF staining (green) is 
present in the LV-GDNF injected root (right), but not in the contralateral (left) intact nerve 
root or within the spinal cord. NF positive axons (red) are thicker and straighter in the intact 
side than in the reimplanted root.
Scale bars ABE 100 μm; CD 50 μm.
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Abstract
Even after reconstructive surgery, major functional impairments remain in the ma-
jority of patients with peripheral nerve injuries. The application of novel emerging 
therapeutic strategies such as lentiviral (LV) vectors may help to stimulate peripheral 
nerve regeneration at a molecular level.
 In the experiments described here, we examined the effect of LV vector-mediated 
overexpression of nerve growth factor (NGF) and glial cell-line derived neurotrophic 
factor (GDNF) on regeneration of the rat peripheral nerve in a transection/repair 
model in vivo.
 We show that LV vectors can be used to locally elevate levels of NGF and GDNF 
in the injured rat peripheral nerve and this has profound and differential effects on 
regenerating sensory and motoneurons. For sensory neurons, increased levels of NGF 
and GDNF do not affect the number of regenerated neurons 1 cm distal to a lesion 
at 4 weeks post-lesion, but cause changes in the expression of markers for different 
nociceptive populations of neurons. These changes are accompanied by significant 
alterations in the recovery of nociceptive function. For motoneurons, overexpression 
of GDNF causes trapping of regenerating axons, impairing both long distance axonal 
outgrowth and reinnervation of target muscles, whereas NGF has no effect on these 
parameters.
 These observations show the feasibility of combining surgical repair of the tran-
sected nerve with the application of viral vectors. Furthermore, they show a difference 
between the regenerative response of motor and sensory neurons to locally increased 
levels of NGF and GDNF. 
Introduction
Peripheral nerve injuries cause sensory and motor impairments of the affected limb. 
At present, the only treatment strategy for severe nerve lesions is microsurgical repair, 
but even then, major functional impairments remain in the majority of patients 1. Fu-
ture advances in the treatment of peripheral nerve injuries are likely to benefit from 
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the improved understanding of the effect of neurotrophic factors on regeneration. 
Schwann cells in the nerve distal to the injury express a range of neurotrophic factors 
9,77 and several of these are differentially expressed in Schwann cells from sensory and 
motor nerves 12. Two neurotrophic factors, nerve growth factor (NGF) and glial cell-
line derived neurotrophic factor (GDNF) may be particularly important for peripheral 
nerve regeneration for several reasons.
 First, nociceptive sensory neurons in the dorsal root ganglion (DRG) can be divided 
in two functionally distinct populations that are either sensitive to NGF or GDNF 175. 
Peptidergic DRG neurons 176 express the receptor for NGF, tropomyosin receptor ki-
nase A (trkA) and respond to NGF 177,178. Non-peptidergic nociceptive neurons express 
a cell surface glycoconjugate that binds the Griffiona Simplicifolia isolectin B4 (IB4) 
179. These IB4-binding neurons express the receptor complex for GDNF, GFRα and 
ret 180,181. In contrast to peptidergic neurons, IB4-binding neurons regenerate poorly 
after peripheral nerve transection 182. 
 Second, NGF and GDNF have both been implicated in the regeneration of motoneu-
rons 9. NGF added to fibrin sealant increases the number of regenerated motoneurons 
in the transected rat sciatic nerve 18. GDNF prevents the atrophy 183 and enhances the 
regeneration 21 of chronically axotomised motoneurons.
 Finally, NGF is specifically upregulated in Schwann cells from sensory nerves, 
whereas the expression of GDNF is more pronounced in Schwann cells from motor 
nerves 12 and the application of these factors could therefore have differential effects 
on the regeneration of sensory and motoneurons.
 The exogenous application of various neurotrophic factors has resulted in relatively 
small and variable effects on regeneration of the injured peripheral nerve 18,20,184. The 
continuous and effective delivery of neurotrophic factors is difficult, as these proteins 
do not diffuse easily into nervous tissue and have a short half-life 32. Recent work has 
demonstrated that lentiviral (LV) vectors can direct long-term, local transgene expres-
sion in Schwann cells in vivo 150. In the experiments described here, we studied the 
effect of LV vector-mediated overexpression of NGF and GDNF on regeneration of 
the rat peripheral nerve in vivo. Specifically, we sought to compare the regenerative 
response of sensory and motoneurons and to examine the regeneration of distinct 
populations of nociceptive sensory neurons.
Materials and Methods
Lentiviral vector preparation
The production of LV vectors encoding NGF and GDNF and the biological activity of 
the neurotrophic factors derived from these vectors has been described previously, 90,183. 
The control vector was LV-GArGFP, which expresses green fluorescent protein (GFP) 
fused to a Gly-Ala repeat (GAr) and was produced according to Hendriks et al. 150. The 
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Gly-Ala repeat prevents a GFP-mediated cytotoxic T-lymphocyte immune response 
170, resulting in long term expression of this foreign protein in the peripheral nerve 150.
 The titers of the LV vector stocks were determined as follows. The LV-GArGFP 
stock titer was 1) evaluated by infecting 293T cells upon serial dilution to determine 
the number of transducing units per ml (TU/ml) and 2) by determining the p24 
content (ng/ml) with an ELISA (Perkin Elmer, The Netherlands). The ratio between 
the TU/ml and p24 content of the LV-GArGFP stock was used to calculate relative 
TU/ml titers for the LV-NGF and LV-GDNF stocks on the basis of their p24 content. 
Final titers were 2x109 TU/ml for LV-GArGFP and 7x109 TU/ml for both LV-NGF and 
LV-GDNF. All experiments described in this paper were performed using the same 
vector stocks. 
Experimental animals and surgical procedure
A total of 96 female Wistar rats (200-250 g; Harlan, Horst, the Netherlands) were 
used. Animals were housed under standard conditions in a 12:12 h light/dark cycle 
with food and water ad libitum. Experimental handling and postoperative care were 
in accordance with the guidelines of the local committee for laboratory animal welfare 
and experimentation. 
Surgery and vector injection 
The left sciatic nerve was exposed through a gluteal muscle-splitting incision, tran-
sected using microsurgery scissors and immediately repaired with four epineurial 10-0 
nylon sutures (Ethilon, Johnson & Johnson, Amersfoort, The Netherlands) under an 
operating microscope (figure 1A). A reference group received no further experimental 
treatment (repair only). For animals in the vector injection groups, 3 μl containing 
6x106 TU (LV-GArGFP) or 2x107 TU (LV-NGF and LV-GDNF) of the vector solution 
was then injected in the distal peroneal and tibial branches of the sciatic nerve using a 
glass capillary with an 80 µm diameter tip attached to a 10 µl Hamilton syringe. Fast 
green (Sigma, Zwijndrecht, the Netherlands) was added in a 0.1% concentration to the 
vector solution to visualize vector spread during injection (figure 1B). The skin was 
closed, after which the animals received Temgesic [buprenorphine 0.03 ml/100 g body 
weight s.c., (Schering-Plough B.V., Maarssen, the Netherlands)] for post-operative 
analgesia and were kept at 37ºC until complete recovery from anaesthesia.
Experimental series 
Table 1 shows the experimental groups, survival times, animal numbers used and 
measurements performed. Briefly, transgene expression was quantified in series 1 of 
these experiments (n=18, survival 4 weeks), regeneration of sensory and motoneu-
rons was evaluated in series 2 (n=32, retrograde tracing at 4 weeks, 5 weeks survival), 
and series 3 was used for additional histology at the level of the sciatic nerve (n=18, 
survival 4 weeks). Since no differences were found in any of the previous experiments 
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between the “repair only” and LV-GArGFP control groups, no “repair only” group 
was included in this third series. Functional recovery was finally evaluated in series 
4 (n=29, survival 12 weeks)
Quantification of transgene expression
Transgene expression was evaluated 4 weeks after surgery in series 1. Fresh sciatic 
nerves were harvested at 4 weeks (after decapitation) and cut into four segments of 1 
cm each, with 2 segments on either side of the repair site. These segments were snap-
frozen on dry-ice and stored at -80˚C until further use. To quantify the amount of 
NGF and GDNF, the frozen nerve segments were ground with a mortar on dry-ice, 
suspended in 250 µl suspension buffer containing 137 mM NaCl, 20 mM Tris/HCl 
pH 8.0, 10% glycerol, 0.1% Tween-20, 0.5 mM sodium orthovanadate 1% Nonidet 
P40 substitute (Applichem, Darmstadt, Germany) and Complete protease inhibitor (1 
tablet/50 ml, Roche, Mannheim, Germany), further homogenised with an ultra-tur-
rax (IKA-Labortechnik, Staufen, Germany) for 30 s, centrifuged and the supernatant 
stored in 50 µl aliquots at -20˚C. The concentration of NGF and GDNF was measured 
using ELISA kits (#G7630 and #G7620; Promega, Madison, USA) according to the 
manufacturer’s instructions and used to calculate total content in pg/cm nerve seg-
ment. The detection limit was 31 and 62 pg/cm for NGF and GDNF respectively.
Quantification of regeneration and sensory neuron size
Retrograde tracing was performed to quantify the number of sensory and motoneu-
rons that had extended a neurite 1 cm across the transection site (series 2). Four weeks 
after transection, repair and vector injection, rats underwent surgery to expose the 
sciatic nerve. The sciatic nerve was cut 1 cm distal from the repair site and the proximal 
end was placed in the cap of a small Eppendorf tube containing 3 µl 5% Fast Blue (FB) 
(EMS-Chemie, Gross-Umstadt, Germany) in saline. The cut nerve end was completely 
immersed in FB for 30 min followed by three saline washes. Animals were allowed to 
recover, again as described above. After allowing one week for retrograde transport 
of the tracer, animals were deeply anesthetized with sodium pentobarbital (Sanofi 
Sante, Maassluis, the Netherlands) and perfused transcardially with ice-cold saline, 
followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer pH 7.4 (PFA). 
Subsequently the L4, L5 and L6 DRGs as well as the lumbar section of the spinal cord 
were removed and post-fixed overnight in PFA at 4˚C. All tissue was cryoprotected in 
25% sucrose in 0.1 M sodium phosphate-buffered saline pH 7.4 (PBS) at 4˚C for 3 days 
followed by embedding in OCT Compound 4583 (Tissue-Tek; Sakura, Zoeterwoude, 
the Netherlands), snap-freezing in 2-methylbutane and storage at -80˚C until further 
use. Two series of 20 µm horizontal longitudinal spinal cord and four series of 20 µm 
DRG sections were cut on a cryostat, mounted on Superfrost Plus slides (Menzel-
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Table 1 Experimental groups, survival times, animal numbers and measurements in the ex-
periments described in this paper. (*) Some animals were lost during the experiment due to 
autotomy. The number in parentheses indicates the number of animals included in functional 
and/or histological analysis. (**) Retrograde tracing was performed 4 weeks after transection 
and repair. Animals were euthanized one week later to allow tracer uptake.
Series Intervention Weeks # Animals* Measurement
1 repair only
LV-GArGFP
LV-NGF
LV-GDNF
  4 5 (5)
6 (5)
3 (3)
3 (3)
Quantification of NGF and GDNF expression: 
ELISA
2 repair only
LV-GArGFP
LV-NGF
LV-GDNF
  4 (5**) 8 (8)
8 (7)
8 (8)
8 (8)
Quantification of regeneration: 
retrograde tracing 1 cm distal from repair site
3 LV-GArGFP
LV-NGF
LV-GDNF
  4 6 (6)
6 (4)
6 (5)
Histology: transgene expression, motoneuron 
staining, neurite outgrowth 1 cm distal from 
repair site
4 repair only
LV-GArGFP
LV-NGF
LV-GDNF
12 6 (6)
8 (7)
7 (6)
8 (7)
Motor reinnervation: target muscle weight
Nociceptive sensory reinnervation: footflick test
Gläser, Braunsweig, Germany) and stored at -80˚C.
Microscopic quantification of regenerated neurons 
All FB-labelled neurons containing a visible nucleus were microscopically counted 
on one series (out of two) of spinal cord sections and one series (out of four) of DRG 
sections using a Zeiss Axioplan 2 microscope. To compensate for duplicate counts of 
partially cut nuclei, the Abercrombie correction factor [nuclear diameter/(nuclear 
diameter + section thickness)] was applied to these neuron counts to calculate the 
number of regenerated neurons per animal 185. To measure the nuclear diameter in FB-
labelled cells for each animal, these visually counted sections were also photographed 
with an Evolution QEi digital camera (MediaCybernetics, Silverspring USA) using 
Image-Pro Plus software (version 6.2, MediaCybernetics, Silverspring USA). 
Automated segmentation of FB-labelled DRG neuron profiles 
A filter algorithm was developed with Image-Pro Plus software to identify all FB-
labelled profiles and measure the diameter on all photographed DRG sections. The 
number of these profiles correlated strongly with the number of neurons that were 
counted microscopically on the same sections (R2= 0.94).The generated profiles were 
plotted in a frequency distribution histogram with diameter intervals of 4 μm and the 
average profile diameter was determined in each animal.
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Regeneration of different nociceptive sensory neuron phenotypes
The second and third set of L4, L5 and L6 DRG sections from the retrogradely traced 
animals of series 2 were used respectively to stain peptidergic nociceptive neurons with 
antibodies against calcitonin gene-related peptide (CGRP) (rabbit anti-CGRP, 1:2000; 
Millipore, Billerica, USA) and non-peptidergic nociceptive neurons with biotinylated 
IB4 (Griffiona Simplicifolia IB4, 1:250, Vector laboratories, Burlingame, USA). Staining 
procedures of glass-mounted sections were performed as described previously 90. Brief-
ly, sections were rinsed three times in 0.1 M Tris/HCl-buffered saline pH 7.4 (TBS), 
incubated in TBS containing 0.3% Triton X-100 and 5% fetal bovine serum (blocking 
buffer) for 1 h and in blocking buffer containing the primary antibody overnight at 
4°C. The next day, sections were washed three times in TBS and incubated for 2 h with 
blocking buffer containing either Alexa594-labelled secondary antibodies or strepta-
vidin (Invitrogen, Carlsbad, USA). Finally, the sections were washed in TBS, mounted 
in Aquatex (Merck, Darmstadt, Germany) and coverslipped. To minimize staining 
variability, DRG sections from control and vector-treated animals were stained in the 
same staining session. Six randomly selected sections per animal (n=3 for both the 
L4 and L5 DRG) were photographed as described above with identical microscope 
and camera settings for all sections to assess CGRP and IB4 staining intensity of the 
retrogradely labelled FB positive sensory neurons. With the filter algorithm mentioned 
above, IB4 and CGRP staining intensity was measured in all FB-labelled profiles. Be-
cause of the established strong correlation between automatically segmented profiles 
and manually counted neurons, these data could be used to calculate the number of 
double-labelled DRG neurons per animal. 
Figure 1  Surgical procedures and transgene expression.
a) Photograph of rat sciatic nerve after complete transection and repair with four 10-0 micro-
sutures. 
b) Directly after repair, 3 µl fluid volume containing viral vector and 1% fast green (to visualise 
vector spread) was injected approximately 5 mm distal from the repair site. 
c) Four weeks after transection, NGF protein levels are elevated in the distal stump resulting 
in a gradient across the repair site. The injection of LV-NGF leads to a twofold increase in 
NGF levels, while the NGF gradient across the repair site remains intact. The application of 
LV-GDNF has no effect on NGF levels. GDNF protein levels are undetectable in all except the 
LV-GDNF treated animals. The injection of LV-GDNF leads to an increase in GDNF levels 
similar to the increase in NGF found after the application of LV-NGF. 
d) Numerous GArGFP positive nuclei (green) are present in the nerve, 4 weeks after vector 
application. Transduced cells are located within the nerve fascicles, in close proximity to neu-
rofilament-positive nerve fibers (red). 
e) In situ hybridisation shows many cells containing GDNF mRNA (black) in a pattern highly 
similar to the GArGFP-transduced cells in panel d. 
Scale bar: 1 mm (AB), 100 µm (DE).
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Transgene expression and neurite sprouting
In series 3, 18 animals were operated and injected with LV vector as described above 
(without the “repair only” group). After 4 weeks, animals were euthanized and per-
fused transcardially with PFA and the sciatic nerve was removed, postfixed and stored 
at -80°C as described above. Five series of 20 µm thick, longitudinal cryostat sections 
were cut, covering a segment from 5 mm proximal to 1 cm distal to the repair site. 
Immunohistology was performed on the first series of sections with antibodies against 
GFP (1:4000, Abcam, Cambridge, UK) to stain GArGFP-transduced cells and against 
neurofilament (1:1000; 2H3; Developmental Studies Hybridoma bank, Iowa City, 
USA) to stain axons using the procedures described above. 
 In situ hybridization was performed on the second series to detect GDNF mRNA 
using probes and procedures described previously 25. Briefly, sections were post-fixed 
with PFA for 20 min followed by acetylation and overnight incubation at 60˚C using 
200 ng/ml heat-denatured DIG-labeled cRNA probe in hybridization solution [5x 
standard saline citrate (SSC), 50% formamide, 5x Denhardt’s, 125 mg/ml bakers yeast 
tRNA (Sigma, Zwijndrecht, the Netherlands)]. After stringency washes (5 min 5x SSC, 
1 min 2x SSC, 30 min 0.2x SSC in 50% formamide all at 60˚C and 5 min 0.2x SSC at 
room temperature) and blocking for 1 h in blocking reagent (Roche Nederland B.V., Al-
mere, the Netherlands), sections were incubated with alkaline phosphatase-conjugated 
anti-DIG antibody (1:3000, Roche, Almere, the Netherlands) in TBS for 3 h. Enzyme 
activity was then visualized by overnight incubation with 300 µg/ml nitroblue-tetrazo-
lium and 170 µg/ml 5-bromo-4-chloro-indolyl phosphate in detection buffer (100 mM 
NaCl, 5 mM MgCl2, 100 mM Tris/HCl pH 9.5), resulting in a dark purple precipitate.
 On the third series, axons of motoneurons were stained with antibodies against 
choline acetyl transferase (ChAT) (1:200; AB144P, Millipore, USA) as described pre-
viously 24. Alexa 594-labeled antibodies (Invitrogen, Carlsbad, USA) were used as 
secondary antibodies as described above.
 From the same nerve pieces, 20 µm thick transverse sections were cut 1 cm distal from 
the repair site to evaluate sprouting of regenerated neurites. These sections were stained 
with primary antibodies against neurofilament (2H3) using Alexa 594-labeled second-
ary antibodies. Three random fields were captured with an LSM410 Zeiss confocal laser 
scanning microscope and a filter algorithm was applied to determine by the number of 
neurofilament positive axons per area. This number was multiplied with the total cross-
sectional area of the nerve (calculated with Image-Pro Plus software) to determine the 
total number of axons in the distal nerve stump 1 cm from the repair site at 4 weeks.
Functional evaluation
Nociceptive sensory reinnervation 
In series 4, return of nociceptive sensory function was evaluated by applying an elec-
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tric stimulus to the lateral foot sole 186. In healthy rats, a current of 0.1 mA elicits a 
prompt withdrawal response, whereas transection of the sciatic nerve results in the 
complete absence of any reaction. Animals were tested weekly, the minimal current 
(up to 0.5 mA to prevent tissue damage) needed to elicit a response was noted and 
expressed as percentage of pre-operative value (0% for no reaction at 0.5 mA to 100% 
for a withdrawal reaction at 0.1 mA). Testing was discontinued at 7 weeks, when the 
withdrawal response had returned to pre-operative levels in all animals. 
Target muscle weight 
Twelve weeks after transection/repair, animals from series 4 were perfused with 4% 
PFA as described above, and the soleus and gastrocnemic muscles were dissected bi-
laterally. The weight of these muscles was regarded as a measure of return of functional 
reinnervation by motoneurons 187. Weights were expressed as percentage of the same 
muscles on the contralateral side.
Analysis of autotomy behaviour 
Because overexpression of NGF and GDNF may affect autotomy behaviour 19,184, au-
totomy was analyzed daily in all four experimental series. The degree of autotomy of 
the left hind paw was scored using a 0-5 point scale 188. A score of 0 corresponds to a 
normal undamaged hind paw, 1 to nails nibbled, damaged or removed, 2 to one digit 
bitten upon or loss of up to one-third of the digit, 3 to one or two digits bitten upon 
or loss of one-third and one-half, 4 to one or two digits lost to more than 50% and 5 to 
more digits chewed upon or completely lost. Animals that reached an autotomy score 
of 5 were promptly euthanized (total n=8; repair only n=0, LV-GArGFP n=3, LV-NGF 
n=3, LV-GDNF n=2) and excluded from all functional and histological data analyses, 
except analysis of autotomy scores. Instead of using the average autotomy score at each 
time point (which may have biased the analysis due to the prompt sacrifice of animals 
with a score of 5), we used the maximum score achieved by each animal (n=96) to 
analyze differences in autotomy scores between groups.
Statistical analysis
Analysis for statistical differences between groups was performed using SPSS software 
(version 12.0; SPSS, Chicago, IL). Nonparametric analysis was performed on autotomy 
scores using Kruskal-Wallis followed by Mann-Whitney U test. Two-way analysis of 
variance (ANOVA) was performed on the nociceptive function test. One-way ANOVA 
was performed on all other data. When significant differences were found, ANOVAs 
were followed by post-hoc Bonferroni testing. Data were considered statistically sig-
nificant if p<0.05. In each case where the application of LV-NGF or LV-GDNF caused 
statistically significant differences compared to the “repair only” control, they were 
also significant compared to the LV-GArGFP control group.
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Results
Transgene expression 
In series 1, the levels of NGF and GDNF following application of LV-NGF and LV-
GDNF (figure 1A) were determined and compared to endogenous levels after sciatic 
nerve transection and repair. The peroperative spread of viral vector was monitored 
with Fast Green and was typically observed from the repair site to approximately 1 
cm distal (figure 1B). In control animals, endogenous NGF levels were significantly 
elevated in the 1 cm segments directly distal from the repair site (7-10 ng vs. ~3 ng 
proximally; figure 1C). The application of LV-NGF led to an increase in NGF levels 
from 2 cm proximal to 1 cm distal to the repair site (LV-NGF vs “repair only”, p=0.004). 
The NGF levels were highest in the first 1 cm distal from the repair site, thereby in-
creasing the NGF gradient across the lesion site as compared to the control interven-
tion. No GDNF could be detected at the repair site of the nerve in control animals 
(detection threshold 62 pg/cm nerve segment), but the application of LV-GDNF led 
to high levels of GDNF in the range of 6-7 ng/cm directly proximal and distal from 
the repair site (figure 1C). In conclusion, both NGF and GDNF levels were elevated 
around the lesion and repair site. Importantly, the application of LV-NGF did not 
significantly influence GDNF levels and vice versa.
 Immunohistochemistry on longitudinal sections (series 3) showed numerous cells 
with GArGFP positive nuclei in close association with neurofilament positive axons 
in all LV-GArGFP-injected animals (figure 1D). These cells could be found both dis-
tal and proximal from the transection and repair site, with the highest number of 
GArGFP positive cells near the repair site. Similarly, in situ hybridization for GDNF 
showed numerous positive cells in all LV-GDNF-injected animals, within the nerve 
fascicles in a pattern similar to that of the GArGFP positive cells (figure 1E). No GDNF 
mRNA was detectable in sections of control peripheral nerve (results not shown). 
Although the diffusion of vector particles may have contributed to the transduction 
of Schwann cells proximal from the transection/repair site, the elevated NGF/GDNF 
levels more than 1 cm proximal from the injection site suggests the migration of some 
transduced cells in a proximal direction as described previously 189,190.
The effect of LV-NGF and -GDNF on peripheral nerve regeneration
Subsequently, the effect of overexpression of NGF and GDNF in the injured peripheral 
nerve on regeneration was studied. To quantify the number of sensory neurons and 
motoneurons with a regenerated axon that reached at least 1 cm distal from the repair 
site at 4 weeks a retrograde tracing experiment was performed. 
Regeneration of sensory neurons 
The total number of FB positive, i.e., regenerated sensory neurons in the L4, L5 and 
L6 DRGs was not significantly different between the groups, and ranged from 6200 
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for the “repair only” control group to 7500 in the LV-GArGFP control group, with the 
averages for the LV-NGF and LV-GDNF groups ranging between these values (figure 
2A). Thus, increased levels of NGF or GDNF at the repair site of the transected rat 
sciatic nerve do not result in a significant change in the number of regenerated sensory 
neurons at one month post-injury. 
Regeneration of motoneurons 
In the “repair only”, the LV-GArGFP-injected and the LV-NGF-injected groups simi-
lar numbers of motoneurons were retrogradely labelled with FB at 4 weeks following 
transection and repair. The numbers of FB-labelled neurons ranged from approxi-
mately 900-1100 per animal (figure 2B). Strikingly, the application of LV-GDNF led 
to a strong and significant decrease in the number of regenerated motoneurons to 
an average of 300 per animal (p=0.000011). Retrograde tracing thus showed that the 
majority of regenerating motoneurons were unable to extend an axon 1 cm distal from 
the repair site after local LV vector-mediated overexpression of GDNF.
T o determine the fate of transected, regenerating motor axons, we performed a ChAT 
staining on longitudinal sections of the repaired nerve. In the LV-GArGFP (control) 
and LV-NGF groups, most regenerating ChAT positive motor fibers were oriented 
longitudinally within the section. In contrast, in all LV-GDNF-treated animals, the 
nerve contained high densities of chaotically oriented motor axons (figure 2). These 
“axon coils” were particularly evident at or near the repair area, which corresponds 
to the area with significantly increased GDNF mRNA and protein expression as de-
termined in series 1 (figure 1). The decreased number of distally regenerated axons 
after the injection of LV-GDNF is apparently the result of trapping of motor axons in 
areas of the nerve that contain high levels of transgenic GDNF. 
LV-NGF and -GDNF cause hypertrophy of sensory neurons
Both NGF and GDNF cause a marked hypertrophy of unlesioned sensory neurons 191. 
To determine whether they have a similar effect on the size of regenerating sensory 
neurons, we developed a filter algorithm to automatically segment all FB-labelled 
profiles in the DRG and calculate their diameter in every fourth section (figures 3AB). 
When the relative proportion of cell profile diameters was plotted in a distribution 
histogram, a clear shift towards bigger profiles was visible in both the LV-NGF and LV-
GDNF groups (figure 3C). Both LV-NGF and LV-GDNF caused a small but significant 
increase in the average diameter of the regenerated, retrogradely labelled cell profiles 
in the L4, L5 and L6 DRGs, (LV-NGF 27.4 µm and LV-GDNF 27.3 µm vs 25.9 µm in 
“repair only” animals, p=0.016 and 0.014 respectively; figure 3D). 
LV-NGF and -GDNF increase CGRP expression in regenerated neurons
Peptidergic nociceptive neurons are sensitive to NGF 177,178. The expression of CGRP 
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Figure 2 Quantification of regeneration through retrograde tracing, 1 cm distal from the repair 
site, 4 weeks after transection/repair.
a) The regeneration of sensory neurons is not affected by either LV-NGF or LV-GDNF, as the 
number of retrogradely labelled neurons is not significantly different in any group. 
b) The application of LV-GDNF severely impairs the regeneration of motoneurons, causing an 
approximate four-fold reduction in the number of motoneurons capable of extending an axon 
1 cm from the transection/repair site (p=0.000011).
c) Immunohistochemistry for ChAT on longitudinal nerve sections shows that in LV-GArGFP 
injected control roots, the majority of motor axons are oriented longitudinally across the 
transection/repair site. 
d) A similar ChAT staining on a nerve section of a LV-GDNF injected animal shows that 
motoneurons are chaotically oriented and trapped within the nerve. 
Scale bar: 50 µm.
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in these neurons can be upregulated by the exogenous application of both NGF and 
GDNF 191 and by peripheral nerve transection 192. We therefore stained for CGRP on 
DRG sections in which the regenerated neurons were retrogradely labelled with FB 
(series 2). In both the “repair only” and the LV-GArGFP control groups, a substantial 
proportion of CGRP positive cells was FB labelled (figure 4), indicating that these 
peptidergic neurons are capable of regeneration. As described by others 187, a striking 
effect of both LV-mediated NGF and GDNF expression distal to the transection site 
was observed on the number and staining intensity of CGRP positive cells in the DRG 
Figure 3 LV- NGF and LV-GDNF cause hypertrophy of sensory neurons.
a) Image of a typical section of a dorsal root ganglion, with regenerated neurons containing 
the retrograde tracer Fast Blue (FB). 
b) Using Image-Pro Plus software, a filter algorithm was developed to measure the diameter 
of all FB-labelled structures. 
c) The average diameter of all FB-labelled profiles is slightly but significantly increased in 
both LV-NGF- and LV-GDNF-treated animals compared to the control animals (p=0.016 and 
p=0.014 respectively. 
d) When all profiles are plotted in a frequency distribution, a clear shift towards bigger struc-
tures can be seen in both the LV-NGF and LV-GDNF groups. 
Scale bar: 250µm.
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compared to control groups (figure 4). In addition, the number of double-labelled (i.e., 
FB and CGRP positive) cells was also higher in both LV-NGF- and LV-GDNF-treated 
animals (1100, P=0.0039 and 1500, P=0.00016, respectively, compared to 400 in the 
“repair only” group). However, combining the observations that a) the total number 
of regenerated sensory neurons was not increased (figure 2) and b) the CGRP was 
evidently increased in the entire DRG, we conclude that LV-NGF and LV-GDNF do 
not specifically enhance regeneration of CGRP-expressing neurons, but instead cause 
a higher number of regenerated neurons to become CGRP positive.
LV-GNDF increases IB4 binding in regenerated neurons
Non-peptidergic, IB4-binding sensory neurons are sensitive to GDNF and regenerate 
poorly after peripheral nerve lesions, presumably due to insufficient GDNF levels 182. 
Furthermore, IB4 binding is downregulated after a peripheral nerve lesion 193. For 
Figure 4 The application of LV-NGF and LV-GDNF increases CGRP expression in regenerated 
DRG neurons 4 weeks after sciatic nerve transection and repair.
a) Immunohistochemistry for CGRP (red) on DRG sections in which all regenerated neurons 
are retrogradely labelled with FB (blue). In “repair only” and LV-GArGFP control groups, 
approximately half of all CGRP labelled neurons have regenerated. Both the application of 
LV-NGF and LV-GDNF increase the number of regenerated and total CGRP labelled cells. 
Scale bar: 250 µm. Arrowheads point at double-labelled profiles. 
b) Automated quantification of double-labelled profiles shows that the number of regenerated 
CGRP positive cells is significantly increased after the application of LV-NGF and LV-GDNF. 
*p=0.0039 and p=0.00016, respectively.
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Figure 5 The application of LV-GDNF increases IB4 binding in regenerated DRG neurons 4 
weeks after sciatic nerve transection and repair.
a) Histochemistry for IB4 (red) on DRG sections in which all regenerated neurons are retro-
gradely labelled with FB (blue). In “repair only” and LV-GArGFP control groups, there is virtu-
ally no colocalisation of IB4 and FB, indicating that the majority of IB4 labelled neurons do not 
regenerate. The application of LV-GDNF increases the overall level of IB4 reactivity in the DRG 
and IB4 staining can be seen in numerous regenerated cells (arrows). Scale bar: 250 µm. 
b) Automated quantification of double-labelled profiles shows that the number of regenerated 
IB4 positive cells is significantly increased after the application of LV-GDNF (p=0.00021 vs 
repair only).
these reasons we performed an IB4 staining to study the effect of LV-NGF and LV-
GDNF. Indeed, in the “repair only”, LV-GArGFP and LV-NGF groups, there was little 
colocalisation with FB-labelled (regenerated) neurons and IB4 staining (figure 5A-C). 
Strikingly, both the number and intensity (visual observation) of IB4-labelled cells was 
strongly increased in LV-GDNF-treated animals and numerous double labelled cells 
could be observed (figure 5A). We subsequently quantified the number of double-la-
belled cells: in control groups, only very small numbers of FB-labelled neurons were 
IB4 labelled (“repair only” and LV-GArGFP had an average of approximately 200 cells 
per animal, figure 5B). No significant change was observed in the LV-NGF group (av-
erage 300; p=0.34), but in the LV-GDNF group the number was significantly higher 
(average 500; p=0.00021). We conclude that high levels of GDNF do not specifically 
enhance regeneration of IB4 positive neurons. Instead, an increase in the expression 
of GDNF, but not NGF, causes increased IB4 labelling intensity in regenerated sen-
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sory neurons, or more precisely, reversal of the lesion-mediated loss of IB4 binding 
193. However, the total number of regenerated sensory neurons with an axon at 1 cm 
distal from the repair site at 4 weeks post-lesion is not affected.
LV-NGF and -GDNF do not increase neurite sprouting distal from the repair site
Retrograde tracing and immunohistochemical staining of motor axons showed that 
regenerating motoneurons were trapped by the local application of LV-GDNF and nei-
ther LV-NGF nor LV-GDNF influenced the regeneration of sensory neurons. However, 
the potential ability of these factors to induce increased sprouting of neurites distal 
from the transection/repair site can not be determined through retrograde tracing. 
To quantify this, we stained transverse sections of the sciatic nerve at 4 weeks after 
intervention, 1 cm distal from the repair site with an antibody against neurofilament. 
The average number of neurites in LV-GArGFP-injected control nerves was 11,000. 
This number is higher than the combined number of regenerated FB-labelled sen-
sory and motoneurons (7,000-8,500) suggesting that a certain degree of sprouting of 
regenerating neurites does occur after peripheral nerve repair and accounts for this 
difference. The number of neurites after the application of LV-NGF and LV-GDNF 
was not significantly different from this control level (figure 6C), indicating that there 
was no effect on neurite sprouting. For LV-GDNF-treated animals, a slight decrease 
might have been expected as it was shown to trap regenerating motor axons (figure 
2C). However, retrograde tracing showed that the majority of neurons projecting 
to the sciatic nerve were sensory neurons (87%; figure 2AB) and therefore an effect 
on motor axons is well within the measured standard error of the means of the total 
number of regenerated neurites.
LV-NGF and -GDNF affect sensory and motor functional recovery
Nociceptive sensory reinnervation 
The return of nociceptive sensory function after peripheral nerve transection was 
determined by applying a noxious electric stimulus to the lateral foot sole 186. After 
transection of the sciatic nerve, no withdrawal response was observed in any of the 
animals, indicating a complete loss of nociceptive function in the hind paw. In “repair 
only” and LV-GArGFP controls, as well as in LV-GDNF-treated animals, a withdrawal 
response gradually returned at 4 weeks and with time, lower currents were needed to 
elicit a withdrawal response until nociceptive function had completely restored at 7 
weeks. The application of LV-NGF caused a significant increase in the recovery rate: 
more animals showed a withdrawal response at lower currents (p=0.037 vs “repair 
only”). At 6 weeks, all LV-NGF-treated animals showed a withdrawal response at 0.1 
mA and the response curves show a one week shift towards earlier recovery of noci-
ceptive sensation in the foot sole of the hind paw (figure 7A).
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Motoneuron reinnervation 
The ultimate measure of functional motor recovery is behavioural analysis of loco-
motor function of the affected hind paw. However, this type of functional recovery 
is strongly influenced by factors such as misrouting of regenerated axons 9,117 and 
central plasticity 120. As a more simple and direct measure for the reinnervation of 
target muscles by regenerated motoneurons, we therefore weighed the gastrocnemic 
and soleus muscles 12 weeks after transection and repair, and compared them to the 
contralateral side 187. In the “repair only”, the LV-GArGFP and the LV-NGF groups, the 
combined weight of these muscles was approximately 60% of the contralateral side. The 
application of LV-GDNF resulted in a 30% lower muscle weight (p=0.00018 vs “repair 
only”; figure 7B). These results suggest that the impaired motor axon regeneration 
found by retrograde tracing and the coiling of axons at the repair site indeed impede 
the reinnervation of target muscles.
Autotomy behaviour 
Both NGF 194,195 and GDNF 18 have been associated with increased autotomy behaviour 
in peripheral nerve lesion models. We therefore investigated if the overexpression 
of these factors influenced autotomy in our study (figure 7C). The development of 
autotomy over time appeared to correspond with the period of nociceptive function 
loss: it gradually increased after nerve transection, but decreased sharply as nocicep-
tive sensation of the hind paw returned. Over this entire period, the average autotomy 
score was highest in the LV-GNDF group, but this difference was most pronounced 
at later time points, when nociceptive function was restored (cf. figures 7A and C). 
Figure 6 Automated quantification of neurofilament positive structures 1 cm distal from the 
transection and repair site of the sciatic nerve at 4 weeks shows that LV-NGF and LV-GDNF 
treatment does not increase neurite sprouting. 
a) Regenerated axons distal from the repair site stained with antibodies against neurofilament 
and quantified using an automated filter algorithm (b). 
c) In LV-GArGFP control animals, approximately12,000 neurites have regenerated across the 
repair site, this number is not affected by the application of LV-NGF or LV-GDNF.
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The average maximum score reached by each animal was significantly higher in the 
LV-GDNF group (p=0.011 compared to “repair only”; figure 7C). The application of 
LV-NGF did not appear to influence autotomy.
Discussion
In this paper we show that LV vectors can be used in vivo to locally elevate levels of 
NGF and GDNF after transection and direct suture repair of the rat sciatic nerve. These 
elevated NGF and GDNF levels have profound and differential effects on regenerating 
sensory and motoneurons. For sensory neurons, increased levels of NGF and GDNF 
did not affect the total number of sensory and motoneurons from which axons had re-
generated 1 cm distal to the repair site 4 weeks after repair, but changed the expression 
of markers for different nociceptive populations of neurons. Functionally, LV-NGF 
increased the rate of recovery of nociceptive function, whereas LV-GDNF increased 
autotomy behaviour. For motoneurons, increased expression of GDNF at the repair 
site was found to cause trapping of regenerating axons, with decreased numbers of 
motoneurons from which axons had regenerated 1 cm distal to the repair site and 
decreased weight of target muscles. NGF had no effect on these parameters.
Lentiviral vectors mediate a long-term increase in neurotropic factor expression 
in the injured rat sciatic nerve
Our quantitative analysis shows, in concordance with previously published data 182, 
that endogenous NGF levels are much higher than GDNF levels in the peripheral 
nerve after a lesion. In fact, we were unable to detect any endogenous GDNF with the 
current protocol, although elevated GDNF mRNA and protein levels 4 weeks after 
peripheral nerve injury have been shown by numerous other studies 12,196,197. In the 
present study, sciatic nerves were divided in 1 cm segments, resulting in very small 
amounts of homogenate that may have been insufficient to detect endogenous levels 
with an ELISA approach. Transduction of Schwann cell with LV vectors results in 
increased levels of NGF and GDNF around the transection/repair site at least up to 4 
weeks. Previously, we have shown that LV-mediated transgene expression continues 
for at least 16 weeks in Schwann cells in reimplanted spinal nerve roots 150,183. In abso-
lute terms, transgenic NGF and GDNF tissue levels are comparable (an additional 7-10 
ng in the 1 cm nerve segment directly distal from the repair site). However, because 
of the different endogenous levels of NGF and GDNF, LV-mediated expression of 
these neurotrophic factors result in an approximately two-fold increase in NGF levels, 
whereas the relative increase in GDNF expression was at least 100-fold. 
The effect of LV-NGF on regenerating sensory neurons
Retrograde tracing shows that the two-fold increase in the expression of NGF in the 
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Figure 7 Functional effects of LV-NGF and LV-GDNF following transection and repair of the 
rat sciatic nerve.
a) Evaluation of nociceptive function by determining the minimal electric current that has to 
be applied to the affected foot sole to elicit a withdrawal response. Transection of the sciatic 
nerve results causes the complete absence of a withdrawal response. Over the course of sev-
eral weeks, gradually lower currents are needed to elicit foot withdrawal until at 7 weeks, the 
required stimulus returns to pre-operative levels. LV-NGF significantly accelerates the return 
of this response with approximately one week. *p=0.037 vs “repair only”. 
b) Evaluation of the weight of gastrocnemic and soleus muscles (% o contralateral) as measure 
for reinnervation by motoneurons at 12 weeks after transection and repair. LV-GDNF causes 
a significantly lower muscle weight *p=0.00018 vs “repair only”, 
c) After sciatic nerve transection, autotomy increases gradually, but drops sharply as nocicep-
tive sensation of the hind paw returns (cf. panel a). The average maximum autotomy score 
reached by each animal is higher in LV-GDNF treated animals (p=0.011 and 0.019 compared 
to the “repair only” and LV-GArGFP control groups, respectively).
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genetically modified nerve does not significantly increase the number of regenerated 
sensory DRG neurons. Moreover, histology of the distal nerve stump reveals that 
distal sprouting of neurons is not significantly enhanced. However, the expression 
of CGRP in regenerated DRG neurons is increased and there is a significantly faster 
return of the withdrawal response after a noxious stimulus to the hind paw. The role 
of NGF in the pathogenesis of pain, specifically in the development of thermal and 
mechanical hyperalgesia, is well documented 10,198,199. In a dorsal root avulsion model, 
the viral vector-mediated overexpression of NGF has been shown to cause hyperalgesia 
200. Furthermore, NGF causes the upregulation of CGRP in sensory neurons 201 and 
CGRP increases neuronal excitability 202. The present observations show that local 
LV-vector-mediated expression of NGF at a peripheral nerve lesion/repair site has no 
effect on the number of regenerated neurons or axons at 1 cm distal at 4 weeks, but 
does induce the upregulation of CGRP in regenerated sensory neurons. The enhanced 
recovery of nociceptive function that was observed after the application of LV-NGF is 
therefore likely the result of the sensitization of regenerated neurons, causing increased 
sensitivity of the hind paw. However, a small effect of LV-NGF on the initial post-lesion 
temporal pattern of neurite outgrowth of nociceptive neurons may have occurred and 
this could have contributed to the earlier return of nociceptive function. 
The effect of LV-GDNF on regenerating sensory neurons
Similar to LV-NGF, LV-GDNF did not stimulate the regeneration of sensory DRG 
neurons, but increased the expression of CGRP in regenerated sensory neurons. In 
addition to this effect, LV-GDNF also strongly increased the number of IB4-binding 
regenerated neurons. These histological findings correspond well with several reported 
effects of pharmacologically administered GDNF on sensory neurons. First, GDNF 
increases CGRP expression in intact sensory neurons without causing increasing ther-
mal or mechanical pain sensitivity 187. Second, GDNF prevents the axotomy-induced 
downregulation of IB4 binding 177. Third, it prevents the loss of IB4 binding in a sciatic 
nerve ligation model for neuropathic pain 193,203. Moreover, increased CGRP expres-
sion and IB4 binding have been observed in a model for chronic nerve compression 
injury, in which GDNF was also shown to accumulate 204.
 Furthermore, we found that LV-vector–mediated expression of GDNF in the distal 
stump of a transected and repaired peripheral nerve significantly affects autotomy 
behaviour, as reported before following the application of GDNF in fibrin sealant 19 in a 
highly similar model for nerve transection and repair. Autotomy is usually interpreted 
as a behavioural response to neuropathic pain 188,195,205,206, but GDNF has been shown 
to posses strong analgesic properties 193,203,207. It is interesting that in our experiments 
the most marked GDNF-mediated increase in autotomy was after 7 weeks when noci-
ceptive function had been completely restored. This suggests that, instead of being the 
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result of neuropathic pain, autotomy behaviour in LV-GDNF treated animals may have 
been caused by reduced pain perception in the innervated hind paw: whereas autotomy 
is limited after re-establishment of nociceptive function in normal animals, the analge-
sic effect of GDNF may have prevented this feed-back, leading to continued autotomy. 
 Although the effect of GDNF on analgesia and on IB4 binding have been reported 
to occur concomitantly in a number of studies 193,203,207, a precise relation between 
IB4 binding and pain perception remains to be elucidated. These phenomena may 
be linked however in the following way: the substrate for IB4 is a splice variant of the 
extracellular matrix proteoglycan versican 208, a component of perineuronal nets that 
stabilise neuronal connections 114. The upregulation may therefore affect cross-excita-
tion of nociceptive DRG neurons 208,209 leading to decreased pain perception in the 
central nervous system.
 In summary, LV-GDNF does not increase the number of regenerating neurons, but 
increases both CGRP immunoreactivity and IB4 binding in sensory neurons of the 
DRG. The analgesic effects of GDNF (possibly related to an increase in IB4 binding) 
could stimulate autotomy behaviour in LV-GDNF treated animals.
Motoneurons fail to regenerate across areas of high GDNF expression
We have previously shown that viral vector-mediated overexpression of GDNF in 
either the spinal cord or the ventral root in a rat ventral root avulsion and reinsertion 
model leads to trapping of the regenerating motor axons 25,179. Motor axons continue to 
grow within the area of GDNF expression, leading to the development of axon-dense 
areas in the ventral spinal cord 24 or neuroma-like “nerve coils” in the reimplanted 
nerve roots 183, a phenomenon we have previously called the “candy store effect”. Here, 
a highly similar effect of LV-GNDF on the regeneration of motoneurons was observed 
in the rat sciatic nerve which contains both motor and sensory neurons. Retrograde 
tracing showed that a significant number of motoneurons fail to extend axons across 
areas of transgenic GDNF expression and staining for (motoneuron-specific) ChAT 
on longitudinal sections revealed that motor axons at the repair site of the nerve have 
a disorganised morphology. Consequently, many regenerating motor axons in the 
LV-GDNF treated animals fail to re-innervate target muscles leading to a significant 
decrease in muscle weight. Apparently, the continuous local expression of very high 
levels of GDNF is detrimental to long distance regeneration, and traps regenerating 
motoneurons in a “candy store”. 
 This “candy-store effect” may have been caused by the relatively large (100-fold) 
increase in GDNF expression, as the trapping of regenerating axons by GDNF ap-
pears to be dose-dependent 210. Therefore, it remains possible that regeneration can 
be enhanced by a more “physiological” elevation (e.g., two-fold) in GDNF levels. This 
may be achieved with viral vectors with regulatable transgene expression 52 or with 
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promoters, like the GFAP 211 or S-100 212 promoter, that would specifically direct more 
physiological levels of transgene expression in non-myelinating Schwann cells. This 
latter approach could limit the expression of GDNF to Schwann cells distal to the tip 
of the transected axon and this approach may thus prevent trapping.
Interestingly, regenerating sensory neurons did not appear to be trapped by high local 
levels of GDNF, although a dose-dependent effect of the regeneration of the central 
projection of DRG neurons into the spinal cord has been described by others 213. This 
differential effect of GDNF on sensory and motor neurons could in theory be used to 
devise a nerve graft that preferentially allows the long distance regeneration of sensory, 
but not motor neurons.
Concluding remarks
In recent years, the focus of peripheral nerve research has increasingly shifted towards 
creating a better understanding of the molecular basis of peripheral nerve regenera-
tion 2,11. In the present paper, we show that LV vectors are highly suitable tools to 
study regeneration at a molecular level, as they make it possible to investigate the 
regenerative effect of the highly localised overexpression of any protein of interest. 
Furthermore, we show that viral-vector–mediated overexpression of two well-known 
neurotrophic factors, NGF and GDNF influences regenerating nociceptive sensory 
and motor neurons in very different ways. These insights have important implications 
for future research. First, the specific neurotropic effect of LV-GDNF on motoneu-
rons could theoretically be applied to direct regenerating motor axons towards the 
appropriate distal endoneurial tubes, although transgene expression would have to be 
switched off after a certain period to allow continued outgrowth. Second, the observa-
tion that motoneurons are trapped by high levels of transgenic GDNF could potentially 
be exploited to create nerve grafts that are specifically permissive for sensory axons (by 
applying LV-GDNF proximal to the nerve graft). Finally, the application of LV-GDNF 
to injured sensory nerves (after surgical repair) may be an attractive adjuvant therapy 
for the treatment of neuropathic pain. 
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Summary and general discussion
Summary of this thesis
In the research described in this thesis, we explored two related questions.
1) What are the molecular properties of the human peripheral nerve lesion, and in 
particular, why is scarring at the lesion site, or neuroma formation, detrimental to 
functional recovery?
2) Can we apply lentiviral (LV) vectors to overexpress neurotrophic factors to enhance 
regeneration after surgical repair?
The first two experimental chapters dealt with the first research question. We studied 
small segments of human neuroma tissue that were removed during reconstructive 
surgery and discovered that they contain the chemorepulsive protein semaphorin3A. 
Staining for semaphorin3A shows that the protein surrounds nerve fibers in a punctate 
pattern and a functional in vitro test shows an inhibition of the neurite outgrowth 
of cells from a neuronal cell line that were cultured on slices of human neuroma tis-
sue. Encouraged by this discovery, in the next chapter we performed a genome-wide 
expression analysis in human neuroma tissue and found that the expression of a sig-
nificant number of genes involved in scar formation and axon guidance is differen-
tially regulated. Further investigations into the precise role of several of these factors, 
specifically their potential influence on phenomena such as repulsion, fasciculation 
and defasciculation of regenerating of axons, will help to improve the understand-
ing of the outgrowth-inhibitory nature of the neuroma. Perhaps more importantly, 
these investigations could yield novel targets for future therapies aimed at improving 
regeneration after peripheral nerve injury.
 In the following chapters, LV vectors were applied to express neurotrophic factors 
in the injured peripheral nerve in an attempt to enhance regeneration after surgical 
repair. First, we developed a protocol to genetically modify cells in cultured segments 
of human sural nerve using LV vectors expressing the marker gene green fluorescent 
protein (GFP). With the application of an LV vector encoding nerve growth factor (LV-
NGF) long-term production of biologically active NGF could be directed in cultured 
human nerve segments. This technique was subsequently used to investigate in vivo 
the effect of LV vector-mediated overexpression of brain-derived neurotrophic factor 
(BDNF) and glial cell line-derived neurotrophic factor (GDNF) on the regeneration 
of rat motoneurons after avulsion and reimplantation of the ventral nerve root. In this 
model, we found positive effects of LV vector-mediated overexpression of GDNF: a 
complete reversal of avulsion-induced motoneuron atrophy and an increased density 
of regenerating axons in the reimplanted roots. However, the strongest effects of LV-
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GDNF were negative: high levels of transgenic GDNF expression induced a truly strik-
ing neuroma-like ‘oasis’ of coiled axons in the nerve root, and the number of regener-
ated fibers more distally was, in fact, lower in comparison with control treatments. 
 In the next chapter, the effect of LV vector-mediated overexpression of NGF and 
GDNF was investigated in a rat model for peripheral nerve transection and repair. 
The regeneration of motoneurons does not appear to be affected by the LV vector-
mediated overexpression of NGF. However, similar to the root avulsion repair study, 
LV vector-mediated expression of GDNF in the transected nerve impaired the long-
distance regeneration of motoneurons. In the affected nociceptive sensory neurons, LV 
vector-mediated overexpression of both NGF and GDNF causes profound phenotypic 
changes that are in line with the notion that these factors play an important role in the 
pathogenesis of pain. Although both the differential regenerative response of motor 
and sensory neurons upon application of these factors and the changes in nociceptive 
sensory neurons could form the starting point for new exciting investigations, these 
findings also highlight the difficulties in improving nerve regeneration and the genuine 
possibility of unwanted side-effects associated with LV vector-mediated overexpres-
sion of neurotrophic factors. 
 In this general discussion I will further evaluate the merits of the results described 
above, as I believe that the experiments in this thesis have yielded both clear “winners” 
and “losers”. I would regard the discovery of semaphorin3A, as well as several other axon 
guidance molecules in the human neuroma and the successful long term transgene ex-
pression in the peripheral nerve after in vivo application of LV vectors as “winners”, i.e. 
results that merit additional investigation and may form the basis of future clinical ap-
plications. As a “loser”, i.e. a strategy that did not live up to expectations, I would consid-
er the exogenous continuous application of neurotrophic factors as a means to enhance 
long-distance regeneration. In the sections below, I will elaborate on these qualifications. 
However, the merits of new therapeutic concepts depend on their ability to advance 
the current clinical practice of nerve repair. Therefore, I will start by giving a concise 
overview of the challenges that exist in the management of peripheral nerve injuries. 
Challenges in nerve repair – opportunities for novel therapies
In this section I will briefly discuss the present state of the art in peripheral nerve re-
pair. This is by no means intended as an exhaustive review of the entire body of knowl-
edge on peripheral nerve regeneration, but instead, I will focus on those issues that are 
relevant to the new therapeutic strategies that have been explored in this thesis.
In contrast to the injured spinal cord, in which the regenerative process is thwarted 
by the abundance of growth-inhibitory factors 57, the lesioned peripheral nerve is ca-
pable of regeneration 81. However, regeneration, and subsequent functional recovery, 
depends on the degree of nerve injury 1.
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Clinically, the most important distinction is between axonotmetic injuries, in which 
axons are severed but the integrity of nerve fascicles is preserved and neurotmetic in-
juries, in which the physical continuity of the entire nerve (including axons and nerve 
fascicles) is lost. Although a regenerative response does occur in neurotmetic lesions, 
axons are unable to bridge the gap that forms between proximal and distal nerve 
stumps and surgical reconstruction is therefore usually indicated 1. In contrast, axo-
notmetic injuries tend to regenerate completely¸ although this does not always result 
in full functional recovery. At a rate of regeneration of 1-5 mm/day 1, it may take sev-
eral months for regenerating axons to reinnervate their distal targets and during this 
time these targets may have atrophied, resulting in a poor restoration of function 11. 
This slow rate of regeneration and associated atrophy of denervated target organs is 
therefore a clinical problem and a potential target for therapeutic intervention.
 In cases of acute neurotmetic injuries (e.g., the complete transection of the ulnar 
nerve in a stab wound), the clinical strategy to treat the injured nerve is relatively 
straightforward and consists of immediate repair surgery, either through the direct 
coaptation of proximal and distal nerve stumps, or through the application of a nerve 
grafts that acts as a scaffold for regenerating axons. 
 However, the treatment strategy is not always this clear-cut, especially if a lesion is 
characterised by extensive intraneural fibrosis. In this so-called neuroma in continu-
ity, both axonotmetic and neurotmetic injury types can be present, and it is therefore 
difficult to assess the likelihood of spontaneous recovery 3. The absence of a reliable 
method to determine the degree of injury at an early time point means that most 
surgeons recommend surgical exploration when clinical examination does not show 
functional recovery of the associated muscle after a certain waiting period 82-84. How-
ever, the regenerative potential of axotomised motoneurons diminishes over time 214 
and therefore, this approach is in effect a trade-off between not waiting long enough 
(running the risk of performing surgery on injuries that would have recovered spon-
taneously) and waiting too long (impairing the outcome of reconstructive surgery for 
severe lesions) 1. This is a second clinical challenge, one that could be addressed by 
either improving the ability to assess the degree of injury at an early time point or by 
enhancing the regenerative capacity of chronically axotomised neurons.
 After nerve repair, both motor and sensory neurons are able to regenerate and 
re-establish functional connections, but there are differences in their regenerative 
response. Motoneurons preferentially reinnervate muscles, a phenomenon that is the 
result of both interaction between the motoneuron and the distal endoneurial tubes at 
the coaptation site 215 and of the “pruning” of motoneuron axons that have inaccurately 
entered endoneurial tubes that lead to sensory organs 216. However, this increased 
likelihood that motoneurons reinnervate muscles, called “preferential motor rein-
nervation” 217, does not mean that these motoneurons are capable of selectively find-
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ing their original targets. Instead, the outgrowth of motor axons is a random process 
that frequently results in the reinnervation of inappropriate, antagonistic muscles 8 or 
even reinnervation of two muscles by branches from one motoneuron 115. This leads 
to the cocontraction of antagonizing muscles and subsequently a failure to recover 
functionally. This “misrouting” phenomenon is the third challenge that provides an 
opportunity for future therapies.
 Finally, the regeneration of motoneurons through grafts derived from purely motor 
nerves is better than through grafts from sensory nerves and vice versa 12,218. Whereas 
some researchers have attributed this fact to the differential expression of several 
neurotrophic factors in motor and sensory nerve grafts 12, others claim that physical 
differences play an important role. Axons of sensory neurons generally have a smaller 
diameter, and the endoneurial tubes in grafts derived from sensory nerves may not 
be ideally suited to accommodate the larger-diameter axons of motoneurons 218. The 
most commonly used graft in human reconstructive surgery is derived from the sural 
nerve, because this sensory nerve can be missed without causing major deficiencies. 
The putative drawback of using sensory nerve grafts to support the regeneration of 
motoneurons is the fourth and final problem in the clinical practice of nerve repair 
that I would like to mention here. 
 In the light of the issues described above, I will now continue to discuss the merits 
of the work described in this thesis, starting with the “losing strategy” of applying 
neurotrophic factors to enhance regeneration. 
Exogenous neurotrophic factors: useful to prevent atrophy, but probably 
not to promote outgrowth
Since the discovery that NGF can promote neurite outgrowth by Rita Levi-Montalcini 
in 1952, neurotrophic factors have arguably been the most widely studied proteins in 
the field of neuroregeneration 9. Interestingly, in the treatment of several neurodegen-
erative diseases (e.g., Alzheimer’s disease and Parkinson’s disease), the application of 
neurotrophic factors has been quite promising 212. Clinical trials with neurotrophic 
factors for these diseases are currently underway and encouraging results have been 
reported 131,219. In contrast, the application of neurotrophic factors to enhance neuro-
regeneration has proven to be far more difficult. One explanation for this difference 
must be that unlike survival, successful regeneration depends on precise time- and 
location-dependent expression of these factors to create an ever-shifting gradient to-
wards which axons continue to extend, sometimes over periods of several months. The 
“candy-store” effect, which was first described in the spinal cord 25 and also observed 
after local application of LV-GDNF in Chapters 5 and 6 shows that in this case, more 
is not necessarily better. Furthermore, we have recently obtained unpublished data 
on the concentration of NGF, Neurotrophin-3, BDNF and GDNF in avulsed nerve 
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roots that clearly show the subtle temporal changes in the expression of these factors. 
In other words, the endogenous expression of these factors in the peripheral nerve 
already appears to be optimised to support continuous regeneration and it is hard to 
envision how their exogenous application will have any other effect than disrupting 
this delicate balance.
 Another striking observation in this respect is that in each paradigm studied in 
this thesis, the peripheral nerve clearly “wants to regenerate”, probably stimulated by 
endogenously elevated levels of neurotrophic factors distal from the lesion site. This 
is exemplified by three observations: (i) the many regenerating axons in the human 
peripheral nerve scar (Chapter 3), (ii) the numerous motor axons crossing spinal cord 
white matter and entering the implanted nerve root (Chapter 5) and (iii) the high num-
ber of neurites that did grow into the nerve stump distal to a peripheral nerve lesion 
(Chapter 6). The robust regeneration in rat models for peripheral nerve injury (ii and 
iii) do not necessarily translate to the human clinical situation, where the distance to 
be bridged from lesion site to target organ is usually much longer 11. Nonetheless, the 
injured human peripheral nerve is also capable of regenerating over long distances 1,4, 
suggesting the presence of a mechanism that shifts the elevated endogenous production 
of neurotrophic factors ahead of regenerating axons. Exogenously and locally increas-
ing the amount of neurotrophic factors in the nerve therefore seems neither needed 
nor helpful. This is disappointing, because the transduction with lentiviral vectors to 
overexpress a combination of motoneuron-specific neurotrophic factors 12 could be an 
interesting strategy to render sensory sural nerve grafts more supportive of the regen-
eration of motoneurons. As described in Chapter 6, the regenerative response to the 
overexpression of GDNF of sensory neurons differs from motoneurons and such find-
ings could theoretically be exploited to create grafts that are specifically permissive for 
the regeneration of either sensory or motoneurons. However, unless it becomes possi-
ble to create a time- and location-dependent gradient of these factors in the nerve, this 
approach is not likely to enhance the long distance regeneration through nerve grafts.
 In summary, the exogenous application of neurotrophic factors still faces signifi-
cant challenges if the goal is to stimulate peripheral nerve regeneration. However, by 
exploiting the survival-enhancing properties of trophic factors, there may be several 
possibilities to enhance the functional outcome of nerve repair.
Firstly, as described in Chapter 5 of this thesis, the viral vector-mediated application 
of GDNF could be a promising approach to prevent motoneuron atrophy after nerve 
root avulsion, “keeping them in shape” prior to reconstructive surgery. This is of par-
ticular importance as the diminished regenerative capacity of chronically axotomised 
motoneurons 214 can be boosted by the temporary application of GDNF 21. This could 
therefore be a way to compensate for the deleterious effect of the waiting period that 
is currently part of the surgical decision-making process.
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Secondly, there may be a role for neurotrophic factors in the prevention of target 
muscle atrophy during the period of denervation. Ciliary neurotrophic factor (CNTF) 
has a strong myotrophic effect on denervated skeletal muscle 220,221, but systemic ap-
plication of CNTF causes unwanted side-effects such as severe weight loss 222. Local, 
LV vector-mediated expression in the muscle 46 of CNTF may be a method to prevent 
muscle atrophy without causing significant side effects, thereby addressing the clinical 
issue of chronic denervation.
 Apart from practical issues involved in applying viral vectors to, for instance, axot-
omised motoneurons in the spinal cord, the success of these strategies will depend on 
two factors: the ability to tightly regulate the amount of neurotrophic factors produced 
and the ability to switch off transgene expression completely when it is no longer help-
ful. This is theoretically possible with viral vectors with regulatable gene expression. 
As discussed in Chapter 1, there are still unresolved issues regarding the safety and 
clinical applicability of vectors that direct regulatable transgene expression. It will 
therefore require several years of additional research before these strategies are ready 
to be tested in a clinical setting.
Failed functional recovery: not the engine is missing, but the steering wheel
As proposed in the previous paragraph, in most cases regeneration of the peripheral 
nerve does not seem to need stimulation by the exogenous application of factors like 
NGF and GDNF as they are already tightly and autonomously regulated to optimise 
continuous outgrowth. Why then, is functional recovery of the peripheral nerve after 
reconstructive surgery often not complete? If this is not the result of an insufficient 
regenerative response, there must be another reason why, for instance, patients with a 
brachial plexus lesion often fail to regain function of distal targets like the hand after 
reconstructive surgery 85. 
 There is an increasing body of evidence suggesting that the misrouting problem is a 
strong contributing factor to the lack of functional recovery after nerve repair surgery 
115,116,223. Younger patients may be able to partially compensate for misrouted axons due 
to the plasticity of their still maturing central nervous system 224,225, but this ability of 
the brain to adapt to the newly formed peripheral connections diminishes with aging. 
To eliminate the cocontraction of antagonising muscles, Botulinum toxin type A has 
been injected in the triceps muscle of patients with brachial plexus injuries 116. The 
purpose of this approach is to facilitate motor learning by temporarily inducing the 
relaxation of antagonist muscles and allowing increased activity in the reinnervated 
biceps muscle. Other than this, there are no pharmacological options to treat misrout-
ing and the problem is usually addressed with intensive physical therapy 226.
 In research, the routing problem has mainly been addressed mechanistically, for 
instance by applying artificial scaffolds with a three-dimensional structure to enhance 
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the physical guidance of regenerating axons 227-230. It is true that the physical prop-
erties of the distal endoneurial tubes determine the fate of regenerating axons and 
thus strongly influence the degree of functional recovery 7. However, surgical recon-
struction of severe neurotmetic nerve injuries is inherently accompanied by a loss 
of continuity of nerve fascicles, impairing the ability of the nerve to physically guide 
regenerating axons. In addition, the sural nerve graft that is most commonly used for 
reconstructive surgery (see above) already contains thousands of aligned Schwann 
cells in longitudinally oriented endoneurial tubes, so it is difficult to imagine how 
this could be improved by artificial guides. Theoretically, one could envision a refine-
ment of surgical techniques up to a level where each individual axon in the proximal 
stump is matched to one endoneurial tube in carefully prepared (artificial or sural) 
nerve grafts, but even then it is hard to imagine how the appropriate distal targets for 
these axons could be identified or how branching at the coaptation site could be pre-
vented. Antibodies against neurotrophic factors have been applied in a rat model for 
peripheral nerve transection to reduce the branching of regenerating axons and thus 
improve the quality of regeneration 231, but this approach carries the risk of interfering 
with the neurotrophic factor signalling that is needed for successful regeneration.
  Another approach could be to allow regeneration to take place after repair as usual, 
but then enhance the ability to use the newly formed connections by increasing plas-
ticity at the level of the spinal cord 120 or brain. Although this approach will not be 
able to compensate for synkinesias caused by the innervation of antagonising muscles 
by branches from the same motoneuron 115, it shows the importance of including 
the central nervous system, perhaps in a multi-level approach, to achieve functional 
recovery after peripheral nerve injury.
Addressing the routing problem at a molecular level
 The reason why I declared the discovery of the expression of semaphorin3A and a 
number of other axon guidance molecules in human neuroma tissue a “winner” is 
that these findings show for the first time that there are molecules present within the 
human nerve scar itself that help determine the fate of regenerating axons. In other 
words, the routing of regenerating axons is not only influenced mechanically by the 
physical alignment of regenerating axons in endoneurial tubes, but also by lesion-in-
duced expression of specific genes in the glial cells of the peripheral nerve. This finding 
may provide several new inroads to address the misrouting problem. 
 Firstly, the chemorepulsive protein semaphorin3A (Chapter 2, and other possible 
inhibitory molecules described in Chapter 3) present in the human neuroma could 
have contributed directly to the observed trapping and disorganisation of axons in 
the human nerve scar. Secondly, in Chapter 3 we describe that the expression of sev-
eral axon guidance molecules is differentially regulated in human neuroma tissue. 
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Although this data is still preliminary, previous literature suggests that some of the 
newly discovered guidance molecules are likely to play a role in the branching, fas-
ciculation (the tendency of regenerating axons to grow in the same direction) and/or 
defasciculation of regenerating axons. All these phenomena are highly relevant for the 
misrouting problem. For instance, if some of the newly discovered proteins stimu-
late neurite sprouting, viral vector-mediated expression of short interfering RNAs to 
knock down the expression of such proteins could limit the number of regenerative 
branches extending from one transected motoneuron. In this way an attempt can be 
made to diminish the likelihood of double innervation of antagonising muscles and 
subsequently the development of unwanted cocontractions. As described in Chapter 
4, the expression of these genes in a sural nerve graft could be manipulated with the 
use of an LV vector.
 Furthermore, some of these newly discovered axon guidance molecules may play a 
role in the phenomenon of “preferential motor reinnervation”, which is in part caused 
by an interaction of axotomised motoneurons and endoneurial tubes at the site of 
axotomy 215. Influencing the expression of these genes could preferentially stimulate 
the regeneration of motoneurons, stimulate or reduce motoneuron sprouting or per-
haps even stimulate the pruning of redundant axons of regenerated motoneurons, 
once again increasing the likelihood of accurate reinnervation of target muscles. 
 Perhaps an even more promising approach to address the routing problem would 
be to use newly discovered axon guidance cues (including semaphorin3A) to actually 
guide regenerating axons towards their original targets by mimicking the patterning 
process that takes place during development. In the developing brachial plexus of 
the chick embryo, axonal outgrowth indeed leads to successful target finding due to 
an elaborate interplay between motoneurons and the differential expression of the 
repulsive guidance cues semaphorin3A and semaphorin3F in the ventral and dorsal 
parts of the developing limb 65. Provided that these motoneurons continue to express 
their respective receptors in the same pattern in the adult human nervous system, 
it may be possible to use semaphorin3A and 3F to help guide them towards their 
original targets after a brachial plexus injury. It is currently not known whether such 
patterning cues are expressed during regeneration in the same way as during develop-
ment. A relatively simple first step to investigate this in humans would be to perform 
a comparative gene expression analysis of the parts of the brachial plexus distal to the 
neuroma. Small segments of the anterior and posterior divisions of the superior trunk 
are sometimes removed during reconstructive surgery of patients with a neuroma of 
the superior trunk. Analogous to the experiments performed in Chapter 3, it may be 
possible to identify axon guidance molecules that are differentially expressed in these 
respective distal trunks. Influencing the expression of such guidance cues in these 
trunks will perhaps provide a truly novel way to help regenerating axons find the 
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right target organ. Naturally, the success of this strategy relies on the assumption that 
the receptors to axon guidance molecules are differentially expressed by subsets of 
regenerating adult motoneurons (see above) which will be harder to study in human 
material and needs to be investigated in animal models 64. A study comparing gene 
expression patterns during development and regeneration of the rat sciatic nerve has 
already shown that approximately half of the regeneration-associated genes were also 
significantly regulated in development, suggesting that regeneration is indeed partly 
a recapitulation of development 55.
Viral vectors: highly suitable tools to study peripheral nerve regeneration
Much has already been said on the maturity and clinical potential of viral vectors in 
Chapter 1 of this thesis. Indeed, the experiments described in this thesis were motivat-
ed in part by recent advances made in the field of gene transfer. Therefore, I will be brief 
on the advantages of the application of viral vectors, but I would like to reiterate here 
their tremendous suitability to study peripheral nerve regeneration. The experiments 
in this thesis and others from our group 150 show that they can be used to transduce 
Schwann cells of the rat peripheral nerve consistently, durably, in significant numbers 
in a well-defined area, without interfering with reconstructive surgery or impairing 
its functional outcome. The relative ease with which new, potentially interesting genes 
can be cloned into these vectors means that the in vivo effect on regeneration of many 
proteins can now be studied in far more efficient ways than previously possible. This is 
the first tangible benefit of these vectors and I expect that this will have a remarkable 
impact on the future direction of peripheral nerve research. 
 Therapies aimed at influencing peripheral nerve regeneration are, inherently, only 
required temporarily. Therefore, it is not unreasonable to question whether it is clini-
cally realistic to inject vectors that will permanently insert a therapeutic gene in 
cells, when the need for a particular protein is only short-term. In addition, there 
are viral vector-related issues that need to be resolved: (i) the presently available 
tetracycline-controlled transactivator necessary for regulatable gene expression is 
of bacterial origin 51 and thus immunogenic 221, (ii) LV vectors may cause side effects 
in transduced cells, and the possibility of insertional mutagenesis is repeatedly men-
tioned in the literature but still not reported 232-234, while this may be prevented with 
the application of non-integrating LV vectors 235 and (iii) safer vectors, like adeno-
associated viral (AAV) vectors, have so far been unable to transduce Schwann cells. 
Furthermore, the experiments described in Chapter 4 highlight another potential 
pitfall of translating results from animal research to the human situation. Whereas 
the application of LV vector results in the efficient transduction of Schwann cells in 
the rat peripheral nerve, fibroblasts are the predominantly transduced cell type in 
human nerve segments. 
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 Therefore, at least in the near future, the most likely role for viral vectors in the 
peripheral nerve will remain as powerful research tools. It will take several years 
to definitively establish the beneficial effect of viral vector-mediated expression of a 
protein in animal models for peripheral nerve injury. During this time, the safety of 
viral vectors for human application will have been established in the clinical trials that 
are currently underway 236 and solutions will probably emerge for the issues described 
above. Depending on the progress that is made in the field of gene therapy, it may be 
possible to translate positive effects of viral vectors in animal peripheral nerve injury 
models directly to a gene therapy approach in humans, or alternatively the therapeu-
tic protein could be delivered by a more conventional method such as biodegradable 
slow-release capsules 225. Either way, viral vectors will have a great impact on the 
development of new therapeutic strategies to enhance the results of peripheral nerve 
repair, and this is why I consider the results obtained with LV vectors in this thesis to 
be “winners”.
 
Future perspective: the continuing miniaturization of surgical and 
diagnostic tools
As described in the introduction of this thesis, the field of peripheral nerve surgery has 
steadily evolved since World War II 1. The introduction of the operating microscope 
and improved microsuturing techniques has had a great impact on the outcome of 
surgery. Essentially, the work described in this thesis forms a logical extension of this 
path of continuous miniaturization by identifying new molecular targets in the human 
peripheral nerve scar and by developing a viral vector-based strategy to influence the 
expression of these targets. In this final section, I would also like to mention another 
form of miniaturization that will likely have a great impact on the clinical practice of 
nerve repair. 
 A significant challenge is the absence of a reliable method to determine the degree of 
injury (and the corresponding need to intervene surgically) in neuroma in continuity 
lesions. New diagnostic tools are much needed as they would enable the early repair of 
the most severe nerve injuries. I believe that it will not be long before novel imaging 
techniques like diffusion-tensor imaging and diffusion-direction-dependent imaging 
will make it possible to assess the integrity of individual nerve fascicles in the lesioned 
peripheral nerve 237, and that this will greatly advance the clinical practice and tim-
ing of nerve repair. Another intriguing option stems from the recent development of 
radio-labelled probes that can be used to detect and quantify collagen in humans in 
vivo 238. As shown in Chapter 3, the expression of several types of collagen is increased 
in the peripheral nerve scar at 5 months post-injury; indicating that formation of a 
fibrotic scar is a process that continues for at least several months. An early assessment 
of the degree of fibrosis in the peripheral nerve scar may constitute a highly reliable 
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way to predict the chances of spontaneous recovery of nerve function. The latter 
putative diagnostic tool may become one of the earliest novel applications based on 
insights obtained from the field of molecular neurobiology. However, in the future, 
basic science will surely have an enormous impact on the treatment of peripheral nerve 
injuries in many other ways as well. I hope that this thesis has provided a glimpse into 
the many opportunities that are provided by looking at peripheral nerve regeneration 
through the eyes of a molecular neurobiologist and that this work will be regarded as 
a small step towards the development of the field of “molecular nerve repair”.
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Inleiding: de behandeling van zenuwletsel
Perifere zenuwen zijn verantwoordelijk voor de communicatie tussen het centrale 
zenuwstelsel (hersenen en ruggenmerg) en de rest van het lichaam (huid, spieren 
en interne organen). De perifere zenuw bestaat uit zenuwcellen (neuronen), die met 
hun cellichaam in, of vlak naast het ruggenmerg liggen en uitlopers (axonen) hebben 
naar hun doelorganen. Deze neuronen geven, door middel van elektrische geleiding 
over hun axonen, bewegingsopdrachten door van het ruggenmerg naar de spieren 
(motoneuronen) of gevoelsinformatie van het lichaam naar het ruggenmerg (sensi-
bele neuronen). Een zenuw is een omhulsel van bindweefsel met daarin duizenden 
axonen die op hun beurt ieder weer omhuld worden door honderden steuncellen 
(Schwanncellen). Deze Schwanncellen zorgen onder andere voor isolatie en een snelle 
elektrische geleiding. 
 Perifere zenuwen kunnen beschadigd of geheel doorsneden worden bij ongeluk-
ken of steekwonden. Een ander type van perifeer zenuwletsel kan ontstaan tijdens de 
geboorte. Als er tijdens de baring aan het hoofd getrokken wordt van een kind dat 
met een schouder vastzit in het baringskanaal, zal overrekking van de zenuwknoop 
van de arm (plexus brachialis) plaatsvinden en kan zelfs een scheuring van de zenuw 
optreden. Op de plaats van overrrekking wordt de continuiteit van de axonen verbro-
ken en ontstaat een litteken dat veel bindweefsel bevat. Perifere zenuwbeschadigingen 
leiden tot verlamming en gevoelsstoornissen in de aangedane ledematen. 
 Als perifere zenuwen beschadigd zijn, of doorsneden of afgescheurd, dan blijven het 
cellichaam en het axon aan de kant van het ruggenmerg (het proximale deel) meestal 
in leven, terwijl het axon aan de kant van het doelorgaan (het distale deel) afsterft 
en door het lichaam opgeruimd wordt. De Schwanncellen in dit distale deel van de 
zenuwschede beginnen vervolgens verschillende “zenuwgroeistoffen” (neurotrofe fac-
toren) te maken. Het beschadigde axon wordt hierdoor tot uitgroei gestimuleerd (er 
treedt spontaan regeneratie op), en kan begeleid worden door de Schwann cellen die 
op een rijtje klaarliggen tot het doelorgaan. Het axon groeit met een snelheid van 1 tot 
5 mm/dag vanuit proximaal naar distaal om uiteindelijk weer opnieuw verbinding te 
maken met het doelorgaan. In het geval van totale doorsnijding zal de chirurg er snel 
aan te pas komen om de uiteinden weer aan elkaar te hechten. Zo wordt de functie 
van de zenuw weer hersteld, hoewel het soms vele maanden kan duren voordat de 
axonen hun doel bereikt hebben.
 Het gebeurt echter regelmatig dat er geen of weinig herstel optreedt. Dit is vooral 
het geval als de continuiteit van de hele zenuw (inclusief steunweefsel en Schwann 
cellen) verwoest is, waardoor een gat ontstaat dat niet te overbruggen is door rege-
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nererende axonen, of omdat de uitgroei van axonen belemmerd wordt door ernstige 
littekenvorming. In die gevallen wordt er operatief ingegrepen. Soms is het nodig om 
eerst littekenweefsel te verwijderen, waarna of de zenuwuiteinden aan elkaar worden 
genaaid of - als dat niet mogelijk is - het onstane defect wordt opgevuld met een “brug-
getje” van een zenuw die elders verwijderd is. Hiervoor wordt meestal de nervus suralis 
opgeofferd, een gevoelszenuw in de kuit die verwijderd kan worden zonder dat dit 
leidt tot ernstige beperkingen. Dit zenuwbruggetje bevat dus geen intacte neuronen 
of axonen (die worden bij het verwijderen doorgenomen en gaan verloren), maar wel 
Schwann cellen die netjes opgelijnd in de zenuw liggen en op die manier de regenere-
rende axonen weer naar hun juiste doelorgaan kunnen leiden. Dit type hersteloperatie 
leidt meestal tot regeneratie en functieherstel. Het herstel is echter nooit volledig en 
patiënten met een ernstig zenuwletsel houden dus altijd levenslange functionele be-
perkingen in de vorm van verlammingen en/of gevoelsstoornissen. 
Het laboratorium: bakermat voor nieuwe therapieën?
Sinds de eerste zenuwhersteloperaties werden uitgevoerd, vanaf het begin van de vo-
rige eeuw, zijn de microchirurgische operatietechnieken enorm verbeterd en uitont-
wikkeld. Toch is het herstel na een operatie is niet optimaal. Verdere verbeteringen in 
de prognose van patiënten met ernstige zenuwletsels zullen dus moeten voortvloeien 
uit de toepassing van nieuwe inzichten en recente technieken uit het laboratorium. 
In Hoofdstuk 1 wordt beschreven dat de toepassing van gentherapie zo’n nieuwe, 
veelbelovende techniek is. 
 Gentherapie houdt in dat er genetisch materiaal wordt ingebracht in de cellen van 
een patiënt met als doel lokaal een therapeutisch eiwit “tot expressie te brengen” om 
een bepaalde aandoening te behandelen. “Tot expressie” wil zeggen, het ingebrachte 
gen wordt afgelezen en het bijbehorende eiwit wordt geproduceerd als lokaal “genees-
middel”. Het inbrengen van dit genetische materiaal kan op vele manieren, maar een 
van de meest gebruikte methoden bestaat uit de toepassing van virale vectoren. Deze 
aanpak berust op het natuurlijke vermogen van virussen om cellen binnen te dringen 
en daar hun genetische materiaal achter te laten. Virale vectoren zijn virusdeeltjes 
waarbij alle ziekmakende virusgenen vervangen kunnen zijn door een therapeutisch 
gen naar keuze. Door het ontbreken van virusgenen kunnen deze vectordeeltjes zich 
niet voortplanten of ziekteverschijnselen veroorzaken. Deze vectoren dringen wel 
nog een cel binnen en laten daar het gen achter. Het inbouwen van een nieuw of een 
extra gen in een cel met behulp van virale vectoren wordt “transductie” genoemd en 
het betreffende gen een “transgen”.
 De meest voor de hand liggende toepassing van gentherapie is in de behandeling 
van aangeboren genetische aandoeningen, waarbij een “normaal” gen in de cel wordt 
gebracht om de functie over te nemen van het defecte of afwezige gen. Er zijn echter 
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verschillende redenen waarom gentherapie ook in het beschadigde zenuwstelsel veel 
potentie heeft. Er zijn vele eiwitten bekend die een positief effect hebben op de uit-
groei van axonen (bijvoorbeeld de hierboven genoemde neurotrofe factoren), maar 
deze eiwitten hebben vaak teveel bijwerkingen als ze in het hele lichaam (systemisch) 
toegediend worden, bijvoorbeeld door inspuiting in de bloedbaan. Ook kun je ze niet 
in pilvorm toedienen omdat ze, net als alle eiwitten al in de maag worden verteerd. 
Bovendien dringen deze eiwitten slecht door in zenuwweefsel als ze lokaal worden 
geïnjecteerd en worden ze meestal snel (binnen enkele minuten) door het lichaam 
afgebroken. Zeer regelmatige lokale toediening of chronische infusie is praktisch ge-
zien niet haalbaar. Het grote voordeel van de toepassing van virale vectoren is dat je 
met één eenmalige vectorinjectie de cellen van het lichaam zelf kan aanzetten tot de 
produktie van het therapeutische eiwit, wat leidt tot een langdurige, plaatselijke afgifte. 
Problemen zoals bijwerkingen op andere plaatsen in het lichaam en de noodzaak van 
meerdere toedieningen zouden daarmee dus tot het verleden kunnen behoren en 
hierdoor zou het gewenste effect van de neurotrofe factoren in theorie veel krachtiger 
kunnen zijn.
 De ontwikkeling van veilige virale vectoren heeft de laatste jaren een enorme vlucht 
genomen. Inmiddels zijn er over de hele wereld honderden mensen behandeld met 
virale vectoren voor een hele reeks aandoeningen, van rheumatoide arthritis tot de 
ziekte van Alzheimer, tot dusverre nagenoeg zonder bijwerkingen. Er zijn verschil-
lende typen virale vectoren die geschikt zijn voor toepassing in mensen. In de proeven 
beschreven in dit proefschrift is gewerkt met zogenoemde lentivirale (LV) vectoren.
De doelstelling van het onderzoek
In dit proefschrift heb ik geprobeerd twee aan elkaar verwante vragen te beantwoor-
den: 1) Waarom remt littekenvorming ter plaatse van het zenuwletsel - zoals hierboven 
beschreven - het functionele herstel? Ik heb op moleculair niveau naar een verklaring 
gezocht voor dit fenomeen, door te kijken of er in het litteken genen tot expressie 
worden gebracht die een rol spelen bij zenuwuitgroei (Hoofdstukken 2 en 3). De 
expressie van deze genen zou dan in theorie met behulp van virale vectoren aan- of 
uitgezet kunnen worden, maar dan moet het wel mogelijk zijn om deze vectoren in 
zenuwweefsel toe te passen. Hieruit volgt de onderzoeksvraag: 2) Is het mogelijk om, 
met behulp van virale vectoren, cellen van de humane zenuw genetisch te modificeren 
(transduceren) om zo lokaal en langdurig de expressie van een therapeutisch eiwit 
te induceren (Hoofdstuk 4) en leidt de virale vector-gemediëerde expressie van een 
neurotrofe factor tot verbeterd herstel van de doorsneden en opnieuw gehechte zenuw 
(Hoofdstukken 5 en 6)?
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Het zenuwlitteken bevat verschillende eiwitten die de axonuitgroei 
beïnvloeden
Om de eigenschappen van het zenuwlitteken te bestuderen, hebben we onderzoek 
gedaan op humaan zenuwlittekenweefsel dat operatief verwijderd was. Het betrof 
hier materiaal van patiëntjes die tijdens de geboorte een ernstig plexus brachialisletsel 
hadden opgelopen, waarbij er 5 maanden na de geboorte nog geen functieherstel was 
opgetreden. Bij deze patiënten werd daarom een hersteloperatie uitgevoerd waarbij, 
na verwijdering van het littekenweefsel, zenuwen uit de kuit in het ontstane defect zijn 
gebracht om uitgroei van axonen naar de doelorganen van de arm te geleiden (zoals 
hierboven beschreven). Om te beginnen onderzochten wij of het verwijderde litteken-
weefsel het eiwit semaphorine 3A bevat (Hoofdstuk 2). Dit eiwit remt de uitgroei van 
axonen sterk af. Het komt ook voor in het litteken dat ontstaat bij beschadigingen van 
het ruggenmerg (dwarslaesies) en is een van de oorzaken van het gebrek aan herstel 
dat optreedt bij mensen met een dwarslaesie. Een voorbeeld: nadat de werking van se-
maphorine 3A was geblokkeerd bij volledig verlamde ratten met een dwarslaesie, trad 
er regeneratie op waardoor de verlamming gedeeltelijk verdween 78. Wij ontdekten dat 
in het litteken van de perifere zenuw inderdaad semaphorine 3A wordt geproduceerd 
(net als in het beschadigde ruggenmerg), dat dit om bundels van uitgroeiende axonen 
heen ligt en dat het een uitgroeibelemmerende functie heeft.
 Aangemoedigd door deze ontdekking hebben we vervolgens een bredere aanpak ge-
volgd door de genexpressie van meerdere genen tegelijk te analyseren (Hoofdstuk 3). 
Met behulp van een “micro-array”, ook wel DNA-chip genoemd, kan in één experi-
ment de expressie van 44.000 genen in het litteken worden bekeken en vergeleken met 
die van een normale zenuw. Uit deze analyse bleek dat er diverse genen in het litteken 
een verhoogde expressie laten zien die bekend waren een rol te spelen bij littekenvor-
ming en en bij het sturen/remmen van axon-uitgroei. Deze gegevens tonen aan dat 
er zelfs 5 maanden na het oorspronkelijke letsel nog littekenvorming plaatsvindt en 
dat de regeneratie van beschadigde axonen beïnvloed wordt door een reeks verschil-
lende eiwitten. Door de expressie van dit soort eiwitten te beïnvloeden (bijvoorbeeld 
door het stilleggen van de expressie van semaphorine 3A), zouden we in de toekomst 
kunnen proberen het herstel van de beschadigde zenuw te verbeteren.
Virale vectoren: een nieuw instrument voor de neurochirurg?
Het tweede doel van dit proefschrift was om te kijken of virale vectoren die een gen 
bevatten dat codeert voor bepaalde neurotrofe factoren de regeneratie van de perifere 
zenuw kon bevorderen. Als eerste hebben we in Hoofdstuk 4 onderzocht of het mo-
gelijk is om een gen in te bouwen in de steuncellen van humane stukjes zenuw. Zoals 
hierboven beschreven, wordt er bij zenuwhersteloperaties vaak gebruik gemaakt van 
de nervus suralis, die dan dient als zenuwbruggetje. De kleine stukjes zenuw die over-
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bleven hebben we gebruikt voor onderzoek. Deze stukjes kunnen gedurende enkele 
dagen in leven worden gehouden in een schaaltje met kweekmedium en hierdoor kon 
onderzocht worden of ze met behulp van een LV-vector genetisch waren te modifice-
ren. Uiteindelijk lukte het, door injectie van de LV-vector, een transgen in de zenuw tot 
expressie te laten brengen. Dit kon eenvoudig waargenomen worden doordat het een 
gen betrof voor “green fluorescent protein”, waardoor alle cellen die het tot expressie 
brachten fluorescent groen werden en makkelijk zichtbaar zijn onder de microscoop. 
Een opvallende bevinding was, dat het niet de Schwanncellen waren die groen werden, 
maar vooral cellen in het omhullende bindweefsel, zogenoemde fibroblasten. Dit was 
onverwacht, aangezien dezelfde LV-vector in rattenzenuwen leidt tot transductie van 
voornamelijk Schwanncellen. Deze bevinding onderstreept hoe belangrijk het is om, 
naast dierproeven, ook onderzoek op humaan materiaal te doen omdat de resultaten 
van dierproeven niet altijd één op één te vertalen zijn naar de humane situatie.
 Vervolgens hebben we onderzocht of het mogelijk was de expressie van de neuro-
trofe factor “nerve growth factor” (NGF) te induceren in deze humane zenuwstukjes. 
Dit bleek mogelijk en het zo (door fibroblasten) geproduceerde NGF was in staat de 
uitgroei van axonen te bevorderen in een kweekschaaltje. Het is dus technisch mogelijk 
om met behulp van een virale vector de produktie van werkzaam NGF in de humane 
nervus suralis flink te verhogen. Het voordeel van het hier beschreven protocol is dat 
het in theorie toegepast kan worden in combinatie met zenuwherstelchirurgie, zon-
der dat er iets hoeft te veranderen aan de dagelijkse praktijk van de operatie zoals hij 
momenteel wordt uitgevoerd. De chirurg neemt de nervus suralis uit, het virus wordt 
in de zenuw geïnjecteerd en direct daarna wordt deze geïmplanteerd als zenuwbrug-
getje. De vraag is natuurlijk of een zodanig lokaal verhoogde produktie van NGF ook 
het herstel van de perifere zenuw bevordert. Dat hebben we dan ook onderzocht in 
de volgende hoofdstukken, gebruik makend van rattenmodellen voor zenuwschade.
Als eerste hebben we onderzoek gedaan naar een zeer ernstig type zenuwletsel, de 
zogenoemde wortelavulsie. Bij wortelavulsies wordt de zenuw uit het ruggenmerg 
getrokken. De cellichamen van de motoneuronen in het ruggenmerg, waarvan het 
axon nu afgerukt is, zijn daarom niet in staat hun axonen te laten regenereren in die 
wortel, immers het contact is volledig verbroken. Ze worden in de loop van enkele 
weken steeds kleiner (atrofie) en gaan na verloop van tijd deels dood. Door het her-
implanteren van de afgerukte zenuwwortel in het ruggenmerg ontstaat er wel weer 
de mogelijkheid tot heruitgroei en kan in principe de motoneuronatrofie gedeeltelijk 
voorkomen worden. Om deze redenen zijn er in de wereld enkele chirurgen die deze 
operatie bij mensen uitvoeren, maar dit is zeer controversieel. Over het algemeen 
worden de risico’s van extra schade van een dergelijke operatie te groot geacht in 
verhouding tot het (slechts een enkele keer optredende) geringe functieherstel. In 
Hoofdstuk 5 hebben we in een rattenmodel onderzocht of dat herstel te verbeteren is 
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met gentherapie voor neurotrofe factoren. Hiertoe hebben dezelfde “risicovolle” reim-
plantatie uitgevoerd in een rattenmodel, maar voordat we de wortels reïmplanteerden 
hebben we ze eerst geïnjecteerd met LV-vectoren die coderen voor de eiwitten “brain-
derived neurotrophic factor” (BDNF) of “glial cell line-derived neurotrophic factor” 
(GDNF). Hiermee hoopten we de atrofie van de motoneuronen te voorkomen en de 
uitgroei van de axonen de wortel in te verbeteren. De injectie van een LV-vector leidde 
tot de langdurige transductie van Schwanncellen in de wortel tot minstens 16 weken. 
Belangrijker nog was dat LV-GDNF de motoneuronatrofie volledig bleek te kunnen 
voorkomen en dat er meer axonen de geïmplanteerde wortel ingroeiden. Helaas werd 
dit bijzondere succes overschaduwd door een onverwacht bij-effect. Door de LV-vector 
gemediëerde expressie werd de GDNF concentratie plaatselijk zo hoog, dat de axonen 
die de wortel ingegroeid waren “bleven hangen” in de wortel, precies op de plek waar 
LV-GDNF geïnjecteerd was en de GDNF concentratie dus het hoogst was. In de loop 
van 16 weken ontstonden er op deze plek dikke kluwens van axonen die continue in 
cirkels leken te groeien. Dit fenomeen werd het “candy store effect” genoemd, omdat 
het doet denken aan kinderen die niet weg willen uit de snoepwinkel. Verderop in 
de zenuw, dichtbij de spieren waar de axonen verbinding mee moesten maken, bleek 
het aantal axonen dan ook verlaagd na toepassing van LV-GDNF, waardoor het oor-
spronkelijke doel, het verbeteren van de functionele herstel na een wortelavulsie, niet 
werd behaald.
 Waar we ons in hoofdstuk 5 specifiek richtten op de uitgroei van motoneuronen, 
hebben we in Hoofdstuk 6 gekeken naar een gemengde zenuw, dat wil zeggen een 
zenuw die axonen van zowel bewegings- (moto)neuronen als gevoels- (sensibele) 
neuronen bevat, de nervus ischiadicus van de rat. Deze zenuw werd doorsneden en 
weer aan elkaar gehecht zoals dat in de kliniek ook zou gebeuren bij patiënten met 
een zenuwdoorsnijding. Vervolgens injecteerden we LV-NGF of LV-GDNF distaal 
van de plaats van reparatie, dus in het deel van de zenuw waar de doorsneden axonen 
naartoe moeten groeien. Deze opzet stelde ons in staat om de regeneratieve respons 
van motoneuronen en sensibele neuronen op deze factoren met elkaar te vergelijken. 
Er zijn verschillende soorten sensibele neuronen die betrokken zijn bij de registratie 
van pijn, en die zijn onder andere te onderscheiden doordat de ene populatie gevoe-
lig is voor NGF en de andere voor GDNF. We konden dus in deze proef ook kijken 
hoe de regeneratie van deze verschillende populaties was na de langdurige LV-vector 
gemediëerde lokale verhoging van de concentratie van deze stoffen.
 Net als in hoofdstuk 5 bleek dat de Schwanncellen in de zenuw getransduceerd 
werden en grote hoeveelheden NGF en GDNF begonnen te produceren. Verder leidde 
ook hier weer het lokaal verhogen van de GDNF expressie ertoe dat de axonen van 
motoneuronen bleven hangen, het inmiddels bekende “candy store effect” ”, maar 
de sensibele axonen niet. LV-NGF had dit effect niet, maar gaf ook geen verbetering 
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van de regeneratie van motoneuronen. De verhoogde concentraties NGF en GDNF 
hadden geen significante effecten op het totaal aantal geregenereerde sensibele neu-
ronen, maar er bleken wel veranderingen op te treden in de verschillende populaties 
(NGF- en GDNF-specifieke) pijn-registrerende neuronen. Dat leidde ook tot functi-
onele effecten: bij LV-NGF toepassing bleek de pijnperceptie in het aangedane gebied 
ongeveer 10% sneller te herstellen, terwijl er literatuuraanwijzingen waren dat LV-
GDNF juist een pijnverminderend effect zou moeten hebben. Het gevonden verschil 
tussen de regeneratieve respons van motoneuronen en sensibele neuronen op GDNF 
(wel vs geen “candy store effect”) en het differentiele effect van NGF en GDNF op de 
verschillende pijngevoelige populaties neuronen zijn beide interessante bevindingen. 
Echter, aangezien deze aanpak niet direct geleid heeft tot een concrete verbetering van 
de uitgroei van beschadigde axonen, zal er eerst nog uitgebreider onderzoek gedaan 
moeten worden voordat deze bevindingen vertaald kunnen worden naar klinische 
therapiën die het functionele herstel voor de patiënt verbeteren. 
Toekomstperspectief: verdere miniaturisatie van de zenuwchirurgie?
In Hoofdstuk 7, waarin ik de resultaten samenvat en het klinische probleem nogmaals 
kort bespreek, probeer ik een oordeel te vellen over de diverse nieuwe bevindingen 
van dit onderzoek voor een mogelijk toekomstige toepassing in de perifere zenuwneu-
rochirurgie. De toepassing van neurotrofe factoren ter verbetering van de regeneratie 
is in de huidige opzet een minder succesvolle aanpak gebleken. De neuronen van de 
perifere zenuw zijn uit zichzelf goed in staat om over lange afstanden te regenereren. 
Ook nieuwe, nog ongepubliceerde resultaten uit ons lab suggereren dat de expressie 
van diverse neurotrofe factoren al is geoptimaliseerd om de continue uitgroei van 
axonen te waarborgen. Zoals we zagen in hoofdstukken 5 en 6 heeft het lokaal verho-
gen van de concentratie van deze neurotrofe factoren (of dit nu met virale vectoren 
of op een andere manier gebeurt) in onze proeven voornamelijk een averechts effect 
gehad, waarschijnlijk omdat hiermee de natuurlijke respons en de delicate balans 
van groeistoffen die nodig is voor de lange-afstandsregeneratie van axonen verstoord 
wordt. Wel zouden neurotrofe factoren toegepast kunnen worden om bijvoorbeeld 
de atrofie van motoneuronen te voorkomen om die cellen beter in staat te stellen tot 
axonregeneratie.
 Wellicht wekt het verbazing dat de beschadigde axonen kennelijk ook zonder hulp 
van buitenaf in staat zijn om over lange afstanden opnieuw uit te groeien, terwijl er 
vaak nauwelijks functioneel herstel optreedt. In hoofdstuk 7 beargumenteer ik dat 
een belangrijke oorzakelijke factor is dat regenererende axonen wel uitgroeien, maar 
niet in staat zijn het juiste eindorgaan te vinden. De ontdekking van semaphorine3A 
(hoofdstuk 2) en andere “axon guidance” moleculen (hoofdstuk 3) is daarom zeer 
interessant, omdat deze misschien gebruikt kunnen worden om richting te geven 
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aan uitgroeiende axonen en de kans te verkleinen dat ze verbinding maken met het 
verkeerde doelorgaan. De gebleken mogelijkheid van toepassing van virale vectoren 
voor de perifere zenuw is een ander positief resultaat omdat hiermee op zeer efficiente 
wijze het effect van elk willekeurig eiwit (dus niet alleen neurotrofe factoren, maar ook 
bijvoorbeeld “axon guidance” moleculen) op regeneratie onderzocht kan worden in 
verschillende proefdiermodellen. De veiligheid en toepasbaarheid van deze vectoren 
wordt momenteel onderzocht in grootschalige “clinical trials”, waardoor het in de toe-
komst wellicht mogelijk wordt om in laboratorium behaalde resultaten met vectoren 
direct te vertalen naar een gentherapeutisch behandeling bij mensen. 
 Zoals beschreven heeft de chirurgie van de perifere zenuw een enorme technische 
verfijning doorgemaakt. In feite hebben we met dit proefschrift een logische ver-
volgstap gezet door het herstel van de zenuw op nog kleinere (moleculaire) schaal te 
bestuderen en te beïnvloeden met virale vectoren. Hoewel het duidelijk is dat er nog 
veel werk verricht moet worden voordat de virale vectoren als zeer verfijnd instru-
ment opgenomen zullen worden in het arsenaal van de neurochirurg, hoop ik dat dit 
proefschrift een kleine bijdrage zal leveren aan het ontstaan van een nieuw vakgebied: 
de “moleculaire zenuwchirurgie”.
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